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ABSTRACT 
The acquired immune deficiency syndrome (AIDS) has caused over 60 million 
deaths since the etiological agent, human immunodeficiency virus type 1 (HIV-1), 
was first discovered in 1981. Over 6000 new HIV-1 infections are reported every 
day, predominantly in economically deprived regions of sub-Saharan Africa. 
Despite impressive developments in antiretroviral therapy, current medical 
intervention is unable to prevent or cure HIV-1 infection, necessitating expensive 
life-long treatment. Difficulties in establishing a vaccine or cure, arise from its 
capacity to cause life-long latent infection, and its extraordinary ability to evolve 
resistance to therapeutic intervention.  
Capsid uncoating is the process by which p24CA proteins (CA) disassemble from 
the viral ribonucleoprotein during the early phase of the HIV-1 lifecycle. Despite 
intensive investigation, much is yet unknown about the spatial and temporal 
occurrence of this process within the cell, and the viral or host cellular factors 
involved. However, studies investigating p24CA mutations which alter the stability, 
and consequently the kinetics of capsid uncoating, have shown that timely capsid 
uncoating is crucial for efficient HIV-1 infection.  
Recent advancements in microscopic techniques have enabled high resolution 
analysis of cellular protein interactions, including the in situ localisation and 
dynamics of these events. We have developed three imaging techniques for the 
analysis of different aspects of HIV-1 capsid uncoating: 1) a dual-fluorescently 
labelled virus 2) a fluorescently labelled antibody targeting a capsid internalised 
repeat peptide array, and 3) a split-luciferase system tagging an internalised 
component of the capsid core.  
Fluorescent labelling of both the CA and IN proteins enabled the sensitive and 
specific analysis of uncoating in response to both restriction factors and CA 
mutations, and the visualisation of CA colocalised pre-integration complexes 
(PICs) within the nucleus. This system is ideally suited for studying the longer-
term kinetics of uncoating, and the in situ visualisation of protein interactions. 
The use of the repeat peptide array in conjunction with fluorescently labelled 
antibodies, reinforced reports of an initial uncoating event early after viral fusion. 
This system enabled the rapid and reproducible imaging of uncoating events in 
real-time, within the same cell sample population. Finally, the split-luciferase 
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system added further weight to a primary early uncoating stage, and showed 
capsid disassembly responses specific to mutations within the p24CA that affect 
the stability of the viral core.  
Put together, these three assays support a model of uncoating involving an initial 
early phase of uncoating, followed by a more gradual disassembly of CA from the 
PICs during cytoplasmic trafficking towards the nucleus. The colocalisation of 
these components within the nucleus suggests incomplete uncoating at the time 
of nuclear docking.  
The user-friendliness of the split-luciferase system, along with its capacity for 
high-throughput, real-time analysis, support great potential for its use as a 
screening assay for testing antiviral compounds targeting capsid uncoating 
events. 
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AIM OF THESIS 
The CA monomer is one of the most conserved of the HIV-1 proteins, with 
studies suggesting it to be stretched to the limit by pressures to produce capsid 
cores of optimal stability, which are still able to interact with the numerous host 
factors necessary for productive infection. This genetic inflexibility, unlike that of 
other HIV-1 proteins, make CA and the process of capsid uncoating, attractive 
targets for therapeutic intervention. 
Studies utilising mutations in the p24CA protein, which alter the stability and 
consequently the kinetics of capsid uncoating, have shown that timely capsid 
uncoating is crucial for the productive infection of HIV-1. Although multiple 
techniques have been employed to understand this process, the fragility of the 
capsid core makes it very sensitive to external manipulation. As such, much is 
yet unknown about the in situ temporal and spatial kinetics of uncoating, and the 
cellular factors involved. 
The principal aim of this thesis was to develop, optimise and evaluate an 
imaging-based system for studying the kinetics of capsid uncoating within the 3-
D spatial context of the cell. This system would be used to visualise the subtle 
cellular/capsid interactions necessary for functional viral core disassembly within 
the cellular environment, to help further the understanding of this complex 
process. 
An additional objective of this project was to adapt the system for the high-
throughput analysis of capsid uncoating for use in the identification of 
compounds which impede the normal process of uncoating, as an alternative 
strategy for pharmaceutical intervention.  
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 INTRODUCTION 
1.1 AIDS 
The Acquired Immune Deﬁciency Syndrome (AIDS) first came to light as a new 
disease in 1981, with the reports of unusual occurrences of pneumocystis carinii 
pneumonia and Kaposi sarcoma in previously healthy, young homosexual men 
[1][2][3]. The causative agent was subsequently isolated and characterised as a 
human T-lymphotropic virus III (HTLV III) in 1983, and was officially named as 
the human immunodeficiency virus (HIV) by the International Committee on the 
Taxonomy of Viruses in May 1986 [4][5][6][7]. Since then the pandemic form of 
HIV-1, also known as the main (M) group, has infected at least 60 million people 
and caused more than 35 million deaths [8] (who.int/mediacentre/factsheets). 
According to World Health Organisation (WHO) statistics, there were 
approximately 36.7 million people worldwide living with HIV-1 by the end of 2015, 
but it is estimated that only 54% of people actually know they are infected 
(who.int/mediacentre/factsheets). 
 
1.2 HIV-1 
The HIV-1 virus is a group VI member of the Retroviridae family. These are 
enveloped viruses characterised by their ability to reverse transcribe their RNA 
genome into double-stranded DNA intermediates, through use of their own 
reverse transcriptase (RT) enzyme, and integrate their genome into host 
chromosomal DNA [9]. The resultant ‘provirus’ then serves as a template for the 
transcription and translation of the genomic RNA and proteins required for the 
development of future viral progeny. These defining features enable the virus to 
maintain a persistent infection within the host despite the activation of antiviral 
immunity. HIV-1 is further categorised as a lentivirus, which are complex viruses 
characterised by having a long incubation period (lente meaning slow in Latin) 
and a unique virion morphology, demarcated by the conical capsid cores [9]. 
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1.2.1 Genomic structure 
The HIV-1 genome is primarily a coding RNA that contains nine open reading 
frames, which translate into 16 proteins, flanked by two long terminal repeats 
(LTR) (Fig. 1) [10]. The three primary translational products (Gag, Pol and Env) 
encode structural proteins which are initially synthesised as polyprotein 
precursors, and subsequently processed into mature particle associated proteins 
through the action of viral or cellular proteases [9]. The 55 kDa group-specific 
antigen (Gag) precursor is cleaved into the matrix (MA), capsid (CA), 
nucleocapsid (NC) and p6 proteins. Autocatalysis of the 160 kDa Gag-pol 
polyprotein generates protease (PR), the heterodimeric reverse transcriptase 
(RT) and the integrase (IN) proteins. The 160 kDa envelope (Env) precursor is 
cleaved into the gp120 surface (SU) and gp41 transmembrane (TM) proteins 
through proteolytic digestion by cellular enzymes. The six remaining regulatory 
proteins (trans-activator of transcription (Tat) and regulator of the expression of 
the virion (Rev)) and accessory proteins (viral infectivity factor (Vif), viral protein 
R (Vpr), viral protein U (Vpu) and negative regulatory factor (Nef)) are translated 
from spliced mRNA transcribed from the integrated provirus [9]. 
 
 
 
Figure 1. Genomic organisation of HIV-1. Illustration depicting the ~9.7 kb HIV-1 genome, 
highlighting the three main open reading frames coding for 16 proteins [11]. Long terminal 
repeats (LTRs) flank the genome of the integrated viruses, and contain important regulatory 
regions for transcription initiation and polyadenylation. The main structural proteins and 
regulatory enzymes (Gag, Gag-Pol and Env) are initially synthesised as polyprotein precursors, 
which are subsequently cleaved by viral proteases and cellular proteases (Env) into 11 subunits 
(Gag = MA, CA, sp1, NC, sp2 and p6; Pol = PR, RT (containing RNAse H) and IN; and Env = SU 
and TM). Ribosomal frame-shifting permits the expression of the 160 kDa Gag-Pol protein 
precursor at a ratio of roughly 1:20 of that of the Gag polyprotein [12][13]. 
Illustration by Thomas Splettstoesser (www.scistyle.com). 
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1.2.2 Replication cycle 
The HIV-1 replication cycle is generally characterised by two stages – the early 
and late phases of infection (Fig. 2). The early phase encompasses the initial 
steps of HIV-1 cellular entry. Primarily, the HIV-1 Env glycoprotein (gp41/gp120) 
sequentially binds with the CD4 receptor and co-receptors (CCR5 or CXCR4) 
present on the surface of the receptive host cell, which initiates fusion with the 
cellular membrane, releasing the viral core into the cellular cytoplasm [14]. A 
series of transformational steps occurs commencing with the reverse 
transcription of the two copies of positive-sense single-stranded viral RNA, at this 
point known as the reverse transcription complex (RTC), into double stranded 
copy DNA (cDNA) to form the pre-integration complex (PIC) [15]. The PIC is a 
~28 nm particle containing the cDNA and various viral (MA, CA, NC, IN, RT and 
Vpr) and host proteins [16][17]. The PIC is then transported through the nuclear 
pore complex, whereupon the cDNA is integrated into the host genome through 
catalases by IN, to produce the provirus [17]. At some point between fusion with 
the cellular membrane and nuclear entry, the viral capsid core goes through a 
process of progressive disassembly from the viral nucleoprotein, in a process 
known as uncoating. This process will be the main subject of this study. 
 
In the late phase of HIV-1 infection, proviral DNA is transcribed by host RNA 
polymerase into full length viral RNA. A subset of the transcripts are spliced and 
exported into the cytoplasm where they are translated into the regulatory proteins 
transactivator of transcription (Tat), which promotes transcription elongation, and 
the regulator of viral gene expression (Rev) [18]. The Rev protein mediates the 
export of singly spliced and unspliced viral RNAs from the nucleus. A 
conformational switch in the 5’ untranslated region (UTR) of RNA determines 
whether it is translated for the expression of the Gag, Pol and Env gene 
products, or dimerised for packaging into new viral particles [19][20]. The 
Pr55Gag precursor polyprotein (Gag) binds to dimerised genomic RNA (gRNA) 
through two zinc finger motifs present within NC [21][22][23] and the gRNA/Gag 
subcomplex traffics through the cytoplasm towards the cellular membrane for 
attachment and assembly [24]. The MA domain undergoes myristoylation at the 
N-terminal domain enabling the gRNA/Gag subcomplex to embed into the 
plasma membrane for early virion assembly [25][26]. This is followed by a rapid 
4 
 
accumulation of Gag, which forms higher-order structures (multimerisation) 
mediated by contacts between adjacent MA, CA and NC domains [27][28]. Viral 
budding is mediated through the interaction of two motifs on the p6 domain of 
Gag (PTAP and YPXnl) with the ‘host endosomal sorting complexes required for 
transport’ (ESCRT) machinery [29][30]. Interactions with the p6 domain also 
mediate the incorporation of Vpr into the assembling viral particle [31]. 
 
 
 
 
 
Figure 2. Schematic depicting the principal stages of the HIV-1 replication cycle [32]. A 
mature virion binds to a CD4 receptor and co-receptors (CCR5/CXCR4) present on the surface of 
a receptive cell, instigating fusion with the cellular membrane and release of the capsid core 
within the cytoplasm. The viral RNA is then reverse transcribed (reverse transcription complex) 
into double stranded linear DNA to form the pre-integration complex, which is translocated into 
the nucleus. At some point during these events the capsid core disassembles, in a process 
known as uncoating. The viral DNA integrates into the host genome forming the provirus, which 
is subsequently transcribed and translated into new viral RNA and protein molecules. These are 
trafficked across the cytoplasm and assembled at the cellular membrane, initiating budding and 
release of the immature virions. Viral proteases cleave the structural polyproteins to create the 
distinctive fullerene capsid core surrounding the viral nucleoprotein complex (VNC), in the 
formation of a mature HIV-1 virus.  
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1.2.3 Maturation 
Viral maturation occurs concomitantly with the budding and release of the 
immature virion from the plasmid membrane [33][34][35]. It consists of a series of 
coordinated cleavages of the Gag-Pol polyprotein by the viral protease at ten 
different sites, producing the fully processed MA, CA, NC, p6, Pr, RT and IN 
proteins [36]. Proteolytic processing is a highly regulated event, with the timing 
and sequence of cleavage shown to be critical for the formation of infectious viral 
particles [37]. The cleavage of spacer peptide 1 (SP1) from the CTD of CA marks 
the final step in this process, and is known to be particularly important for 
structural rearrangement from a spherical immature core to the mature conical 
morphology [38]. The exact means by which rearrangement occurs have yet to 
be fully defined. The MA proteins remain associated with the inner layer of the 
viral membrane, whilst the CA monomers form a geometric lattice composed of 
~250 CA hexamers, with 12 CA pentamers defining the curvature of the core and 
its typical cone shaped appearance [36]. The capsid core surrounds the two 
single strands of positive-sense RNA and the various enzymes and accessory 
proteins required for successful HIV-1 replication.  
 
1.3 Capsid structure 
The HIV-1 ‘capsid’ is a term which is often used to refer to both the p24CA 
monomers and the capsid fullerene core. To reduce confusion, ‘CA’ will be used 
to describe the p24CA protein monomers, and ‘capsid’ to describe the assembled 
conical core. 
 
1.3.1 CA p24 monomer 
The HIV-1 CA monomer (p24CA) is composed of two independently folded 
domains, a ~150 amino acid (aa) amino-terminal domain (CANTD) and an ~80 aa 
carboxyl-terminal domain (CACTD), bound by a 5-residue flexible linker [39] (Fig. 
3). Both domains have a predominantly α-helical secondary structure: the CANTD 
is arrowhead shaped, with seven α-helices (numbered 1–7) and an amino-
terminal β-hairpin, whilst the CACTD is more spherical, with a short single-turn 310-
helix followed by an extended strand and four α-helices (numbered 8–11) 
[39][40]. The alpha helices act as stabilisers for the CA subunits. The CANTD, or 
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core domain, contains the exposed cyclophilin binding loop and is located on the 
outer surface of the mature capsid core, whilst the CACTD, also known as the 
dimerisation domain, is orientated towards the interior of the capsid core. The CA 
protein is relatively well conserved amongst the Gag proteins, with the major 
homology region in the N-terminus of CACTD displaying significant aa identity 
between divergent retrovirus genera [41]. 
 
 
 
Figure 3. Structural model of the HIV-1 CA protein [42]. An annotated p24CA model depicts the 
7 alpha helices and the cyclophilin-A binding loop of the amino-terminal domain (NTD) 
connected, by a 5-resdue flexible linker, to the carboxyl-terminal domain (CTD) comprising 4 
alpha helices and the major homology region (MHR) in green. The helices highlighted in blue and 
red are involved in the intermolecular interactions which contribute to the formation of hexameric 
and pentameric rings, and the subsequent hexagonal lattice [42]. 
 
1.3.2 Capsid structure – capsid core 
During virion budding and maturation the Gag polyprotein is cleaved through the 
action of the autogenous protease enzyme, and the CA monomers reassemble 
to form the geometric fullerene core [43]. The CA monomers are organised into 
hexameric (Fig. 4B and D) and pentameric rings (Fig. 4C and E), which are 
stabilised by interactions between the first three helices of the CANTD [36]. The 
capsid rings are in turn stabilised by an exterior ‘girdle’ formed by the CACTD that 
also forms inter-subunit contacts with adjacent CANTD. The CACTD also makes 
inter-ring contacts across the local two- and three-fold axes, which stabilises the 
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extended lattice. Larger assemblies of hexamers and pentamers are maintained 
by hydrophobic residues within the CACTD, which provide the structural support 
for the mature capsid core [44]. When assembled into the mature conical core 
(Fig. 4A) the CANTD is orientated towards the outer surface of the structure, 
whereas the CACTD is located within the interior of the core. The CANTD and 
CACTD interface forms a binding pocket between helices 3, 4, 5 and 7, which 
interacts with various host cellular factors intrinsic to HIV-1 infection, such as 
nucleoporin (Nup) Nup358 and cleavage and polyadenylation specificity factor 6 
(CPSF6), and is also a target for the small molecular restriction compounds 
PF74 and BI-1 [45][46][47][48]. 
 
 
A B C 
 
  
D E 
  
 
 
Figure 4. Model of an HIV-1 capsid core and structure of the CA hexamers and pentamers 
[49]. (A) 3D representation of a mature capsid core, showing the spatial configuration of the 
hexamers, pentamers and dimers highlighted in orange, yellow and blue, respectively. The 
arrangement of 12 CA pentamers at polar ends of the structure create the distinctive cone 
shaped appearance of the capsid core. (B and C) Top view of a CA hexamer and pentamer, 
respectively, with their corresponding side views depicted directly underneath (D and E). Helices 
are represented as ribbons, and each subunit is presented in a different colour. 
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1.4 Capsid – roles in the early phase of infection 
Early work using biochemical methods for isolating the RTC/PICs implied that 
capsid only had a small role in the early phase of the HIV-1 replication cycle, 
delivering the viral genome and associated proteins into the cytoplasm of the 
target cell [15]. The viral capsid core is a relatively fragile complex, and the 
detergents/low salt conditions used for hypotonic lysis and removal of the viral 
membrane were probably stripping the core from the viral nucleoprotein, 
precluding its detection in immunoprecipitation assays [16][50][51][52][53]. 
Advances in genome-wide analysis and cellular imaging techniques, however, 
have enabled the detection of PIC associated CA within the nucleus, suggesting 
a more prominent role in HIV-1 infectivity [54][55][56][57][58]. 
 
Below is a list of some of the roles in the early phase of infection that CA/capsid 
has been linked with. 
 
1.4.1 Housing of the viral ribonucleoprotein 
The principle role of the capsid core is to provide an encapsulating sheath with 
which to contain two copies of the viral RNA genome and proteins necessary for 
infection, such as PR, RT, IN, NC, Nef and Vpr [17][59]. This is produced during 
maturation of the nascent viral particle through protease cleavage of the Gag 
polyprotein, and ensures the correct delivery of the viral ribonucleoprotein 
complex into the target cell. 
 
1.4.2 Immune evasion 
Several reports suggest a role in immune evasion for the viral core [60] 
[61][62][63]. A recent study by Rasaiyaah and co-workers provided evidence of 
the innate immune sensor evasion properties of the capsid core in monocyte-
derived macrophages (MDMs) [60]. HIV-1 is able to replicate in primary human 
macrophages without stimulating innate immunity, despite the production of 
cDNA, a key trigger for interferon (IFN) mediated restriction in HIV-1 infection 
[64]. The capsid mutants N74D and P90A, however, cannot replicate in MDMs 
because they trigger innate sensors leading to type 1 IFN production and an 
antiviral state [60]. Using the RT (D185E) or IN (D116N) mutants in combination 
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with the N74D capsid mutant, IP10 expression (an IFN stimulated gene) was 
induced with the CA/IN double mutant but not with the CA/RT double mutant. 
This data indicated that viral DNA produced by reverse transcription was the 
pathogen-associated molecular pattern (PAMP) that triggered the innate immune 
response in MDMs. Depletion or pharmacological inhibition of the cofactors 
CPSF6 and cyclophilin A (CypA,) which interact with the CA mutants N74D and 
P90A, respectively, also induced wild-type HIV-1 infection to stimulate IFN 
secretion in MDMs. The authors propose that CPSF6/CypA recruitment to CA 
suppresses premature viral DNA synthesis, allowing evasion of innate immune 
sensors, adding weight to the importance of correctly orchestrated HIV-1 
uncoating and nuclear entry [60]. 
 
1.4.3 Reverse transcription 
The capsid core may also act to maintain both the viral genome and RT in a 
spatially enclosed environment. Numerous strand transfers are necessary for the 
conversion of the viral genome into double stranded DNA, and it has been 
suggested that the HIV-1 capsid is essential for maintaining a high stoichiometry 
of RT relative to the viral RNA, to offset its tendency to detach from the template 
during reverse transcription [65][66]. Dilution of RT in the cellular cytoplasm 
would substantially reduce the efficiency of reverse transcription [15]. 
Interestingly, several studies support a functional link between reverse 
transcription and uncoating [67][68], demonstrating that suppressing reverse 
transcription delays uncoating. Alternatively, several CA mutations altering in 
vitro core stability generated fewer reverse transcripts, indicating that it was 
capsid stability that affected reverse transcription [65][69][70]. One theory behind 
this relationship is that the double-stranded reverse-transcription product forms a 
more rigid structure, which could provide an outward force to destabilise the core 
[67]. Thus, the viral core may act as a reaction chamber containing the 
necessary reagents just long enough for the completion of reverse transcription. 
Another hypothesis holds that at least partial uncoating is required to enable 
entry of the cellular factors (nucleic acid binding proteins, DNA repair and 
splicing factors) necessary for completion of reverse transcription [54][71][72]. 
However, the capsid lattice is reported to be an open structure containing inner-
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ring gaps of up to 10 nm which would allow, at the least, the entry of the cellular 
nucleotide triphosphates for reverse transcription [73]. 
 
1.4.4 Trafficking towards the nucleus 
HIV-1 capsid/p24 has also been reported to play a role in transporting the viral 
nucleoprotein towards the nucleus through the interaction with the host cell 
microtubules, hijacking the cytoskeletal networks to support their movement 
across the cell [44][74]. Various experiments have been employed to support this 
role, including disrupting microtubule mediated trafficking using nocodazole, and 
pharmacological or small interfering RNA (siRNA) inhibition of the dynein and 
kinesin-1 microtubule motor complexes which interact with the virus particles 
[75][76][77]. In vitro assembled HIV-1 CA-NC complexes were shown to directly 
interact with the kinesin-1 adaptor protein fasciculation and elongation factor zeta 
1 (FEZ1), which regulates movement towards the nucleus [76]. Fluorescently 
labelled capsid particles have also been visualised associating with the 
microtubule network, providing further evidence of a possible role in CA 
mediated cytoplasmic trafficking of HIV-1 particles [53][78]. 
 
1.4.5 Nuclear entry 
Nuclear pore complexes (NPC) are multiprotein channels that pepper the nuclear 
envelope and act as a selective barrier against infection from retroviruses unable 
to infect non-dividing cells, such as Murine leukaemia virus (MLV) [79][80][81]. 
HIV-1 is able to actively transport through the NPC of non-dividing cells by 
hijacking the cellular transport machinery [82][83][84]. Capsid was first identified 
as having a role in nuclear import when an HIV-1 chimera, in which the HIV-1 CA 
coding sequences were replaced with MLV, lost the ability to efficiently infect 
non-dividing cells [79]. Several genome-wide siRNA screenings identified a 
number of nuclear transport factors as potential cofactors in HIV-1 infection 
[54][56][58], with CypA, transportin 3 (TNPO3), CPSF6, and the nucleoporins 
Nup358 and Nup153 seeming to have a direct interaction with CA during nuclear 
translocation [85][86][87]. It is difficult to determine the significance of these CA-
mediated interactions as depletion of nuclear transport factors alters the structure 
and function of the NPC, leading to concerns that the knockdown effects were 
actually due to indirect consequences caused by perturbations of cellular activity 
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[85]. The role of CA in nuclear trafficking, however, is supported through studies 
using a number of CA mutants. For example, the CA mutants T45A/N57A and 
Q63A/Q67A exhibit cell cycle dependent infectivity responses as attested to by 
PCR quantification of two-long-terminal-repeat (2-LTR) circles, with cell cycle 
arrest leading to a decrease in infection after nuclear import with the T45A/N57A 
CA mutant, but before nuclear import with the Q63A/Q67A CA mutant [88][89]. 
Also, the N74D CA mutation was shown to be insensitive to the knockdown of 
TNPO3, Nup358 or Nup153 [90][91][92], and the G89V and P90A CA mutants 
were less sensitive than WT virus to Nup358 and Nup153 depletion 
[90][91][92][93]. 
 
1.4.6 Integration 
Evidence is growing that CA may also play a role in post-nuclear events, 
including integration [94]. HIV-1 preferentially targets clusters of active genes 
within gene dense regions of chromosomes [95]. Although lens epithelium-
derived growth factor (LEDGF/p75) is the predominant factor in directing 
integration within active gene bodies [96][97], knockdown studies have revealed 
that the nuclear factors TNPO3 and CPSF6, and the Nups 358 and 153 may 
have a part in targeting the gene dense regions of chromosomes 
[91][98][99][100][101][102]. Similar shifts in integration-site preferences have also 
been observed when using CA mutants, suggesting a post-nuclear entry 
targeting role for this protein. The HIV-1 CA cyclophilin-binding mutants G89V 
and P90A generally integrated in genomic regions with a higher density of 
transcription units compared to WT virus, whereas the N74D and N57A CA 
mutants, which are insensitive to Nup358 and TNPO3 depletion, favoured 
integration in genomic regions sparse in transcription units [91]. Inhibition of 
CypA-CA binding through the presence of cyclosporine A (CsA) led to integration 
of wild type (WT) virus in regions of higher transcription density, similar to that of 
the G89V and P90A binding mutants, suggesting that the CA-CypA association 
has a role in influencing nuclear import, and subsequently, site of integration [91]. 
Studies using the gyrase B targeting antibiotic Coumermcin-A1 (C-A1), which 
binds to hexameric CA in a binding pocket defined by two adjacent monomers, 
showed that C-A1 inhibits integration in a CA-dependent way, without affecting 
reverse transcription [103]. The N74A and A105S CA mutants negated the 
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restrictive capacity of CA-1, enabling normal integration. Further experiments 
using the tripartite motif-containing protein-cyclophilin (TRIM-Cyp)/CsA washout 
assay seemed to link integration-site selection with earlier CA uncoating events, 
influencing the cofactors the PIC associated with during nuclear translocation. 
 
Recent studies employing the knockdown of CPSF6, or the deletion of the CA 
binding domain of CPSF6, revealed an obstruction of HIV-1 integration within 
transcriptionally active gene-dense regions, intron-rich genes, and the specific 
location of integration within the genes [98][99]. Capsid staining revealed a 
similar location of CA within the nucleus for WT virus within CPSF6 depleted 
cells, to that of control cells infected with a N74A CA mutant virus which prevents 
binding with CPSF6 [99]. A preference for proviral integration at the periphery of 
the nucleus was also shown for WT type virus in CPSF6 depleted cells, and the 
CPSF6 non-binding CA mutants N74D and A105T in control cells. 
 
Collectively, these data indicate that TNPO3, Nups 153 and 358, and particularly 
CPSF6, play important roles in the regulation of sites of HIV-1 integration, and 
that CA is the component of the PIC most likely to interact with these proteins. 
 
1.5 Models of capsid uncoating 
Historically, capsid uncoating has been considered from a structural perspective, 
and is defined as the specific dissociation of the capsid shell from the viral core 
in the host cell cytoplasm [104]. However, based on recent demonstrations that 
CA influences late events including nuclear import and integration [92][98][99] 
[100][101][102][105], and has been visualised colocalised with IN within the 
nucleus [55][57], it is unlikely that CA loss from the RTC is a single, discrete 
event. Thus, some re-evaluation of the traditional definition of uncoating is 
required [44]. 
 
Although there is general agreement that uncoating occurs after fusion 
dependent entry into the cytoplasm and before nuclear entry, the field remains 
divided as to the precise moment and location at which this takes place, and the 
extent of capsid disassembly from the viral nucleoprotein complex (VNC) before 
nuclear translocation. One of the defining features of HIV-1 infection is its ability 
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to infect non-dividing cells [79], which necessarily incurs the translocation of the 
PIC from the cellular cytoplasm into the nucleus through the NPC. Studies have 
revealed that the upper size limit for passage within the NPC to be ~39 nm, 
which is considerably smaller than the 50-60 nm diameter of the wide end of the 
capsid cone [39][106][107], affirming the model of cytoplasmic capsid uncoating. 
 
Three main models of uncoating have been proposed (Fig. 5): 
 
i. A rapid core disassembly following cellular entry 
ii. A more gradual uncoating as the virus traverses the cytoplasm 
towards the nucleus 
iii. Uncoating at the nuclear pore 
 
i) Rapid uncoating 
With this model the capsid core disassembles close to the cellular membrane 
almost immediately following viral fusion (Fig. 5A). Although most of the capsid 
is described to disassociate from the VNC, this does not rule out the presence of 
a residual amount of CA remaining with the RTC/PIC after uncoating 
[17][108][109][110]. This model was proposed due to the absence of detectable 
CA when using biochemical means to study the content of the RTC [16][50]. This 
model, however, does not account for the cytosolic sensors that would be 
activated in the presence of viral cDNA PAMPs upon rapid core disassembly 
[60][61][63], or the loss of a closed environment to facilitate reverse transcription. 
 
ii) Gradual/biphasic uncoating 
This model proposes that the viral core remains intact for some time post-fusion, 
and that uncoating takes place gradually during passage towards the nucleus 
through interaction with cytoplasmic host cell factors and reverse transcription 
(Fig. 5B) [67][72][111]. Experiments using the intact capsid core targeting 
properties of TRIM-Cyp, and immunofluorescent imaging, support this model 
[53][67]. Loss of sensitivity to TRIM-Cyp binding was observed 3-4 h post-
infection, and approximately two thirds of RTCs were observed still containing 
detectable amounts of CA 4 h post-infection. Some authors suggest that the CA-
CA interactions that create the delicate lattice of the viral core would not tolerate 
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a gradual disassembly of CA and, like the rapid uncoating model, the cDNA 
would be exposed to cytosolic sensors [44][86]. However, cellular factors 
recruited to the RTC/PIC during capsid uncoating may be able to mask the 
nascent viral cDNA from antiviral innate immune detection [44]. 
 
iii) Uncoating at the nuclear pore 
A third model proposes that the capsid core remains intact during transport 
towards the nucleus, and uncoating takes place at the nuclear pore (Fig. 5C) 
[86]. In this model, premature uncoating is supressed through the interaction of 
CypA and CPSF6. Upon arrival at the NPC the capsid core binds to Nup358 and 
uncoating is triggered with the assistance of CA-associating factors (TNPO3, 
CypA and CPSF6), upon which the PIC is released and is translocated through 
the nuclear pore into the nucleus [86]. With this model the viral genome would be 
protected by the capsid core, thus excluding the triggering of the innate DNA 
sensor of cyclic GMP-AMP synthase (cGAS). This system is supported by work 
performed in MDMs which have been shown to be infected with WT HIV-1 
without triggering an innate immune response [60]. Capsid mutations, however, 
and HIV-1 infection in CPSF6 and CypA-depleted macrophages, which 
potentially generate the premature release of cDNA, activate an antiviral state 
within the cell. 
 
There is evidence based data supporting and opposing all of these models for 
capsid uncoating, and it may be that the real system contains aspects from each 
model. Uncoating may also vary depending on the cell type and the activation 
state of the cell at the time of infection [44]. Contemporary thinking seems to 
support a model of uncoating involving the initial loss of integrity of the intact 
core, leaving a residual amount of CA associated with the viral nucleoprotein for 
interaction with the host proteins [44]. 
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Figure 5. Illustrations depicting the principal models of HIV-1 capsid uncoating [44]. Three 
models of uncoating have been proposed, subjective to the methods deployed for analysis: A) 
Immediate uncoating of the entire capsid core directly after viral fusion with the cellular 
membrane; this model was supported by early biochemical studies [16][44]; B) Gradual/biphasic 
uncoating, in which a measurable amount of capsid disassembly occurs as the VNC traffics 
through the cytoplasm, with a portion of the capsid remaining to mediate nuclear docking and 
translocation. This model is supported by several imaging-based assays and the CsA washout 
assay [67][111]; (C) Uncoating at the NPC, in which the capsid core remains intact up until 
mooring at the nuclear pore, whereby uncoating is facilitated through interaction with Nups. With 
this model the viral dsDNA is shielded from cellular cytosolic sensors [60][63]. 
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1.6 Capsid uncoating – why study? 
Experiments studying CA mutations that affect the stability of the capsid core 
have shown a direct link with the timing of capsid uncoating and the subsequent 
infectivity of the virus [65][67][112]. This unique characteristic, along with the 
distinctive structure and nature of the individual CA proteins, makes the process 
of capsid uncoating a promising target for pharmaceutical intervention. The 
gregarious nature of CA, which associates with many cellular host factors during 
the early phase of HIV-1 infection, indicates that there are a large number of 
processes at which intervention can take place, and binding sites within the CA 
protein for small molecular compound interaction. The CA CypA-binding loop and 
a binding domain formed through the molecular interaction of helices 1, 2, 4 and 
7 of the CANTD, which have been shown to bind to host factors such as CypA, 
TNPO3, CPSF6, and Nups 358 and 153, have already been targeted by a 
number of small-molecule inhibitors [48]. 
 
CA is one of the most conserved proteins within HIV-1, with the MHR in the NTD 
and the zinger-finger motif in NC being the only sequences in Gag that show 
significant amino acid identity between divergent retrovirus genera [9]. The 
assembled HIV-1 capsids also exhibit remarkable structural homology between 
those of other retroviruses, despite an overall lack of sequence homology 
between these proteins [113][114]. This suggests that CA molecules between the 
genera have evolved to capacitate the delicate balance of functional burdens 
placed upon them. As such, they are likely to be stretched to the limit by the 
pressure to produce functional cores of optimal stability, which are still able to 
interact with the numerous host factors necessary for infection [44]. Thus, CA is 
unlikely to have the genetic flexibility employed by other HIV-1 proteins, such as 
RT and protease, for evolving resistance to restrictive compounds. 
 
The fragility of the CA core, as attested to by the numerous CA mutations 
affecting core stability [65][112], makes it an attractive target for therapeutic 
intervention at the early stage of infection, whereby it would be possible to 
activate intrinsic host defence pathways that induce production of type-1 
interferons and the ‘antiviral state’ [60]. This would enable manipulation of 
pathways that restrict or alter the sites of productive integration, and the 
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stimulation of an innate immunity that would both reduce viral infectivity and 
induce an antiviral immune response that would obstruct subsequent infection 
cycles [44]. Put together, the conserved structural nature of the capsid core, the 
large number of host factors with which CA interacts, and the tight relationship 
between infectivity and the kinetics of capsid disassembly, make the process of 
capsid uncoating an attractive target for antiviral drug action. 
 
1.7 Systems for studying uncoating 
Several in vivo and in vitro methods of studying uncoating have been employed 
over the years with varying levels of success. The highly conserved nature of the 
p24CA monomers, and fragility of the capsid core, make it very difficult to detect 
in pull-down assays, and to label without affecting the maturation and quaternary 
structure of the core. Many of the assays measure core stability and uncoating 
events in bulk viral samples and therefore would not exclude the analysis of 
defective particles. In the field of CA uncoating, the main techniques employed 
for studying this process can be grouped into four basic approaches [44]: 
 
1.7.1 In vitro core-stability and disassembly assay 
This method involves the isolation of HIV-1 cores from the viral supernatant by 
ultracentrifugation through a detergent layer (removing the viral membrane) into 
a sucrose gradient [65][115][116]. Pelleted capsid cores containing the viral RNA 
and associated proteins, but lacking the envelope proteins, can then be removed 
from the appropriate sucrose fraction. Disassociation of p24CA from the purified 
cores can then be measured by incubation at 37°C and further 
ultracentrifugation. This technique has provided valuable information regarding 
the stability and infectivity of capsid cores plus/minus mutations or following 
pharmacological treatment. However, the assay measures bulk core samples of 
which only a proportion may be infectious, and core stability in vitro does not 
necessarily reflect in vivo uncoating events [44]. 
 
18 
 
1.7.2 Fate of capsid assay 
In this system, lysates from infected cells are centrifuged through a sucrose 
cushion enabling the fractionation of intact capsids cores from soluble CA 
proteins and vesiculated virions [44]. Thus, the relative amounts of intact capsid 
cores over time following infection can be determined, through which an 
estimation of uncoating events can be calculated. This method has been used to 
measure the capsid core destabilisation and stabilisation properties of the 
restriction factors TRIM5α [117] and myxovirus-resistance 2 (Mx2) [118], 
respectively, and the effects of reverse transcription [68][119] and microtubule 
trafficking on capsid uncoating [75][120]. As with the in vitro core-stability assay, 
this method focuses on bulk populations of cores, of which only a small 
percentage may be infectious [44], and the stability of the core can be effected 
during processing. 
 
1.7.3 Cyclosporine A washout assay 
This assay takes advantage of the HIV-1 restriction properties of a TRIM-
cyclophilin A (TRIM-CypA) protein first described in Owl monkeys [121]. TRIM-
CypA binds intact capsid cores prior to the onset of uncoating and, by some as 
yet identified process, affects restriction leading to premature uncoating 
[122][123]. Binding of TRIM-CypA to the viral capsid can be blocked by the 
addition of CsA, allowing the core to go through the normal process of uncoating 
and infection. At various time points post-infection, CsA is washed from the cells 
allowing TRIM-CypA to resume restriction. Because TRIM-CypA binds to intact 
capsid cores, insensitivity to restriction is a good indicator for initiation of 
uncoating. The half-life of uncoating can be calculated by the time post-infection 
of CsA washout. Using GFP labelled viruses, infection can be measured by flow 
cytometry. Unlike the previous assays that measure the uncoating of bulk sample 
viruses, many of which may not be infective, this system measures the uncoating 
of infective viruses that have escaped TRIM-CypA restriction [44]. However, 
because uncoating is being indirectly measured by a capsid-binding restriction 
factor, it is possible that host factors may be competing with TRIM-CypA for a 
limited number of capsid binding sites [86]. 
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1.7.4 Imaging assays 
Many imaging-based techniques have been employed for the direct visualisation 
of uncoating through the use of fluorescently tagged capsid core components. 
The systems generally involve the fluorescent labelling of a cellular or viral 
component within the capsid core, such as Vpr, IN, an APOBEC3 protein or the 
viral genome itself, and the level of associated CA can be comparatively 
analysed by immunofluorescence using capsid-specific antibodies 
[53][57][67][111][124][125][126][127]. Microscopically based techniques enable 
the visualisation and analysis of individual virus particles within the spatial 
context of the cell, and various approaches have been used to track virions live 
over time. The labelling of p24CA protein can, however, disrupt the proteolytic 
processing and proper assembly of the viral cores, and the insertion of 
fluorophores into the Gag polyprotein can give rise to fluorescently labelled 
vesicles which are difficult to distinguish from true viral particles [127]. 
 
Despite the complications associated with studying capsid uncoating using 
imaging based assays, we turned to these techniques for our investigation of the 
process. This was because of the additional information that can be obtained 
through use of visual examination, which is often not possible when using other 
techniques, such as the dynamics of uncoating within the spatial-temporal 
localisation of the cell. 
 
The methods described above are a general outline of the main approaches 
used for studying capsid uncoating, and many novel adaptations have been 
employed with these methods, some of which will be described later [section 
1.9]. One of the main questions these assays attempt to answer is the precise 
timing of capsid uncoating, from which it may be possible to determine the 
specific factors (viral and cellular) that are involved in this process.  
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1.8 Factors affecting the kinetics of uncoating 
As described earlier [section 1.6], timely capsid uncoating is thought to be 
crucial for the productive infection of HIV-1 and therefore many factors affecting 
the kinetics of uncoating have been investigated, both for the better 
understanding of this process and for the establishment of new therapeutic 
strategies. These factors, in turn, have proved useful as controls for validating 
new assays for measuring uncoating. The main approaches used in the 
uncoating assays for influencing the kinetics of capsid disassembly include the 
use of CA mutations in the viruses used for transduction, restriction compounds, 
and the knockdown of host cell proteins; all of which either directly or indirectly 
effect the stability of the capsid core. 
 
1.8.1 Capsid mutations 
Many studies have been performed involving mutations in p24CA, as these have 
been found to have a knock-on effect on the stability of the viral core [65]. This, 
in turn, has been found to influence events in the early phase of the HIV-1 life 
cycle, including uncoating, the initiation or completion of reverse transcription, 
and viral infectivity [65][128]. CA mutations have also revealed insights into the 
interaction of the capsid core with specific cellular host factors, and have been 
shown to influence the pathway with which the PIC enters the nucleus and 
integrates [91][103]. Some of the CA mutations that have a significant effect on 
the dynamics of capsid uncoating are described below [65][112]. 
 
1.8.1.1 Mutations that effect the stability of the capsid core 
Many experiments conducted in vitro and in vivo have shown a pronounced 
effect of CA mutations on the stability of the viral core. In vitro, the CA mutations 
Q63A/67A caused the viral core to disassemble more rapidly than WT capsid, 
whilst the mutations E45A and R128A/R132A caused the capsid core to 
disassemble more slowly [65]. Similar uncoating kinetics have been observed in 
vivo, with the CA mutations E45A, T54A/N57A, N74D, E128A/R132A, 
E45A/R132A and 5Mut reported to delay uncoating, whereas the mutations 
A92E and K203A induced premature uncoating [67][89][103][111][124][129]. All 
the viruses containing mutations that altered the stability of the capsid core in 
vivo and in vitro exhibited a decrease in relative infectivity from 0 to 20% of that 
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compared to viruses containing WT cores [65][112]. Interestingly, the viruses 
containing CA mutant cores that disassembled with similar kinetics to the WT 
cores in vitro (Q4A, G116A, T119A, N139A and P207A) exhibited similar 
infectivity as the WT virus. These observations support a functional correlation 
between capsid uncoating and infectivity. The reason why a change in the 
stability of the capsid core should affect infectivity has not yet been established, 
but may be due to subsequent effects on reverse transcription, cellular trafficking 
along the microtubules, interactions with nuclear pore proteins, or even 
integration events. 
 
1.8.2 Restriction compounds 
Many studies have employed the use of restriction compounds to investigate the 
kinetics of HIV-1 uncoating. The CA protein is a popular choice for targeting with 
restriction compounds because it is the more conserved of the Gag-Pol proteins, 
the structural fragility of the core making it less likely that resistant forms will 
evolve. The cyclophilin-binding domain also provides a convenient pocket with 
which many of the small molecule inhibitors bind. The binding of these small 
molecules often brings about structural changes within the viral core, thereby 
increasing or decreasing its stability, which in turn effects its uncoating kinetics.  
 
1.8.2.1 Pfizer-3450074 (PF74) 
PF-3450074 was originally identified in a high-throughput screening assay as a 
small-molecule inhibitor of HIV-1 that targets the CA protein [47]. Structural 
analysis indicates that PF74 binds in a preformed pocket encompassing the 
NTD-CTD interface, binding with a higher affinity to intact CA hexamers than to 
the monomeric form [130]. Recent studies suggest that it has a multi-modal 
action for HIV-1 inhibition, interacting with host proteins CPSF6 and NUP153 at 
low doses (<5 µM) and CypA at high doses (≥5 µM) [131]. High concentrations of 
PF74 have been reported to destabilise the capsid core [111][115][130]. 
 
1.8.2.2 Ebselen 
Ebselen, an organoselenium compound, was identified as an inhibitor of CA 
dimerization in a high-throughput screening method based on time-resolved 
fluorescence energy transfer, using the CTD of HIV-1 [132]. Electrospray 
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ionisation mass spectrometry analysis revealed that ebselen covalently bound to 
the CTD of capsid, most likely through a selenylsulfide linkage with Cys198 and 
Cys218. A fate of capsid assay revealed an increase in pelletable capsid in the 
presence of ebselen [20 µM], suggesting a stabilisation of the capsid core and 
inhibition of capsid uncoating [132]. 
 
1.8.2.3 Boehringer-Ingelheim compounds 1 and 2 (BI-1/BI-2) 
BI-1/BI-2 are examples of a novel class of pyrrolopyrazolone HIV-1 inhibitors, 
identified in a phenotypic cell-based viral replication screening assay [45]. The 
compounds were demonstrated to directly bind within an ‘inhibitor binding pocket’ 
between CA helices 4, 5, and 7 on the surface of the CANTD, an area 
corresponding to the binding site for the host factors CPSF6 and Nup358. The 
compounds were shown to modestly stabilise purified HIV-1 cores in vitro, but BI-
2 did not alter the uncoating kinetics of HIV-1 in a CsA washout assay [55]. 
Further experiments suggest that BI-2 may exert its effect during the nuclear 
import of the PIC, by binding to residual CA particles still present after uncoating. 
 
1.8.2.4 Coumermycin-A1 
Coumermycin-A1 (C-A1) is an antibiotic that is predicted to bind to an extended 
binding pocket delineated by two adjacent capsid monomers within the capsid 
hexamer of a viral core [103]. A CsA washout assay in the presence of C-A1 
significantly reduced the period for which the capsid cores were sensitive to 
TRIM-CypA restriction, indicative of premature uncoating. 
 
1.8.2.5 Nevirapine 
Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1, 
which binds allosterically to the enzyme and blocks the RNA and DNA-
dependent DNA polymerase activities by disruption of the enzyme’s catalytic site 
[133]. It was discovered by Hargrave and co-workers at Boehringer Ingelheim 
Pharmaceuticals, Inc [134]. Binding of nevirapine leads to opening of the NNRTI-
binding pocket, which causes the 3’-end of the DNA primer to shift by ~5.5 Å 
from its polymerase active site position [133]. As a result, the interactions 
between DNA and the polymerase domain are reduced, the dNTP-binding site is 
deformed, and the RNase H active site is shifted with respect to the site of 
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polymerase activity. The inhibition of reverse transcription has been found to 
delay HIV-1 uncoating [55][67][135]. The relationship between reverse 
transcription and uncoating is unsure, but it is thought the transformation of the 
more flexible compact viral RNA genome into the more rigid double-stranded 
DNA extended structure may provide an outward force that destabilises the 
capsid core [67]. 
 
1.8.3 Protein knockdowns – CA interaction with host proteins 
Protein knockdown studies through the use of short interfering (siRNA) or short 
hairpin RNA (shRNA) have provided important information on the specific host 
cell proteins that interact with p24CA [54][56][58]. Using these approaches it has 
been possible to identify the effects of these proteins on the stability of the capsid 
core, and the knock-on effect of the timing of capsid uncoating on reverse 
transcription, nuclear entry and integration, and ultimately HIV-1 infectivity [87]. A 
few of the key host factors that have been reported to interact with CA, and 
therefore have a potential role in capsid uncoating, are listed below. 
 
1.8.3.1 Microtubules 
Microtubules are comprised of α/β-tubulin heteropolymers that form polarised 
filaments within the cellular cytoplasm, with the ‘minus-ends’ attached to the 
centrosome, the perinuclear microtubule-organising centre (MTOC) of the cell, 
and the ‘plus-ends’ extending towards the plasma membrane [136]. Specialised 
motor complexes bind the protein cargoes and traffic their movement along the 
microtubules, with the minus-end (retrograde) movement predominantly directed 
by dynein, whilst the plus-end (anterograde) motion is directed by kinesins [137]. 
Viruses have evolved a number of approaches for hijacking the cytoskeletal 
networks to support their movement across the cell [74]. HIV-1 RTCs have been 
shown to interact with both actin and the microtubule cytoskeleton, using the 
actin microfilaments for short-range transport towards the plasma membrane, 
and microtubule motors for more extensive intracellular movement 
[53][138][139][140][141][53]. Various studies have substantiated the movement 
of HIV-1 in a dynein-dependent manner along the microtubules to the nucleus, 
during which uncoating and reverse transcription take place [53][78][142]. In vitro 
assembled HIV-1 CA-NC complexes were also shown to interact with the 
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kinesin-1 adaptor protein FEZ1, which regulates HIV-1 movement towards the 
nucleus [76]. This study reported that both dynein and kinesin-1 were needed for 
viral transfer to the nucleus. Two studies have reported that microtubule 
disruption and knockdown of microtubule motors delays HIV-1 uncoating 
[75][120]. These observations have led to the suggestion that capsid uncoating 
may be mediated through the interaction between the opposing motor proteins 
dynein and kinesin-1, creating a ‘tug-of-war’ type effect [44]. 
 
1.8.3.2 Cyclophilin A 
Cyclophilin A (CypA) is a peptidyl prolyl isomerase that catalyses the cis-trans 
isomerisation of proline peptide (xaa-pro) bonds [143]. X-ray crystallography 
revealed that CypA binds via an extended loop (the cyclophilin-binding loop) 
which encompasses residues 85-93 within helices 4 and 5 of the NTD of CA 
[144]. CypA is packaged into HIV-1 virions during the late phase of infection 
through interactions with the CA domain of Gag, but its main role in HIV-1 
infection is recorded to be in target cells, and the previously packaged molecules 
do not appear to play a role in this [145][146][147]. In the mature capsid core the 
CypA-binding loop is exposed towards the external surface of the viral core 
enabling interaction with target cell CypA proteins. Cyclophilin A has been 
reported to catalyse the isomerisation of the Gly89-Pro90 peptide bond of CA, 
inducing conformational changes in the CANTD remote from the CypA-binding 
loop [148]. It has been speculated that this change may provide the mechanical 
force for the disassembly of the capsid core, but experimental data supporting 
this has been contradictory [44][149][150]. Through cryoEM structural elucidation 
of CypA in complex with the assembled HIV-1 capsid, a non-canonical, second 
CypA binding site was revealed, bridging two CA monomers from adjacent 
hexamers, thereby strengthening the lattice [151]. It was shown that sub-
stoichiometric amounts of CypA stabilise the capsid assembly, whereas high 
levels of CypA reduced capsid stability and promoted capsid disassembly [151]. 
These apparently contradictory observations can be explained by the steric 
hindrance induced between two CypA molecules when simultaneously binding to 
neighbouring CA hexamers at high concentrations, weakening the dimer 
assembly interface of an intact capsid core. This interaction may explain the 
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variations in uncoating times observed between different cell types that express 
different levels of CypA [147][152][153]. 
 
Cyclophilin A interaction with CA may also play a role in the pathway with which 
the PIC transverses the nuclear membrane, and the subsequent host genomic 
integration site, through interplay with Nups 358 and 153 [91]. Inhibition of CypA-
CA binding with CsA or the CA cyclophilin-binding domain mutants G89V and 
P90A [145][154][155], impairs subsequent PIC interactions with Nup358 and 
Nup153, resulting in proviral integration in areas with a high density of 
transcription units (less productive). 
 
1.8.3.3 Myxovirus-resistance B 
Myxovirus-resistance B (MxB/Mx2) is an IFN-inducible myxovirus resistance (Mx) 
protein belonging to the dynamin-like family of GTPases. Recently, MxB has 
been implicated in having potent inhibitory activity against HIV-1 infection 
[156][157][158][159]. HIV-1 viruses containing the capsid mutations P90A, G89V 
and N57S escaped MxB restriction, suggesting that capsid was the principle 
factor in MxB mediated interactions [157][158][159]. Myxovirus-resistance B was 
subsequently shown to interact with in vitro assembled CA-NC complexes [118]. 
Further investigation using a benzimidazole-based capsid-binding compound and 
domain mapping experiments, identified an MxB binding domain next to the base 
of the cyclophilin binding loop of CA [118]. The binding of MxB with the HIV-1 
core has been shown to inhibit capsid uncoating [118]. The function of MxB 
appears to be linked to CypA, as CypA depletion or disruption of CypA/CA 
interaction prevents MxB mediated restriction [159]. As yet the exact mechanism 
of HIV-1 inhibition by MxB is still under investigation, and may occur through 
restriction of uncoating, inhibition of nuclear import, or through perturbatory 
effects on proviral stability or integration [118][160]. 
 
1.8.3.4 Transportin3/transportin-SR2 
Transportin 3 (TNPO3) is a member of the karyopherin β superfamily of proteins, 
which bind serine/arginine (SR) rich proteins and governs their nuclear 
localisation [87][161][162]. It was first identified as a potential HIV-1 infection co-
factor in a number of genome-wide RNA interference screens [54][56][58], and 
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the subsequent depletion of TNPO3 in HIV-1 infected cells showed a reduction of 
infectivity [91][93]. A decrease in infectivity was not observed, however, when CA 
mutant viruses (N74D, E45A or Q63A/Q67A) were used to infect TNPO3 
depleted cells, providing the first link between CA and TNPO3 [90][150][163]. A 
study analysing viral DNA concentrations within the cytoplasmic and nuclear 
fractions of TNPO3 depleted cells, revealed an accumulation of HIV-1 DNA 
within the nucleus [150]. This, in line with various other experiments, provided 
evidence that TNPO3 was not required for HIV-1 entry into the nucleus 
[164][165], and therefore, the TNPO3-depleted restriction of infection occurred 
somewhere between nuclear entry and integration [150]. Wild type capsid (but 
not the N74D mutant capsid) was also shown to accumulate in the nuclei of 
TNPO3 depleted cells, indicating that TNPO3 may contribute to the removal of 
capsid from the nucleus [163]. TNPO3 has also been linked to HIV-1 capsid 
uncoating. The addition of recombinant TNPO3 to purified capsid cores in vitro 
has been shown to accelerate their disassembly [150]. Conversely, the N74D CA 
mutant reduced the effect of TNPO3 on HIV-1 uncoating. Cyclophilin A stabilised 
HIV-1 cores, however, seemed to antagonise this TNPO3-mediated uncoating 
effect. Taken together, this gave rise to the speculation that TNPO3 and CypA 
may interact in the coordinated control of HIV-1 uncoating [150]. 
 
Depletion of TNPO3 and/or infection with the TNPO3-independent capsid mutant 
viruses (E45A and N74D), has also been shown to alter the integration site of 
HIV-1 [90][93][101][150]. Recent models suggest that TNPO3 participates in the 
nuclear translocation and maturation of the PIC in a RanGTP dependent system, 
in which TNPO3 coordinates a series of steps where different host factors bind to 
and are released from the PIC in a regulated manner, until host genomic 
integration [44][87][94]. 
 
1.8.3.5 Cleavage and polyadenylation specificity factor 6 
Cleavage and polyadenylation specificity factor 6 (CPSF6) is an mRNA-
processing protein that dynamically shuttles between the cytoplasm and the 
nucleus [166]. Although active both within the nucleus and cytoplasm, a 
serine/arginine (SR)-rich nuclear localisation signal (NLS) on its C-terminus 
retains its predominantly nuclear localisation [44][57][167]. This protein has been 
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shown to attach to the binding-pocket formed through intermolecular interactions 
between the CANTD and CACTD of adjacent CA monomers [130][167][168]. An 
interaction between CPSF6 and CA has been reinforced by additional studies, 
which showed that cytoplasmic CPSF6 stabilised CA-NC tubes in vitro and viral 
cores in vivo [93][149]. Further evidence of CA interaction was supplied with a 
truncated murine form of CPSF6 lacking the SR-rich C-terminal domain 
(CPSF61-358), rendering it predominantly cytoplasmic in its localisation [90]. This 
mutant construct potently inhibited HIV-1 infection, but a N74D mutation in the 
CA rescued the virus from restriction. The C-terminally truncated form of CPSF6 
has also been reported to interact at a stage before reverse transcription, 
delaying both reverse transcription and uncoating [93][169][170]. 
 
It has also been proposed that CPSF6 binding to HIV-1 CA facilitates its use of 
nuclear import factors such as TNPO3, and this was backed up by studies 
showing that TNPO3-dependence of HIV-1 infection is correlated with the ability 
of CPSF6 to bind to CA [93][167][170]. Thus, it seems likely that the binding of 
CA with full length CPSF6 has a role in mediating the nuclear import of the RTC 
[44]. Two recent studies have revealed that CPSF6 may also play a role in HIV-1 
integration [98][99]. Knockdown of CPSF6 or deletion of the CA binding domain 
of CPSF6 led to proviral integration in less gene dense and transcriptionally 
active regions of the chromosome, towards the periphery of the nucleus. 
Infection of control cells with the CPSF6 non-binding CA mutants N74D and 
A105T revealed a similar predilection in the location of proviral integration, and a 
matching CA orientation was revealed by immunostaining; thus suggesting that 
CSPF6 mediated PIC navigation was implemented by CA binding. 
 
1.8.3.6 Nucleoporins 
Genome-wide RNA interference screening identified a number of nucleoporins 
as potential nuclear transport factors for HIV-1 infection [54][56][58]. Of these, 
Nup358 and Nup153 have been the most extensively investigated in relation to 
HIV-1 nuclear translocation. The CA binding motifs of these Nups have led to the 
speculation that these proteins may also play a role in late phase capsid 
uncoating at the nuclear pore [86][91]. 
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Nucleoporin 358 is a large 3224 aa protein that forms cytoplasmic filaments 
extending from the NPC into the cellular cytoplasm. These filaments possess 
phenylalanine/glycine repeat motifs that actively regulate the traffic of molecules 
~40 kDa through the nuclear pore [171][172]. A CypA homology domain is 
located at the C-terminus of Nup358, which binds to the NTD domain of CA, with 
a slightly weaker affinity than CypA [173][174][175], although NMRZZ-exchange 
spectroscopy indicates that Nup358 catalyses a more rapid cis/trans 
isomerisation of the G89-P90 bond than CypA [160][175]. This has led to the 
speculation that Nup358 may have a role in CA uncoating [86][91]. Nup358 
depletion reduced HIV-1 infectivity three to eightfold [91][176][177]. 
Contrastingly, the CA mutants N57A, N74D, P90A and G89V have been shown 
to infect host cells independently of Nup358, and have been shown to retarget 
integration within different gene dense regions of the chromosome, suggesting a 
role for Nup358 in the CA associated guiding of proviral integration 
[91][101][178]. 
 
Nucleoporin 153 is 1475 aa protein which is found anchored to the rim of the 
nuclear side of NPC by its N-terminal domain [179]. Its highly flexible CTD 
consists of Phe/Gly (FG)-repeats which can traverse the nuclear basket towards 
the cytoplasmic side of the NPC, where it plays a large role in nucleocytoplasmic 
transport [180][181][182]. Nup153 has been shown to bind directly with CA within 
a site that overlaps the region at which PF74 and BI-2 bind [105]. This protein 
has been shown to interact with WT CA and the N74D CA mutant, although the 
CA binding mutants G89V, P90A and N74D are less sensitive to Nup153 
knockdown compared to WT CA [91][90][92][93][100][105]. Depletion of Nup153, 
also significantly reduced viral cDNA integration within gene dense regions of 
chromatin [102]. 
 
The large number of CA mutations, restriction compounds, host cell (and viral) 
proteins that have been shown to affect the stability of the capsid core, and in 
turn modulate the timing and thus cellular location of capsid uncoating, attests to 
the complexity of this process. Collectively, these accounts suggest a specific 
and structured interplay between the CA/capsid and viral/host cell proteins which 
is crucial for the productive infection of HIV-1. The capsid binding properties of 
the host factors localised within different regions of the cell, also suggests that 
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CA is involved in many parts of the early phase of HIV-1 infection, such as 
reverse transcription, nuclear entry, and viral integration. This raises important 
questions to our understanding of the definition of capsid uncoating, and 
suggests that at least a portion of capsid proteins remain with the RTC/PIC for 
interaction with host factors within the nucleus. 
 
1.9 The role of imaging methods in studying uncoating 
Much attention has been paid to the studying of capsid uncoating, and many 
methods employed for studying this process, but this particular area of the HIV-1 
life cycle still remains an enigma. This may be, in part, due to the many different 
and novel techniques that have been used for investigating this process, which 
may focus on distinct aspects of capsid uncoating. With many of the biochemical 
methods for analysing the RTC/PIC failing to detect CA proteins associated with 
these complexes, we decided to focus more on the imaging based systems for 
investigating uncoating. As such, it is worth exploring these systems in further 
detail, with particular reference to some of the more innovative approaches that 
have expounded our knowledge of this process. 
 
1.9.1 Imaging within living cells – Vpr-GFP 
The observation of HIV-1 in living cells was first made possible by hijacking one 
of its accessory proteins for incorporation of a fluorescently labelled protein 
within a budding virion [53]. A GFP fluorophore was fused to the NH2-terminus of 
Viral protein r (Vpr), which is incorporated into newly assembling viruses through 
interaction with the p6 region of Gag [183][184]. Approximately, 100 to 200 Vpr 
molecules are incorporated into each virus during conventional viral assembly, 
and even more so when Vpr is overexpressed during DNA transfection 
[185][186]. Using this system, it was possible to visualise GFP-labelled viral 
particles accumulating around the nucleus in close proximity with the 
microtubule-organising centre [53]. Virus particles were also observed 
associating and trafficking along microtubules in a dynein dependent manner. 
Lastly, the Vpr-GFP labelled viruses were observed colocalised with significant 
amounts of immunostained CA particles, providing the first evidence of CA 
associating with a reverse transcribing complex. Although the direct fusion of 
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fluorophores to Vpr still remains a valuable system for studying HIV-1 
intracellular interactions, there is speculation as to whether some of these 
particles are non-specifically endocytosed particles rather than productively 
fused viruses [187]. 
 
1.9.2 Fluorescently labelled integrase 
One of the issues perceived with fluorescently labelled Vpr was that it could not 
be observed within the nucleus, thereby limiting the portion of the HIV-1 life cycle 
that can be observed with this system [187]. However, the period for intra-cellular 
viral visualisation was extended to include post-nuclear entry steps by using 
various techniques for labelling the HIV-1 IN protein. One system involved the 
insertion of a small tetracysteine tag within IN, which could be visualised through 
the addition of the fluorescein arsenical hairpin (FlasH) [78]. Fluorescein 
arsenical hairpin is a non-fluorescent compound when complexed with 
ethanedithiol (EDT), but becomes fluorescent upon binding to tetracysteine 
motifs [188][189][190]. This, along with the small size of the tetracysteine tag 
making it less prone to disrupting the structure and function of the protein into 
which it is inserted, made it an attractive candidate for intra-cellular imaging. This 
system enabled the observation of viral kinetics during trafficking towards the 
nucleus, including a decreased mobility attributed to peri-nuclear docking, and 
the more restrained diffuse movements within the nucleus itself [78]. However, 
this system was complicated with non-specific binding to endogenous cysteine-
rich proteins, and low sensitivity within the nucleus, possibly due to the fixed 
analysis time required for its functioning [125]. 
 
An alternative system for tracking the VNC up to and including nuclear 
translocation employed the use of a fluorescently labelled IN protein [125]. An 
Enhanced GFP (EGFP) fluorophore was fused to the C-terminus of codon 
optimised IN, and the resultant IN-EGFP fusion protein subsequently fused to the 
C-terminus of Vpr for trans-incorporation into assembling viral particles via 
interaction with Gag p6. An HIV-1 sensitive proteolytic site was introduced 
between Vpr and IN-EGFP, to enable separation of the proteins during viral 
maturation, so that the IN-EGFP molecule could effectively catalyse integration. 
By exploiting the Vpr/p6 interaction for incorporation of labelled IN, this system 
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effectively avoided the reduced infectivity levels usually observed with the 
introduction of a large fluorescent tag within the viral genome [125]. Using this 
construct in conjunction with nuclear lamina staining, it was possible to establish 
the time point for peak PIC association within the nucleus (6 h post-infection), 
and the preferential distribution of PICs at the periphery of the nucleus within 
actively transcribed genes in the decondensed areas of chromatin. The Vpr-IN 
system of incorporating a moiety within the capsid core was used in all three of 
the systems we developed for studying capsid uncoating. 
 
1.9.3 Cyclosporine A washout and internalised GFP (iGFP) 
As described above (section 1.7.3), the CsA washout assay uses the CA 
specific restricting properties of TRIM-CypA, along with a GFP labelled HIV-1 
proviral clone (R7ΔenvGFP) [67]. This clone contains a GFP-coding sequence in 
place of the Nef-coding sequences, providing a fluorescent marker for 
quantitation of viral infection [191]. By blocking the TRIM-CypA mediated 
restriction of intact capsid cores using CsA, Hulme and co-workers determined a 
50% uncoating time for HIV-1 of approximately 39 min post-infection [67]. In the 
presence of nevirapine, the half-time of uncoating time was increased to 112 min 
post-infection. The same group concurrently performed experiments using Vpr-
GFP and immunostaining for p24CA as an alternative method for measuring 
uncoating. A 50% uncoating time between 1 and 2 h was recorded with a non-
capsid mutated virus, and earlier and delayed uncoating was observed with less 
stable (K203A) and more stable (E128A/R132A) capsid mutants, respectively 
[65][67]. The use of a fluorescently labelled membrane targeting protein, S15-
mCherry, enabled the differentiation between productively entered and 
endocytosed viral particles [192]. 
 
Interestingly, a difference in the half-time of uncoating time was also detected in 
this study when pseudotyping with different viral envelopes [67]. An average 50% 
uncoating time of ~39 min and ~74 min was observed when pseudotyping with 
vesicular stomatitis virus G (VSV-G) protein or with WT HIV-1 envelope, 
respectively. Using fusion inhibitors, a half-time of ~16 min was determined for 
VSV-G and ~48 min for HIV-envelope mediated fusion, suggesting that the 
differences in uncoating times could be attributed to viral fusion pathways. 
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Hulme and co-workers also used a fluorescent based system for determining 
capsid integrity [55]. This consisted of a GFP molecule flanked by proteolytic 
cleavage sites, cloned between the MA and CA sequences of Gag – designated 
internalised GFP (iGFP). Upon viral maturation, GFP is cleaved out of Gag, and 
a subset is retained within the capsid core, which can be used as a marker of 
capsid integrity. A CsA washout assay determined that HIV-1 remained 
susceptible to the action of two capsid binding drugs (PF74 and BI2) for hours 
after initial uncoating, suggesting that a residual amount of CA remained with the 
VNC after the loss of the capsid core [55]. However, addition of these 
compounds had no effect on capsid integrity as determined by iGFP, suggesting 
that PF74 and BI2 do not effect uncoating, but a CA associated step at a later 
step in viral replication. 
 
1.9.4 Evidence of a biphasic model of capsid uncoating 
Xu and co-workers employed the use of ‘click labelling’ for the tracking of viral 
RNA and monitoring of the associative capsid uncoating events [111]. This 
system involved the incorporation of the modified nucleoside, 5-ethynyl uridine 
(EU), into viral RNA during virus production, and the subsequent detection 
through microinjection of an azide-containing fluorescent dye. Uncoating was 
determined by when the fluorescent dye could enter the core and bind to the EU 
labelled RNA, allowing detection by confocal microscopy. This study showed an 
initial increase in fluorescently labelled viral RNA 15 to 45 minutes post-infection, 
suggestive of an early uncoating phase soon after viral fusion. This was followed 
by a steady, reproducible loss of viral RNA detection consistent with uncoating 
and the instability of RNA within the cellular cytosol. The kinetics could be altered 
through the introduction of PF74, and CA mutants known to affect the stability of 
the capsid core. Interestingly, the inhibition of reverse transcription did not affect 
the early events of HIV-1 capsid uncoating. Also, studies using the E45A CA 
mutation (creating a more stable capsid core in biochemical assays [65]) showed 
an initial early uncoating phase, followed by an independent more gradual 
disassociation of CA from the VNC. In conjunction with findings from the 
biochemical assay [65], this lead to the hypothesis that capsid uncoating was a 
biphasic process: an early uncoating step allowing entry of cellular factors 
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necessary for reverse transcription, and a subsequent more gradual disassembly 
to prevent disassociation of key components from the RTC. 
 
1.9.5 Live imaging of HIV-1 uncoating 
Recently, a group has managed to track the uncoating of individual HIV-1 
particles over time using live microscopy [127]. This was accomplished through 
the labelling of a known capsid-targeting cellular protein, CypA, with a tetrameric 
DsRed fluorescent protein. The oligomerisation properties of the DsRed protein, 
in turn drove the oligomerisation of CypA, enabling its high affinity binding to the 
capsid core. Various experiments determined that the loss of the CypA-DsRed 
fusion protein from superfolder GFP (sfGFP) labelled IN was concomitant with 
that of capsid, suggesting it to be an effective tool for studying live uncoating 
events. Using this system, the group was able to determine that the majority of 
cores uncoated relatively early after fusion (~23 min post-infection), but a small 
proportion of VNCs retained their capsid cores for a few hours after infection. 
Analysis of the CypA-DsRed capsid labelling system in the presence of 
nevirapine and BI-2, and with the K203A CA destabilising mutant, revealed 
uncoating kinetics similar to that reported by Hulme and co-workers [67]. 
Interestingly, the E45A CA mutation reported to stabilise the capsid core in vitro 
[65], had little effect on the uncoating dynamics in vivo. However, a moderate 
affect in capsid uncoating was detected with the addition of PF74.  
 
1.9.6 Capsid within the nucleus 
Two groups have recently reported the visualisation of CA colocalised with IN 
PIC within the nucleus of infected cells [55][57]. As described above (section 
1.9.3), the effects of the CA binding compounds PF74 and BI-2 on later stages of 
viral infectivity led Hulme and co-workers to suspect that a residual amount of CA 
remained with the VNC after ‘uncoating’ [55]. CA associated PICs were 
subsequently identified within the nucleus via high-resolution structured 
illumination microscopy (SIM), using GFP labelled IN viral complexes stained for 
p24CA. An average ~6-fold lower level of CA intensity was detected in viral 
complexes localising within the nucleus compared with those present at the peri-
nuclear membrane or cytoplasm, indicating a measure of CA loss during nuclear 
import [55]. Peng and co-workers also managed to detect CA colocalised PICs in 
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the nuclei of primary MDMs, again using GFP labelled IN stained with p24CA, and 
super-resolution microscopy [57]. Almost all (97%) of PICs were positive for CA 
in MDMs, however, CA was absent from all but one nuclear PIC in a HeLa 
derived (TZM-bl) cell line. This contrasts with their observations preceding 
nuclear translocation, where almost all the VNCs associated with CA in the TZM-
bl cells and less than half associated with CA in the MDMs. The authors 
speculate that the CA negative viral complexes within the cytoplasm of MDMs 
represent dead end products, which possibly contribute to the strong antiviral 
state reported with HIV-1 infected MDMs [60]; and that capsid or a capsid-
derived structure remains associated with the VNC during reverse transcription 
and nuclear import, at least in the case of MDMs. The lack of CA associated 
PICs in the nucleus of TZM-bl cells may indicate a more rapid loss of CA prior to 
or after nuclear import with these cells compared to MDMs [57], although it may 
also be due to lack of sensitivity of the CA staining method employed in this 
study [55]. 
 
The above studies (section 1.9) seem to suggest an uncoating model which 
includes an initial uncoating phase, or the uncoating of a large fraction of the 
capsid cores, early after (10-45 min) fusion with the cellular membrane with VSV-
G pseudotyped viral particles. This is then followed by a more gradual 
disassembly phase, with a portion of the capsid core remaining with the VNC up 
to and including nuclear translocation. To assist in the further elucidation of this 
process of capsid uncoating, we employed the use of a few recently developed 
novel labelling strategies, which will be examined in further detail below. 
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1.10 Novel labelling systems 
Many systems have been developed over the years to enhance the labelling and 
studying of host cell interactions in situ, which have recently led to the long-term 
imaging of single proteins within living cells [193]. Some of the latest 
developments, which have been employed in this study, will be described below. 
 
1.10.1 Intra-capsid core labelling using APOBEC3F and G 
Recent work by Burdick and co-workers 2013, describes how they managed to 
label HIV-1 PICs using apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC) proteins APOBEC3F (A3F) and APOBEC3G (A3G) 
fused to yellow fluorescent protein (YFP) [124]. These catalytic proteins belong 
to a family of DNA cytidine deaminases, inhibiting viral replication in Vif protein 
deficient HIV-1 by inducing G-to-A hypermutation, blocking viral DNA synthesis 
and impeding viral DNA integration [194]. The incorporation of A3F and A3G into 
the capsid of Vif-deficient virions is reported to occur through the non-
discriminate binding of RNA during viral assembly [195]. Minus-strand DNA is the 
target for both A3F and A3G-mediated cytidine deamination, although A3G 
obstructs the removal of the tRNA primer forming an aberrant viral DNA end, 
whereas A3F specifically inhibits the 3’ processing reaction catalysed by IN 
[196]. As such, both A3F and A3G are likely to remain associated with the PIC 
during DNA synthesis, although the dsDNA targeting properties of A3F suggest a 
longer affiliation [124]. Although a fivefold reduction of viral infectivity was 
recorded with A3F and a cytidine deficient E25Q A3G mutant (A3G*), 
approximately 60-84% of the virions produced were labelled with these proteins, 
and A3F, and to a lesser extent A3G*, were observed associated with the PIC up 
to and including nuclear entry. Using this system in combination with 
fluorescence in situ hybridization (FISH), a reverse transcriptase mutant (D110E) 
and the addition of nevirapine, the authors could detect A3F-YFP signals 
colocalised with HIV-1 RNA within the nucleus of infected cells, showing that 
inhibition of RT had no impact on the nuclear import of HIV-1 PICs. Previous 
studies have suggested a link between RT and capsid uncoating [67], but these 
findings indicate that the viral uncoating that is associated with RT is not required 
for nuclear import. Two mutations that render the capsid core less (K203A) or 
more (E128A/R132A) stable were tested with this system. Although only a 
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twofold decrease in cytoplasmic A3F-YFP particles was recorded after 6 h 
compared to WT virus (non-mutated CA), a 54- and 13-fold decrease in nuclear 
PICs were observed with the K203A and E128A/R132A capsid mutants, 
respectively. 
 
1.10.2 SUperNova Tagging (SunTag) 
Recently, a novel protein tagging system has been developed enabling 
amplification of a signal to the extent by which single protein molecules can be 
observed within living cells [193]. This method utilises single-chain variable 
fragment (scFv) antibodies, in which the light and heavy chains of the epitope-
binding regions of the antibody are fused to form a single polypeptide, allowing 
successful expression in soluble form within cells. This is used in conjunction 
with a short peptide epitope, EELLSKNYHLENEVARLKK, derived from the 
transcription activator GCN4 (endogenously expressed in the budding yeast 
Saccharomyces cerevisiae) with which the scFv binds tightly [197]. Superfolder 
GFP was used as the reporter fused to the scFv antibody (scFv-sfGFP), as a 
reduced amount of protein aggregation was observed with this compared to 
when using other fluorophores [198]. The addition of a small solubility tag (GB1) 
to the C-terminal domain of sfGFP, effectively eliminated protein aggregation, 
even at high expression levels [193][199]. The addition of short flexible linkers 
(GGSGG) between repeat peptide epitopes enabled saturation of the epitopes 
without steric hindrance from competing antibodies. Using this system, it was 
possible to design a scaffold containing up to 24 repeats of the GCN4 epitope 
allowing full occupancy of the scFv-sfGFP fused antibodies (Fig. 6). Because of 
the brightness of a fully saturated peptide scaffold, the tagging system was 
named SUperNova (SunTag) after the extremely bright stellar explosions. The 
authors managed to successfully use this system for single molecule imaging 
and tracking, and for measuring the movements of cytoskeletal motors in vivo. 
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Figure 6. SUperNova SunTag system of signal amplification. Peptide epitopes flanked by 
short flexible linkers are fused together to form a ‘scaffold’, comprising up to 24 of these peptide 
epitopes, which can be fused to a target protein. Each epitope can be sterically bound by 
fluorescently labelled single chain variable fragment (scFv) antibodies, facilitating extensive 
signal amplification and in situ single molecule tracking [193]. 
 
There are many positive features associated with this labelling system. The 
brightness of the SunTag enables visualisation of single molecules with low 
expression levels, and imaging of organelles and molecules with lower laser 
intensities, reducing the phototoxicity and bleaching effects associated with 
longer-term imaging. Another advantage of indirect labelling compared to 
traditional methods (i.e. fusing the peptide epitope, instead of a fluorophore, 
directly to the target protein) is that signal intensity can be increased without the 
addition of extra fluorophores, which can affect the tertiary structure of the 
resultant protein. However, the large size of a fully saturated 24x repeat array 
(~1.4 mDa) gives rise to a slower diffusion kinetic through the plasma membrane 
(0.76 µm2/s) compared to an averaged sized protein labelled with a single GFP 
(~20 µm2/s) [193].  
 
1.10.3 NanoBit 
Protein-fragment complementation assays are commonly used for investigating 
the complex interactions that occur within the cellular microenvironment. These 
systems consist of a split reporter molecule, whereby the individual fragments 
display little reporter activity separately, but regain activity when re-assembled 
through the interaction of the molecules to which they are fused. Assays using 
split luciferases are often favoured over fluorescent based systems for cellular 
investigation, due to their sensitivity, simplicity and the instantaneous reporter 
activity generated with addition of substrate to the growth medium. NanoLuc is a 
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small (19 kDa), stable engineered luciferase obtained from the deep sea shrimp 
Oplophorus gracilirostris, which is capable of producing bright and sustained 
luminescence within intracellular systems [200]. Circularly permutated variants 
were created in a method to identify the optimal dissection point within NanoLuc 
for the production of a split reporter, resulting in an 18 kDa polypeptide (Large 
BiT) and 1.3 kDa (11 aa) peptide (Small BiT) with luminesce properties similar to 
that of NanoLuc (Fig. 7) [201]. The system was further enhanced through the 
structural optimisation of the individual fragments. Further analysis ascertaining 
the interaction aﬃnities and kinetics of the fragments for effective use in protein 
complementation assays determined an intrinsic affinity (equilibrium and 
dissociation constant - KD) of 190 µM, and association constants of 500 M-1 s-1 
Kon, and 0.2 s-1 Koff; outside the range for protein interaction [201]. 
 
 
 
 
 
Figure 7. Model of the two subunit NanoBiT split luciferase enzyme. The NanoBiT is a 
structurally engineered luciferase, derived from the deep-sea shrimp, capable of bright and 
sustained luminescence within intracellular systems. Further engineering led to the production of 
an 11 aa peptide with an affinity (KD) for the large fragment of 700 pM, making it ideal for use in 
determining primary uncoating stages. 
 
Further modifications on the small bit peptide resulted in its increased affinity for 
the large bit polypeptide, subsequently termed the HiBiT (Promega). The small 
size (11 aa) of the peptide and the spontaneous bright luminesce achieved 
through fragment complementation, make it an attractive tool for use as a 
molecular marker of intracellular events; although as it has only recently been 
developed the effectiveness of this system has yet to be evaluated.  
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We employed the use of the SUperNova tagging (SunTag) and protein-fragment 
complementation (NanoBiT) systems, in conjunction with Vpr-IN and 
APOBEC3F/G* capsid trans-incorporation, in the development of two novel 
assays for studying HIV-1 capsid uncoating. 
 
1.11 Summary 
The above account suggests that CA, and the structure of the capsid core, have 
an intrinsic role in many parts of the early phase of the HIV-1 replication cycle, 
and it is an area that still requires a lot of investigation for the clarification of 
these roles. The large number of systems and methods that have been deployed 
for studying capsid uncoating attest to both the importance with which this 
process is held, and the difficulties associated in the investigation of this event. 
The link between the actual process of uncoating and effective viral genomic 
integration seems to play a key part in HIV-1 infection, and therefore the 
development of authentic systems for the elucidation of this relationship is 
essential. Understanding this process could lead to the development of new 
therapeutic approaches for targeting this infection which, due to the conserved 
nature of the assembled capsid structure, would be less subject to the 
development of resistant mutants. 
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METHODS 
2.1 Cell lines 
HeLa P4 cells stably expressing CD4 were a kind gift from Dr. Zeger Debyser, 
(University of Leuven). HEK293T and U-2 OS cells were purchased from the 
American type culture collection ATCC. TZM-bl cells were a kind gift from (Dr. 
Massimo Pizzato (CIBIO, University of Trento). All cell lines were maintained at 
37ºC and 5% CO2 and were cultured in Dulbecco's Modified Eagle medium 
(DMEM) (GIBCO, Thermo Fisher Scientific) supplemented with 10% Fetal 
Bovine Serum (GIBCO, Thermo Fisher Scientific), 2% Glutamine (GIBCO, 
Thermo Fisher Scientific) and 100 units penicillin/streptomycin (GIBCO, Thermo 
Fisher Scientific), henceforth termed as DMEM complete. 
 
2.1.1 Stable cell lines: 
2.1.2 ScFv-sfGFP: 
Stable clones expressing the single-chain variable fragment antibody fused to 
superfolder GFP (scFv-sfGFP) ± a nuclear localisation signal (NLS) were 
prepared to use in conjunction with the GCN4 SunTag peptide. The scFv-sfGFP 
fluorescent antibody was digested from the pHR-scFv-GCN4-sfGFP-GB1-±NLS 
plasmid (Addgene) using NheI and NotI and ligated into the XbaI and NotI 
restriction sites of the puromycin resistant pAIP transfer vector, and viruses 
prepared by pseudotyping with VSV-G (10 µg: 3.5 µg). HEK293T, HeLa P4 
(including TZM-bl 126/322 stable clones) and U-2 OS cell lines were transduced 
with 1 to 4 reverse transcription units (RTU) of pAIP-scFv-sfGFP + VSV-G. 
Stable clones were produced by limiting dilution, puromycin selection (1 µg/ml in 
293T, U-2 OS cells and HeLa P4 cells, the TZM-bl 126/322  cells were already 
puromycin resistant) and visual selection of scFv-sfGFP production under a 
fluorescent microscope. Cells expressing a lower intensity of sfGFP in the 
nucleus or cytoplasm were selected as too much background made it difficult to 
distinguish the scFv-sfGFP antibody bound to the GCN4 peptide repeat arrays. 
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2.1.3 LgBiT 
The LgBiT was PCR amplified from the pBiT1.1-C [TK/LgBiT] vector (Promega) 
with BamHI and EcoRI restriction sites to enable ligation into the blasticidin 
resistant proviral vector pAIB (pAIB-LgBiT): 
 
(BamHI)LgBiT fwd: 5’-ATTAGGATCCACCATGGTCTTCACACTCGAAGATTTCG-3’  
(EcoRI)LgBiT rev: 5’-TAATGAATTCTTAGCTGTTGATGGTTACTCGG-3’ 
 
HeLa P4 cells were transduced with 1 to 4 RTU of pAIB-LgBiT and selected 
using 6 µg/mL Blasticidin. Stable clones were produced by limiting dilution. 
 
2.1.4 TRIM-CypA 
TZM-bl cells stably expressing TRIM-CypA (TZM-bl 322) or a mutated 
inactivated form (TZM-bl 126) were kindly supplied by Massimo Pizzato (CIBIO, 
University of Trento), and kept under selection using DMEM complete 
supplemented with 2 μg/mL puromycin (GIBCO, Thermo Fisher Scientific). 
 
2.2 Virus production 
Vectors were produced using the viral protein R (Vpr) and envelope (Env) 
mutated molecular clone pNL4-3.Luc.R-E- (pNL4-3) [10 µg] and either the 
vesicular stomatitis virus envelope glycoprotein (VSV-G) [3.5 µg] or the WT 
HXB2 envelope [4 µg] (NIH AIDS Research and Reference Reagent program). 
 
Transfection was performed using polyethylenimine (PEI) reagent (Sigma). 
Briefly, 10-cm-diameter culture dishes were seeded with 3.5 x 106 HEK293T 
cells and grown to approximately 90% confluency. Plasmid DNA was added to 1 
mL DMEM (minus supplements) and 45 μL PEI, vortexed briefly, and incubated 
at RT for 10 min. Culture media on the HEK293T cells was replaced with 5 mL 
Opti-MEM Reduced Serum Media (GIBCO, Thermo Fisher Scientific) and the 
DNA/PEI mixture added drop-wise. Plates were incubated for a minimum of 7 h 
before the media was replaced with 10 mL DMEM plus supplements and the 
plates re-incubated. Virus containing supernatant was collected at ≥36 h post 
media change, centrifuged at 500 x g for 5 min to remove cellular debris, passed 
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through 0.45 μM pore size syringe filters (Sarstedt), aliquoted into 1 mL 
microfuge tubes and stored at -80°C. 
 
2.3 Virus quantification 
Quantification of HIV-1 was achieved through measurement of reverse 
transcriptase activity by real-time PCR or through antibody detection of the p24CA 
protein. 
 
Measurement of reverse transcription activity was performed using the SYBR 
Green (SG) I qPCR-based product-enhanced RT (PERT) assay (SG-PERT) 
[202][203]. Briefly, 5 μL of cell-free virus was mixed with 5 µL of 2x concentrated 
lysis buffer (0.25% Triton X-100, 50 mM KCl, 100 mM Tris-HCl pH7.4, 40% 
glycerol) centrifuged at 10,000 x g for 10 min at RT and diluted up to 1 mL with 
1x core buffer (50 mM (NH4)2SO4, 20 mM KCL, 20 mM Tris-HCL pH 8.3). Ten 
microlitres of PERT master mix (5 mM (NH4)2SO4, 200 mM KCL, 200 mM Tris-
HCL pH 8.3, 10 mM MgCl2, 0.2 mg/ml BSA, 1/10,000 SYBR Green I, 400 μM 
dNTPs, 1 μM each of forward 5’-TCCTGCTCAACTTCCTGTC-GAG-‘3 and reverse 5’-
CACAGGTCAAACCTCCTAGGAATG-3’ primer, 7 pM/ml MS2 RNA) was aliquoted into 
a 96-well PCR plates along with 10 µL of the sample and centrifuged briefly. 
PCR amplification was performed using a Bio-RAD C1000 Thermo Cycler using 
the following parameters:  
 
Temp (°C) Time (min) Cycles  
42 20:00  Reverse transcription 
95 2:00  Hot-start Taq activation 
95 0:05 
x39 
Denaturation 
55 0:05 Annealing 
72 0:15 Extension 
82 0:05 Acquisition 
65  
to 
95 
0:05  
Melting analysis 
 
Fluorescence acquisition was recorded at the end annealing phase. Cycles of 
quantification (Cq) were analysed using Bio-Rad CFX Manager 3.0 software and 
RTU values extrapolated from a standard curve of MS2 bacteriophage RNA 
(Sigma-Aldrich). 
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Capsid protein quantification was achieved using the Immunodeficiency Virus 
type-1 p24CA protein (high sensitivity) AlphaLISA detection kit per the 
manufacturers standard protocol (PerkinElmer). 
 
2.4 Infectivity assay 
HEK 293T cells were seeded at 6.0 x 104 cells/well in 24-well cell culture plates 
(Eppendorf) and incubated at 37°C for 24 h. Culture media was replaced with 1 
mL of 1 RTU/mL viral supernatant and spinoculated (1400 x g, 90 min, 16°C). 
Four hours post spinoculation the supernatant was replaced with fresh media 
and the cells re-incubated for 36-48 h. The cells were then washed 2x with PBS, 
trypsinised with 200 µL 0.25% trypsin for 4 min, resuspended in 1 mL of DMEM 
complete and centrifuged at 1500 x g for 5 min. The cells were rinsed in 1 mL 
PBS, centrifuged (1500 x g/5 min) and the PBS aspirated. The cells were 
resuspended in 100 µL RT Glo Lysis buffer (Promega) and lysed for 5 min. Thirty 
microliters of sample was added to 30 µL of Bright-Glo Assay Reagent 
(Promega) in a 96-well plate, mixed briefly and the relative luminescence units 
(RLU) measured using an Infinate M200 multimode reader (TECAN). 
Fluorescence intensity was normalised to protein concentration using the 
Bradford assay (Sigma-Aldrich) according to the manufacturer’s protocol. 
 
2.5 Immunostaining 
Viral particle immunostaining was performed by adsorbing viral supernatants on 
microscope slides (Superfrost Plus, Thermo Scientific) for 2 h at 37°C with 10 
µg/ml of polybrene (Sigma-Aldrich), followed by rinsing with phosphate-buffered 
saline (PBS) and fixation with 4% paraformaldehyde (PFA) in PBS for 10 min at 
RT. Intracellular immunostaining was performed in cells grown on coverslips. 
Coverslips were fixed with 4% PFA in PBS for 10 min at RT followed by 
permeabilisation with 0.1% Triton X-100 in PBS for 5 min. After treatment in 
blocking buffer (0.1% Tween and 1% BSA in PBS) for 30 min, primary antibodies 
were incubated for 1 h at 37°C in blocking buffer followed by incubation for 1 h at 
37°C with secondary antibodies. Coverslips were mounted with VECTASHIELD 
Antifade Mounting Medium (Vector Laboratories Inc.)  before microscopy 
analysis. Primary and secondary antibodies used include: 
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Primary antibodies used: HIV-1 p24CA mouse monoclonal antibody (AG3.0) (NIH 
AIDS Research and Reference Reagent program); Lamin B goat polyclonal 
antibody (M-20): sc-6217 (Santa Cruz Biotechnology); HIV-1 Integrase Antibody 
(IN-2) mouse monoclonal: sc-69721 (Santa Cruz Biotechnology); and GFP (FL) 
rabbit polyclonal antibody: sc-8334 (Santa Cruz Biotechnology). 
 
Secondary antibodies used: Alexa Fluor 633 goat anti-rabbit (Thermo Fisher 
Scientific); Alexa Fluor 633 rabbit anti-mouse (Thermo Fisher Scientific); Alexa 
Fluor 488 donkey anti-mouse secondary antibody (Thermo Fisher Scientific); and 
DyLight 633 rabbit anti-goat  IgG (Thermo Fisher Scientific). 
 
2.6 Restriction compounds 
All HIV-1 restriction compounds used in this project were resuspended in DMSO 
and were used at the following concentrations: Nevirapine (NIH AIDS Research 
and Reference Reagent Program) at 5 to 20 µM; Ebselen (Merck Millipore) at 20 
µM and PF-3450074 (Sigma-Aldrich) at 10 to 20 µM. 
 
2.7 Preparation of capsid mutants 
Viruses containing the p24CA point mutations E45A (delayed uncoating), 
E128A/R132A (delayed uncoating) and K203A (premature uncoating) were 
created in pNL4-3, pNL4-3-IN-HiBiT, pcDNA3 MA-CA-GFP, and ∆8.91/psPAX2 
packaging vectors using site-directed mutagensis and phusion high-fidelity DNA 
polymerase (Thermo Fisher Scientific). Forward and reverse complimentary 
primers were used to create mutations: 
 
In pcDNA3 MA-CA-GFP, ∆8.91 and psPAX2: 
E128A/R132A: 5’-CCTATCCCAGTAGGAGCGATCTACAAGGCGTGGATAATCCTGGG–3’                
K203A:  5’-GTAAGACCATCCTGGCGGCTCTCGGCCCAGCG-3’; 
 
In pNL4-3.Luc.R-E: 
E45A: 5’–GTTTTCAGCATTATCAGCAGGAGCCACCCCACAAG-3’ 
E128A/R132A: 5’–CTATCCCAGTAGGAGCAATCTATAAAGCATGGATAATCCTGGG-3’ 
K203A:  5’-GATTGTAAGACTATTTTAGCAGCATTGGGACCAGG-3’ 
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2.8 Capsid uncoating assays: 
 
2.8.1 Dual-labelled system: 
 
2.8.1.1 Matrix-Capsid-EGFP (MA-CA-GFP): 
The Matrix and Capsid sequences, were PCR amplified from pNL4-3.Luc.R-E- 
and ligated into pcDNA3-EGFP using the KpnI and BamHI restriction sites, to 
give pcDNA3-Matrix-Capsid-EGFP (pcDNA3-MACA-EGFP): 
 
(KpnI)MACA fwd: 5’-ATTAGGTACCATGGGTGCGAGAGCGTCGGTATTAAGC-3’ 
(BamHI)MACA rev: 5’-TAATGGATCCCAAAACTCTTGCTTTATGGCC-3’ 
 
The fluorescent protein mRuby2 (pmRuby2-C1), and those from the mKusabira 
Orange family mKO, mKO2 and mKOk (pmKO-N1, pmKO2-N1, pChicken 
Mermaid S188, respectively, addgene) were also PCR amplified from their 
respective host plasmids and cloned into pcDNA3-MACA-EGFP, in place of 
EGFP, using the restriction enzymes BamHI and NotI: 
 
(BamHI)mRuby2 fwd:  5’-TAATGGATCCGTGTCTAAGGGCGAAGAGCTG-3’ 
(NotI)mRuby2 rev:  5’-TAATGCGGCCGCTTACTTGTACAGCTCGTCCATCC-3’ 
(BamHI)mKO/mKO2/mKOk fwd: 5’-TAATGGATCCGTGAGTGTGATTAAACCAG-3’ 
(NotI)mKO/mKOk rev:  5’-TAATGCGGCCGCTTAGGAATGAGCTACTGCATC-3’ 
(NotI)mKO2 rev:  5’-TAATGCGGCCGCTTAGCTATGAGCTACTGCATC-3’ 
 
2.8.1.2 Vpr-IN-mCherry (VINC): 
pVpr-IN-mCherry was assembled using a construct previously prepared within 
the Molecular Virology group [125].  Briefly, pVpr-IN-ECFP was constructed by 
cloning PCR amplified Vpr (pNL4-3) in frame with codon optimized IN into the 
pECFP-N1 vector (Clontech Laboratories, Inc., Saint-Germain-en-Laye, France). 
An HIV-1 protease cleavage site (IRKVL), flanked at both C- and N- termini by a 
flexible linker (KRIQST), was introduced between Vpr and IN. ECFP was 
removed from the C-terminal of pVpr-IN-ECFP and replaced with an mCherry 
fluorophore. 
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Trans-incorporated virions were produced by transfection of HEK293T cells with 
16 μg of pNL4-3, 4 μg of MA-CA-GFP, 6 μg of VINC and pseudotyped with 4 μg 
of either VSV-G or HXB2 (WT) envelope. Control viruses were prepared as 
above minus either MA-CA-GFP, Vpr-IN-mCherry or both plasmids. 
 
2.8.1.3 Time course: 
Fifteen-millimetre cover-slips (Thermo Fisher Scientific) were placed into 24-well 
cell culture plates (Eppendorf), treated for >30 min with 0.01% poly-L-lysine 
(Sigma-Aldrich), rinsed 2x with phosphate-buffered saline (PBS) and dried for 2 h 
under a class II biological safety cabinet. Wells were seeded with 1.2x 10^5 or 
6.0x 10^4 HeLa P4 cells for confocal or infectivity assays, respectively. Twenty-
four hours post-seeding media was aspirated from the cells and replaced with 1 
mL of virus at 1 RTU/mL and infection synchronised by spinoculation at 1400 x 
g/16°C for 90 min. After spinoculation the plates were incubated at 37°C for 30 
min (VSV-G pseudotyped) or 50 min (HXB2 Env pseudotyped), the media 
aspirated and the cells washed 2x with PBS. The cells were then treated with 
250 μL of 0.05 % trypsin (GIBCO, Thermo Fisher Scientific) for 1 min/37ºC to 
remove non-fused virions and the media replaced with 0.5 mL DMEM. Plates 
were re-incubated and fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich) 
for 10 min at 15, 30 or 60 min intervals post-trypsinisation, and stored in PBS at 
4ºC until mounting. 
 
The fixed samples were either stained with immuno-fluorescent antibodies or the 
coverslips mounted directly on to microscope slides (Superfrost Plus, Thermo 
Scientific) using 8 µL VECTASHIELD Antifade Mounting Medium (Vector 
Laboratories) and sealed using nail varnish. The cells were then visualised using 
confocal microscopy. 
 
2.8.2 SunTag – capsid-Tag 
The SunTag peptide was inserted into various regions of the cyclophilin-A 
binding loop of p24CA through site directed mutagenesis. The matrix and capsid 
genes from pCMVdeltaR8.91 were primarily inserted into the cloning vector pUC-
21 using SpeI to facilitate mutagensis. Two systems were employed: 
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Firstly, region 87 to 97 (11 aa) of the CypA binding loop was exchanged with the 
19 amino acid SunTag (CA-Tag v2.1) as this region was predicted to have a 
minimal effect on the structure of the protein using LOOPP protein folding 
recognition software (http://cbsu.tc.cornell.edu/software/loopp/). 
 
CA-Tag v2.1 fwd and rev complimentary primers: 
5’-GAATGGGATAGAGTGCATCCAGTGGAAGAATTATTAAGTAAGAATTATCATTTAGAAAATG 
AAGTAGCAAGATTAAAGAAAGAACCAAGGGGAAGTGACATAGCAG-3’ 
 
Secondly, region 79 to 94 (16 aa) of the CypA binding loop was exchanged for 
the 19 amino acid sequence of the SunTag peptide (CA-Tag v1) due to a slight 
complementarily (2 aa) between the two sequences. 
 
CA-Tag v1 fwd and rev complimentary primers: 
5’-GAATGGGATAGAGTGCATCCAGTGGAAGAATTATTAAGTAAGAATTATCATTTAGAAAATG 
AAGTAGCAAGATTAAAGAAAGAACCAAGGGGAAGTGACATAGCAG-3’ 
 
The CA-Tag v2.1 construct was used as a template for these primers and the 
resultant PCR product was used as a primer to insert the CA-Tag v1 into pNL4-3 
and pUC21-∆8.91 (through a pCDNA3 intermediate containing the matrix and 
capsid genes). All mutations were verified by sequencing. 
 
Vectors were produced in HEK293T cells (both in cells expressing or not-
expressing scFv-sfGFP) using a self-inactivating lentivirus vector (SIN-Luc), 
VSV-G envelope, and different ratios of ∆8.91-CA-CypA v2.1 to WT ∆8.91 to see 
the effects of the CA-Tag on viral infectivity (measured via PERT, luciferase 
assay and western blot). Vectors were also prepared using increasing ratios of 
the NL4.3-CypTagV1 vector with WT NL4-3. 
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2.8.3 SunTag – repeat peptide array 
The 10x and 24x GCN4 (SunTag) peptide repeats were PCR amplified from the 
transfer vectors pHRdSV40-dCas9-10xGCN4_v4-P2A-BFP and HRdSV40-NLS-
dCas9-24xGCN4_v4-NLS-P2A-BFP-dWPRE (Addgene), respectively: 
 
(AheI)10x/24xSunTag fwd: 5’-ATTAACCGGTGGCAGCGGCAGCGGCGAAGAACTTTTGA 
GCAAGAATTAT-3’ 
(EcoRI/XhoI)10xSunTag rev: 5’-TAATCTCGAGAATTCTCACTTTTTGAGCCTAGCAACTTC-3’  
(SalI)24xSunTag rev:  5’-TAATGTCGACTCACTTTTTAAGTCGGGCTACTTC-3’ 
 
The resultant bands were then digested and ligated onto the C-terminus of HIV-1 
integrase in either a ∆8.9 packaging vector (∆8.9-IN-10xSunTag) or an 
expression vector (pcDNA3) containing HIV-1 Vpr-IN for trans-incorporation into 
virions (pcDNA3-Vpr-IN-10x/24xSunTag). 
 
Vectors were produced using 10 µg of the transfer vectors pNL4-3 (for pcDNA3-
Vpr-IN-nxST) and SIN-Luc for (∆8.9-IN-10xSunTag), and were pseudotyped with 
3.5 or 4 µg of VSV-G or HXB2 derived envelope, respectively. A titration study 
was then perfomed to determine the effects of increasing concentrations of ∆8.9-
IN-10xSunTag versus ∆8.9 packaging vector, and pcDNA3-Vpr-IN-
10x/24xSunTag trans-incorporation on virus production (measured using PERT 
assay) or infectivity (measured through luciferase activity). The viruses were then 
analysed using confocal and and Operetta high-content imaging. 
 
2.8.3.1 APOBEC SunTag 
The apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 
(APOBEC) 3G and 3F (A3F and A3G) genes were incorporated into the 
pcDNA3-Vpr-IN-24xSunTag plasmid through PCR amplification of the pBTe2-
A3F/G*-HiBiT vector (section 2.8.4), using a forward primer (containing a KpnI 
restriction site) complementary to the 5’ end of both A3F and A3G*, and a 
reverse primer (containing an AgeI restriction site) complementary to the 3’ end 
of the V5 tag: 
 
(KpnI)A3FG* fwd: 5’-ATTAGGTACCGCCACCATGAAGCCTCACTTCAGAAACACAG-3’ 
(AgeII)A3FG* rev: 5’-TAATACCGGTCCCCGTAGAATCGAGACCG-3’ 
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The A3F/G* PCR fragments were ligated into the pcDNA3-Vpr-IN-24xSunTag 
plasmid in place of Vpr-IN. Viruses were prepared as with the A3F/G* HiBIT 
(section 2.8.4), but with a SIN-Luc transfer vector (in place of SIN-GFP) which 
does not express Vif or GFP: SIN-Luc (10 µg), ∆8.91/psPAX2 (6.5 µg), A3F/G* 
(5 µg) and VSV-G (3.5 µg) or HXB2 Env (4 µg).  
 
2.8.4 NanoBiT 
The sequences for the Large Bit (LgBiT) and High Bit (HiBiT) of the two-subunit 
based system were obtained from pBiT1.1-C [TK/LgBiT] and 
pBTe2(CtermHiBiT), respectively (NanoBiT PPI MCS Starter System, Promega). 
 
The A3F and A3G genes were PCR amplified from cDNA derived from HEK293T 
cells using reverse primers containing the sequence for a V5-tag on the C-
terminal of the APOBEC genes. NheI (forward), and EcoRI/SalI (reverse) 
restriction sites were incorporated into the primers for ligation of the A3F/G 
genes into pBTe2(CtermHiBiT), subsequently named pBTe2-A3F/G-HiBiT: 
 
(NheI)A3F/G fwd: 5’–ATTAGCTAGCGCCACCATGAAGCCTCACTTCAGAAACACAG–3’  
(SalI)A3F rev:  5’–TAATGTCGACCCCGTAGAATCGAGACCGAGGAGAGGGTTAGGG 
  ATAGGCTTACCCTCGAGAATCTCCTGCAGCTTG–3’ 
(EcoRI)A3G rev: 5’-TAATGAATTCCCCGTAGAATCGAGACCGAGGAGAGGGTTAGGGA 
  TAGGCTTACCGTTTTCCTGATTCTGGAGAATGG–3’ 
 
Site-directed mutagenesis was used to incorporate a glutamic acid to glutamine 
mutation at point 259 of A3G to create a cytidine deaminase deficient mutant 
(pBTe2-A3G*-HiBiT). Forward and reverse complimentary primers: 
 
pBTe2-A3G* fwd: 5’–GAAGGCCGCCATGCACAGCTGTGCTTCCTGG–3’  
 
The HiBiT was also cloned into pNL4-3 (pNL4-3-HiBiT) using a method 
described by Petit and co-workers whilst cloning hemagglutinin (HA) and flag 
epitopes into an HIV-1 BRU infectious molecular clone [204]. Briefly, two sets of 
primer pairs were used. For the 1st set a forward primer (AgeI pre-IN forward) 
was designed overlapping an AgeI restriction site upstream from the IN gene and 
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was used in conjunction with a reverse primer (BspEI HiBiT reverse) 
complementary to the C-terminal sequence of IN and containing part of the 5’ 
sequence of the HiBiT epitope including a BspEI restriction site. For the 2nd set 
the forward primer (BspEI HiBit forward) contained the remaining part of the 
HiBiT epitiope, including the BspEI restriction site, and a portion complementary 
to the sequence downstream of IN, and a reverse primer (PfIMI post-IN reverse) 
overlapping a PfIMI restriction site further downstream. After PCR amplification 
and digestion, equimolar concentrations of the two PCR products were ligated 
forming a template for further PCR amplification using the AgeI pre-IN forward 
and PflMI post-IN reverse primers. The resultant PCR product was digested with 
AgeI and PfIMI and ligated into pNL4-3. The sequences for the primers were as 
follows: 
 
(AgeI)pre-IN fwd: 5’-GATTCTAAAAGAACCGGTACAT-G-3’ 
(BspEI)HiBiT rev: 5’-CGCCATCCGGACACATCCTCATCCTGTCTACT-TGC-3’ 
(BspEI)HiBiT fwd: 5’-ATGTGTCCGGATGGCGGCTGTTCAAGAAGATTAGCTAACACATG 
GAAAAGATTAGTAAAACAC-3’ 
(PflMI)post-IN rev: 5’- TTCCTCCATTCTATGGAGACTC-3’. 
 
Viruses were prepared using the self-inactivating vector pHR.SIN.CSBgalIGW-
GFP (10 µg), which does not express the Vif or luciferase proteins, the 
packaging vectors ∆8.91/psPAX2 (6.5 µg), APOBEC 3F/G* (5 µg), and were 
pseudotyped with either VSV-G (3.5 µg) or HXB2 (4 µg) envelope. 
 
2.8.4.1 NanoBiT assay 
HeLa P4 pAIB-LgBiT stable clone and HeLa P4 WT cells were seeded at 
1.5x10^4 cells/well into 96-well tissue culture plates (PerkinElmer). Twenty four 
hours later the control cells were transfected with 50-100 ng of pNL4-3-HiBiT or 
pBTe2-A3F/G*-HiBiT plasmid DNA using Lipofectamine 3000 Reagent (Thermo 
Fisher Scientific) and re-incubated for 20-24 h. The following day the cells were 
infected with 200 µL of virus plus associated restrictive compounds and 
spinoculated for 90 min at 1400 x g/16ºC. During spinoculation a stock of Nano-
Glo Live Cell Reagent was prepared according to the NanoBiT PPI 
Luminescence protocol (Promega). After spinoculation the virus was replaced 
with 100 µL pre-warmed (37ºC) DMEM complete plus HEPES (plus associated 
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restrictive compounds) and 25 µL of Nano-Glo Live Cell Reagent per well, and 
analysed using an Infinate M200 multimode reader (TECAN). The plate reader 
was pre-warmed to 37ºC before use, and upon insertion mixed the plate with an 
orbital motion at 500 rpm for 15 seconds. Luminescent readings were acquired 
every 5 min for 150 min, using an integration time of 2 s. 
 
2.9 Operetta High-Content screening 
Ninety six-well cell carrier plates (PerkinElmer) were treated with poly-L-lysine 
and then seeded with 1.5x10^4 HeLa P4 scFv-sfGFP stable clone cells per well. 
Twenty-four hours later the cell culture media was replaced with 200 µL of virus 
containing the Vpr-IN/APOBEC-24xSunTag constructs and spinoculated for 90 
min at 1400 x g/16°C. The virus was replaced with pre-warmed 200 µL 
fluoroBrite (Thermo Fisher Scientific) supplemented with HEPES (GIBCO, 
Thermo Fisher Scientific) and imaged directly in the live cell chamber (5% 
CO2/37°C) of the Operetta high-content imaging system (PerkinElmer). Images 
were acquired every 5 min over a 150 min time frame and analysed using the 
Harmony High-Content Imaging and Analysis Software. 
 
2.9.1 Harmony High-Content Imaging and Analysis Software 
Input Images were selected and a flat-field correction using the ‘Advanced’ 
method was applied to correct uneven illumination in the field of view. To 
facilitate the segmentation of cells in the images, the signal to background 
window was enhanced using the ‘Calculate Images’ building block, and an 
arbitrary formula was applied to keep only the pixels with a green fluorescence 
intensity greater than 150, with the rest reset to zero. Cells were segmented 
using the ‘M’ method of the ‘Find Cells’ building block, with the cell lower limit 
diameter set at 40 µM, the splitting coefficient at 0.45, and a common threshold 
(the lower level of pixel intensity for the whole image that may belong to cells) of 
0.15 (Fig. 8A). Since applying a common threshold resulted in a reduced area of 
segmentation in these image conditions, the cells were then resized by 10 pixels 
to ensure the inclusion of the cell border (Fig. 8B). 
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E F 
  
 
 
 
Figure 8. Segmentation and counting of cells and spots using the Harmony high-content 
imaging and analysis software. (A) Cells were primarily segmented using the ‘Find cells’ 
building block. (B) Cells were resized by 10 pixels to incude the cell borders. (C) Spots were 
segmented using the ‘Find spots’ building block (total spot count). (D) Spots were resized to 
define a ring region that include the background of the area immediately surrounding the spot to 
determine the S-B of the spots. (E-F) A threshold was set based on the value of S-B in the 
negative control cells (E) to remove aspecific segmentation (red) and identify true spots (green) 
representing the ‘spot selected’ population. 
 
Spots were detected using method ‘A’, which detects the local intensity maxima, 
and the relative intensity of the spot peak to background was set at >0.020, with 
a splitting coefficient of 1.0 (Fig. 8C). The spot region was resized by -0.5 pixels 
of ‘Inner Border’ and -1.5 pixels of ‘Outer Border’ to select a ring region in which 
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the background value immediately surrounding the spot was determined (Fig. 
8D), and the signal minus background (S-B) value calculated. A threshold was 
set based on the value of S-B in the negative control cells (infected with NL4-3 + 
VSV-G minus the epitope peptide array) to be able to distinguish a true spot from 
segmentation artefacts (red spots) (Fig.8E). This selection was applied to derive 
the ‘spot selected’ population (green minus red spots) (Fig. 8F) displayed in the 
results. 
 
2.10 Confocal Microscopy 
Images were acquired using a Leica TCS SP5 laser-scanning confocal 
microscope and the Leica Application Suite Advanced Fluorescence (LAS AF) 
user interface. High resolution images were obtained using the 63x/1.4 NA HCX 
PL APO oil immersion objective. An argon (Ar) and Helium Neon (HeNe) laser 
was used for excitation of EGFP/sfGFP (λ = 488 nm), mKO/mCherry (λ = 543 
nm), and Alexa-633/680 (λ = 633 nm). Unless otherwise stated the Ar laser was 
set at 29% power and 15% intensity, and the HeNe laser at 30% intensity. The 
fluorescence emission spectra were collected in the ranges of 493-510 (sfGFP), 
493-550 (EGFP), 550-700 (mKO), 560-630 (mCherry) and 645-795 nm (Alexa-
633/680). A pinhole of 1.5 and 1.0 airy units (AU) was used when acquiring the 
CA-GFP/IN-mCherry and CA-mKO/IN-sfGFP images, respectively. A pinhole of 
1.0 AU is the standard setting for confocal acquisition, producing images with 
high contrast and low background in the presence of sufficient fluorescence, as 
with the CA-mKO and IN-sfGFP labelling. However, due to the reduced signal 
obtained with the mCherry fluorophore, a pinhole of 1.5 AU was employed which 
enabled greater exposure of mCherry-labelled particles without significantly 
affecting resolution from out of focus light. Sequential imaging was used for two 
and three-colour acquisition to reduce the crosstalk between the signals. Unless 
otherwise stated, A zoom 6x was used in the time courses, and cells were 
selected (~4 cells per field) using the bright-field illumination to reduce bias in cell 
selection.  
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A z-step (axial resolution) of 300 nm was used for acquisition of the images in 
the time courses, determined from the numerical aperture of the objective using 
the following formula: 
 
𝑟𝑎𝑥𝑖𝑎𝑙 =
1.4𝜆 ∙ 𝜂
𝑁𝐴2
 
 
Where λ is the emission wavelength (543 nm), η is the index of refraction (1.5) 
and NA is the numerical aperture (1.4); thus giving a raxial of 582 nm. According 
to the Nyquist criterion the optimal sampling rate is half that of the axial 
resolution, approximately 300 nm. The CA-GFP/IN-mCherry images were 
acquired using a frame/line average of 1 and 3, and the CA-mKO/IN-sfGFP 
signal was captured using frame/line averages of 2 and 5. 
 
2.10.1 Semi-automatic colocalisation 
The first set of images (up until the capsid was tagged with the mKO fluorophore) 
were analysed in a semi-automated approach using the open source image 
processing package ImageJ. A macroinstruction (Macros) was developed using 
the ‘Record…’ function plugin detailing a sequential set of tasks for segmenting 
and determining colocalisation between the fluorescently labelled CA and 
integrase proteins. After acquisition the images were imported into ImageJ and 
the channels were split. The channel containing the images of the IN 
fluorescence were processed using the Gaussian Blur 3D function, a filter that 
uses convolution with a Gaussian function for smoothing (using an X, Y and Z 
sigma of 1.0) to reduce the background signal and enable segmentation. 
Segmentation was performed using the ‘3D Objects Counter’ function and a 
threshold that was manually determined for each time course. This resulted in a 
map of ‘objects’, with the number of voxels (volume picture elements) constituent 
for each object. The objects map was imported into the ‘3D Manager’ plugin (Add 
Image) followed by the channel containing the images of CA fluorescence 
(Select All). Colocalisation was performed using the ‘Quantif 3D’ function of 3D 
Manager and derived from the maximum ‘Max’ colocalising voxels readout. 
Colocalisation was calculated as the number of CA objects colocalising with IN 
objects (over various thresholds) divided by the total number of integrase objects 
and was presented as a percentage. 
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2.10.2 Bleed-through 
In the calculation of the percentage of colocalised vs. uncoated PICs, the number 
of colocalised CA-GFP and IN-mCherry particles was determined using the 3D 
Manager plug-in (ImageJ) and then divided by the total number of IN-mCherry 
particles counted within that time point. A readout was displayed listing the IN-
mCherry segmented objects and the highest CA-GFP signal colocalised within 
that object. Because of the closeness between the excitation and emission 
spectra a small amount of bleed-through was transferring from the GFP into the 
mCherry channel (GFP excites at ~2.12% with the HeNe laser (λ = 543 nm), 
which meant a certain amount of ‘mCherry’ signal was colocalising with itself 
(Fig. S1), giving artificially high percentages at low colocalisation thresholds (Fig. 
9). Although some of the localisation at low thresholds would be true data, to limit 
bias from false spots a colocalisation threshold from 10 to 20 of the gray level 
range was chosen.  
 
A                      ≥3 B                         ≥20 
  
 
Figure 9. Percentage of colocalisation between CA-GFP and IN-mCherry depending on the 
threshold for colocalisation selected. Colocalisation was determined by segmenting the IN-
mCherry puncta using the 3D Object Counter (ImageJ) and establishing the maximum CA-GFP 
signal within the segmented object using the 3D Manager plug-in (ImageJ); percent colocalisation 
was then calculated by dividing the number of colocalised objects by the total number of 
segmented IN-mCherry objects. (A and B) Examples of colocalisation when the threshold 
(determining colocalisation of CA with IN) in the green channel (CA) was set at ≥3 of ≥20 gray 
level units. 
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2.10.3 DeconvolutionLab 
To reduce the time it took to analyse colocalisation between the capsid 
(EGFP/mKO) and integrase (mCherry/sfGFP) proteins a pipeline was developed 
to automate the process, in collaboration with the Predictive Models for 
Biomedicine & Environment (MPBA) and the Molecular Imaging groups in 
Fondazione Bruno Kessler (FBK). Using DeconvolutionLab open source software 
and Python scripting the pipeline used a series of algorithms to improve the 
contrast and resolution of the image. Deconvolution was performed using an 
experimental point spread function (PSF) and a Tikhonov-Miller algorithm, which 
consisted of 30 iterations and a regularisation factor of 0.01 (determined 
experimentally). The deconvolution was comparable to that performed with 
(Huygens Remote Manager), but the former was used as it was compatible with 
DeconvolutionLab open software. 
 
The images were then segmented, a process of partitioning a digital image into 
multiple quantifiable segments through image thresholding and connexity 
analysis to locate the objects or ‘spots’ to be colocalised and the boundaries of 
the image. The individual spots were detected using ImageJ based on the local 
maxima of the fluorescence intensity, each pixel being marked as a ‘spot’ if its 
intensity was maximum within its surrounding region. Colocalisation was 
determined if a fluorescent spot denoting a CA particle fell within 5 pixels 
distance of the centroid (central pixel) of a fluorescent spot signifying an IN 
particle.  
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RESULTS 
3.1 A dual-fluorescent virus for studying uncoating 
The ultimate system for studying capsid uncoating would be to visualise single 
capsid cores and their associated viral nucleoprotein in real time. This would 
make it possible to determine exactly when, where and how the capsid cores 
disassemble in relation to the nucleoproteins, within the 3D spatial context of the 
target cell. This requires labelling of both the p24CA protein and a component of 
the RTC/PIC. Albanese and co-workers developed a system for labelling the 
RTC without impairing the genome processing capacity of the provirus by cloning 
Vpr in frame with codon optimised IN into a pEGFP-N1 vector [125]. During viral 
assembly and budding Vpr-IN-EGFP is incorporated into the viral particle through 
interaction with the p6 domain of Gag without significantly impairing infectivity. 
Using this system, it was possible to track the virus from fusion with the target 
cell membrane until integration with the host genome. 
 
We developed a p24CA labelling system that could be used in conjunction with 
fluorescently labelled Vpr-IN, to allow visualisation of capsid disassembly 
(uncoating) from the RTC/PIC. The MA and CA proteins from an envelope and 
Vpr deficient provirus, pNL4-3.Luc.R-E- (pNL4-3), were cloned into pcDNA3 and 
an enhanced green fluorescent protein (EGFP) was fused to the C-terminus of 
the CTD of capsid (MA-CA-GFP). During viral maturation the matrix protein 
would be cleaved from the NTD of capsid leaving the CA-GFP fusion protein. 
Similarly, the mCherry fluorophore was fused to the CTD of Vpr-IN (Vpr-IN-
mCherry) as it had good brightness and bleaching profiles, and its fluorescent 
spectra was compatible with the EGFP fused to capsid. As the insertion of 
exogenous coding sequences into the Gag gene can lead to loss of viral 
infectivity [205], we tested this by producing virions with the pNL4-3 provirus and 
the WT HXB2 envelope, and different concentrations [µg] of the MA-CA-GFP, 
Vpr-IN-mCherry and pcDNA3 (control) vectors. HeLa P4 cells were transduced 
with 1 RTU of the subsequent vectors and infectivity was measured through 
luciferase activity 48 h post infection (Fig. 10). A loss of infectivity compared to 
the WT control (pNL4-3 + HXB2) was observed with all the trans-incorporated 
viruses. An infectivity of 28% and 18% with respect to WT was observed with 
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trans-incorporation of 2 µg or 4 µg of MA-CA-GFP with 6 µg of Vpr-IN-mCherry, 
respectively. However, the latter combination was chosen for use in the future 
experiments to increase the probability of CA-GFP incorporation into the viral 
 core. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Infectivity of viruses transfected with increasing concentrations of MA-CA-GFP 
and Vpr-IN-mCherry vectors. HeLa P4 cells were transduced with viruses prepared with pNL4-
3 and HXB2 envelope, and varying concentrations [µg] of the MA-CA-GFP, Vpr-IN-mCherry and 
pcDNA3 (plasmid control) vectors. Infectivity was measured 48 h later through luciferase activity 
against a standard WT (non trans-incorporated) virus. Graph showing SEM of n = 3 technical 
repeats, with the left vertical access displaying the RLU and the right vertical access showing the 
percentage of infection normalised to the WT control (100%).  Labels on the x axis = [MA-CA-
GFP] [Vpr-IN-mCherry] [pcDNA3]. 
 
The insertion and/or deletion of sequences from the Gag gene can also have an 
effect on the protease cleavage of the precursor Gag polyprotein during 
maturation of the virus [206][207], influencing the rate of cleavage and, 
subsequently, the proper assembly of virions. As the SP1, NC, spacer peptide 2 
(SP2), and p6 sequences were absent from the MA-CA-GFP vector, we wanted 
to assess the effect this would have on the assembly of the trans-incorporated 
virus and, specifically, the cleavage of capsid from the matrix protein. Virions 
were produced with increasing concentrations of the MA-CA-GFP vector and 
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pelleted through ultracentrifugation. Western blot was performed on the 
concentrated virus, and lysate from the producer cells, using antibodies specific 
for CA (24 kDa), EGFP (27 kDa) and IN (32 kDa). Bands corresponding to the 
expected cleavage products were observed, confirming that protease cleavage 
at the expected sites was occurring, including CA-GFP (~51 kDa) (Fig. 11). A 
large proportion of the matrix, however, remained attached to CA-GFP (MA-CA-
GFP ~68 kDa). Apart from this, bands of similar intensity were observed to that 
of the NL4-3 control, including: Gag (~55 kDa), MA-CA-SP1-NC (~48 kDa), MA-
CA (~41 kDa) and CA (~24 kDa). The intensity of the band corresponding to CA-
GFP, however, was substantially lower to that of p24CA. 
 
 
 
 
Figure 11. Protease cleavage of CA-GFP. Viruses were prepared with pNL4-3, HXB2 envelope 
and increasing concentrations of MA-CA-GFP and pelleted by ultra-centrifugation through a 20% 
sucrose cushion. Samples were analysed by western blot using antibodies targeting p24CA, 
integrase and GFP. DC = dual colour (MA-CA-GFP + Vpr-IN-mCherry). 
 
3.1.1 Colocalisation of CA-GFP with IN-mCherry in CD4+ cells 
Because of the relatively low cleavage product obtained with CA-GFP compared 
to p24CA, we wanted to see if enough CA-GFP molecules were present to 
observe colocalisation with IN-mCherry. Vectors were prepared using the pNL4-3 
provirus [16 µg], MA-CA-GFP [4 µg], Vpr-IN-mCherry [6 µg] and the WT HXB2 
envelope [4 µg] and used for transducing HeLa P4 cells containing the CD4 
receptor as well as HeLa WT cells lacking the CD4 receptor. These cell lines 
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were used to distinguish between productive HIV-1 entry (HeLa P4) and 
endocytosis (HeLa WT). The cells were fixed and mounted on microscope slides 
for confocal acquisition. Images were acquired using the argon (λ = 488 nm) and 
Helium Neon (λ = 543 nm) lasers, and fluorescent emission collected at 500-550 
and 560-700 nm, respectively (Fig. 12). For HeLa WT cells (Fig. 12A), 
fluorescent puncta were only observed surrounding the cell, in accordance with 
the HXB2 enveloped viruses being unable to productively fuse to the cell. The 
high intensity profiles of the GFP spots also demonstrated that the capsid-EGFP 
proteins were being incorporated sufficiently into the virus to enable confocal 
visualisation. 
 
Fluorescent puncta were, however, observed within HeLa P4 CD4 expressing 
cells (Fig. 12B), indicating the productive entry of HXB2 enveloped viruses. 
Measurement of the fluorescence profiles of these puncta established the 
overlapping of EGFP and mCherry fluorophores within the same pixels. This 
colocalisation of fluorescence confirmed that MA-CA-GFP and Vpr-IN-mCherry 
were being incorporated into the viruses. 
 
A B 
  
 
Figure 12. Colocalisation of CA-GFP and IN-mCherry can be observed within HeLa P4 
cells. (A) HeLa WT cells (not expressing the CD4 receptor) were transduced with HXB2 
enveloped viruses produced with the MA-CA-GFP fluorescent protein. Fluorescent puncta were 
only observed on the outside of the cells (white arrows). (B) HeLa P4 cells stably expressing the 
CD4 receptor were transduced with HXB2 enveloped viruses produced with both the MA-CA-
GFP and Vpr-IN-mCherry fluorescent proteins. EGFP and mCherry colocalised puncta were 
observed within the cells (white arrows). Colocalisation was conformed using the ‘Plot Profile’ 
plugin (ImageJ). 
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3.1.2 Development of a time course for studying uncoating 
An assay was designed to see if the dual-labelled virus could be used to study 
the process of uncoating. Briefly, HeLa P4 cells were seeded on coverslips 
treated with poly-L-lysine in 24-well plates. The following day the media was 
replaced with 1 RTU of the dual labelled virus and the plates spinoculated at 
1400 x g for 90 min at 16°C, to synchronise infection [208]. The plates were then 
incubated at 37°C for 30 min or 50 min, for VSV-G and HXB2 enveloped viruses, 
respectively, to allow fusion with the cellular membrane [67]. The cells were then 
trypsinised, briefly, to remove non-bound viruses, acting as a ‘0 min’ time point at 
which the maximum number of viruses with intact capsid cores would be present. 
The cells were then re-incubated, fixed at regular intervals after trypsinisation 
and mounted on to microscope slides for confocal acquisition. Images were 
acquired with the standard excitation and emission parameters (section 2.10), 
together with: zoom (x4), line average (x4) and a z-step of 0.3 µm (Fig. 13). In 
the preliminary images the IN-mCherry spots were appreciably dimmer than 
those of the CA-GFP and so the pinhole was increased to 1.5 AU to be able to 
capture the less intense IN-mCherry spots. Although this interfered with the 
resolution of the image, particularly on the XZ axis, and is not the recommended 
setting for confocal acquisition, the enhanced signal-to-noise ratio (SNR) enabled 
the discernment of more spots. Since the viral particles are smaller than the PSF, 
and the actual position of the particle is defined by the xyz position of the 
centroid, there was no real loss of 3D resolution.  
 
Large numbers of yellow (CA-GFP (green) and IN-mCherry (red)) puncta were 
observed both intra- and extracellularly (Fig. 13A), and subsequent plot profiles 
confirmed a high level of colocalisation. A brief trypsinisation removed most of 
the particles that remained outside of the cells (Fig. 13B). Although high 
numbers of green spots could be observed at this stage (Fig. 13A and B), plot 
profiles revealed the presence of colocalised IN-mCherry. A steady increase in 
the number of IN-mCherry puncta compared to CA-GFP/colocalised spots could 
be observed 60 min after trypsinisation, indicating the disassembly of CA-GFP 
from IN-mCherry (Fig. 13C). Finally, only a small number of spots remained 360 
min post-trypsinisation (Fig. 13D). These preliminary, qualitative, examinations of 
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the data, encouraged the further analysis of the images using more quantitative 
means of establishing colocalisation. 
 
 
Figure 13. Example images from a representative time course used in the measuring of 
capsid uncoating.  HeLa P4 cells were transduced with viruses trans-incorporated with MA-CA-
GFP + Vpr-IN-mCherry. The cells were then incubated for 50 min (HXB2 envelope), and either 
directly fixed (A), or trypsinised for 1 min to remove non-bound viruses and fixed at 0 min (B), 60 
min (C) or 360 min post-trypsinisation (D). Images were acquired using confocal microscopy. 
Green spots represent CA-GFP, red spots IN-mCherry, and yellow spots are indicative of 
colocalisation.  
 
 
 
A         0 min (- trypsin)  B         0 min (+ trypsin) 
 
 
 
C   60 min post-trypsinisation  D   360 min post-trypsinisation 
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3.1.3 Effects of restriction compounds and capsid mutants 
Capsid uncoating was determined by the loss of colocalisation between CA-GFP 
and IN-mCherry over time. To determine the amount of colocalisation between 
CA-GFP and IN-mCherry, a semi-automated system was developed to segment 
and count the fluorescent puncta and establish colocalisation, using the 3D 
Objects Counter and 3D Manager plugin (ImageJ), respectively (section 2.10.1). 
Capsid uncoating was calculated by dividing the total number of colocalised CA-
GFP and IN-mCherry puncta by the total number of IN-mCherry spots per Z-
stack.  
 
To assess whether the fluorescently labelled virus was behaving like WT virus, 
HIV-1 restriction compounds and viruses prepared with capsid mutations known 
to alter the kinetics of capsid uncoating were tested in the time course assay 
(Fig. 14). The restrictive compounds nevirapine, a non-nucleoside reverse 
transcriptase inhibitor, and PF74, a molecule that binds to the NTD of capsid, 
were tested due to their reported capsid destabilisation properties [131][115]. 
TZM-bl cell lines stably expressing the TRIM5-CypA fusion protein were also 
tested, as this protein has been reported to target intact capsid cores for 
premature disassembly [209][126]. Two mutations, which have been shown to 
effect the stability of the viral core both in vitro and in vivo, were introduced into 
the capsids of both pcDNA3-MA-CA-GFP and the pNL4-3 provirus - a lysine to 
alanine mutation (K203A) and a glutamic acid/arginine to alanine double 
mutation (E128A/R132A), which have been reported to decrease and increase 
core stability, respectively [67][65]. 
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A 
 
  
    
B 
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D 
 
E 
 
    
F 
 
G 
 
 
Figure 14. Effects of restrictive compounds/proteins and capsid mutations on the 
uncoating kinetics of the dual-labelled virus. HeLa P4 cells were transduced with dual-
labelled viruses and fixed at regular intervals post-trypsinisation. Images were acquired using 
confocal microscopy, segmented, and colocalisation between CA-GFP and IN-mCherry 
determined using the 3D Manager plug-in (ImageJ). (A-G) Colocalisation of the dual labelled 
virus over time: (A) compared to an IN-mCherry only trans-incorporated virus immunostained with 
an p24CA antibody, (B-C) ± the restriction compounds nevirapine and PF74, (D) in TZM-bl cell 
lines stably expressing a TRIM-CypA fusion protein or a non-restrictive mutant, (E) compared to 
viruses containing the less stable (K203A) and (F-G) more stable (E128A/R132A) capsid 
mutations. Graphs show the SEM from n = 5 technical repeats. 
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Generally, an initial peak of colocalisation was observed at the zero-minute time 
point (plus/minus trypsinisation), followed by a steady loss of colocalisation over 
time (CA uncoating); but colocalised puncta were always detected at the end of 
the time course (up to 360 min post-trypsinisation) (Fig. 14A-F). A half-time of 
uncoating (the time by which 50% of the particles had uncoated compared to the 
‘0 hr’ time point) was recorded from 60 to 240 min post-trypsinisation with the 
regular dual-labelled virus without the addition of restriction compounds. A similar 
kinetic of uncoating was observed with the dual-labelled virus compared to the 
IN-mCherry only trans-incorporated virus stained with an anti-p24CA antibody 
(Fig. 14A). A 50% uncoating time of 175 min post-trypsinisation was recorded 
with the dual-labelled virus, and 240 min with immunostaining, but visibly larger 
puncta when staining may have exaggerated colocalisation. The addition of 
nevirapine delayed the 50% uncoating time from 85 to 170 minutes compared to 
the DMSO control (Fig. 14B). The addition of PF74 resulted in a slight premature 
uncoating event compared to the DMSO control (Fig. 14C), in line with the 
capsid destabilising properties reported with this small molecule compound 
[111][115][130]. A 50% half-time of uncoating was recorded at the 180 min time 
point ± PF74, with a subsequent stabilisation of uncoating in the presence of 
PF74 compared to the DMSO control. A sharp decrease in colocalisation was 
observed in both TZM-bl cell lines infected with the dual-labelled virus (Fig. 14D).  
A 50% half-time of uncoating was recorded at the 0 min ‘plus’ trypsin time point 
with the TRIM-CypA producing cell line, and at 60 min post-trypsinisation with the 
cell line producing a mutated non-restrictive form of TRIM-CypA. The former 
result can be explained by the presence of a large amount of colocalised 
(coated) particles external to the cellular membrane in the directly fixed 0 min 
timepoint, whereas the 0 min ‘plus’ trypsin time point would contain only fused 
and internalised particles; most of the internalised particles in this case having 
already uncoated. A similar drop in colocalisation at the 0 min ‘plus’ trypsin time 
point was also observed with the dual-fluorescent virus containing the less stable 
(K203A) capsid mutation (Fig. 14E). A slightly delayed 50% half-time of 
uncoating was observed when the dual-labelled virus was assayed in parallel 
with the more stable (E128A/R132A) capsid mutant. However, a higher 
percentage of colocalisation was observed throughout the time course with the 
E128A/R132A CA mutant (Fig. 14F). When the threshold determining capsid 
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colocalisation with IN was increased (Fig. 14G), a substantial drop in the area 
under the curve (AUC) was observed with the non-mutated capsid compared to 
the more stable mutant. This suggests that increased uncoating was occurring 
with the virus without the CA mutation, but a certain amount of capsid was 
remaining with the IN to enable colocalisation at lower thresholds. A small 
increase in colocalisation was also observed at the end of the time point (300 
min post-trypsinisation) with both the WT and more stable capsid mutant (Fig. 
14F and G). 
 
These results suggest that labelling of both the CA and the IN is an effective 
system for tracking uncoating, but biological replicates are needed to further 
evaluate this.  
 
3.1.4 High-throughput analysis of uncoating 
To improve the method for analysing capsid uncoating, we exchanged the 
fluorophores used for labelling the proteins with ones more suitable for the lasers 
on the confocal microscope. The IN-mCherry fluorophore was exchanged for 
superfolder GFP (sfGFP). As CA-EGFP was no longer compatible with IN-
sfGFP, we tested four different fluorophores for their suitability in labelling capsid 
based on their excitation and emission profiles, brightness and photostability 
(Table 1) - monomeric Kusabira Orange (mKO), mKO2, mKOk and mRuby 
[210][211]. 
 
Table 1: Values for the excitation, emission, brightness and photostability of the 
fluorophores used for labelling the capsid and integrase proteins [210]. 
Fluorophore λ ex (nm) λ em (nm) Brightness Photostability* 
EGFP 488 507 33.6 174 
sfGFP 485 510 54.1 157 
mKO 548 559 31.0 122 
mKO2 551 565 39.6 228 
mKOk 551 563 64.0 ? 
mRuby2 559 600 43.0 123† 
mCherry 587 610 15.8 96 
† (Bajar et al. 2016) 
* Time for bleaching from an initial emission rate of 1,000 photons/s down to 500 photons/s; data are not 
indicative of photostability under focused laser illumination 
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The fluorophores were exchanged for EGFP on the CTD of capsid, viruses 
prepared with the pNL4-3 provirus and VSV-G envelope, and HeLa P4 cells 
transduced by spinoculation. Images were acquired under confocal microscopy 
using the HeNe laser excitation λ 543 nm (50% intensity), an acquisition window 
of 550-700 nm, a pinhole of 1 AU, and a frame and line average of 2 and 4, 
respectively. The signal to noise ratio was determined using ‘Plot Profile’ analysis 
from ImageJ (Fig. 15), the average of >10 plot profiles for each image can be 
seen in the table (Fig. 15F). 
 
A B C 
   
D E F 
   
 
Figure 15. Signal to noise ratios of mKO, mKO2, mKOk, mCherry and mRuby fluorophores 
in HeLa P4 cells. HeLa P4 cells were transduced with viruses trans-incorporated with the 
following fluorescent fluorophores fused to the CTD of capsid: (A) mKO, (B) mKO2, (C) mKOk, 
(D) mCherry and (E) mRuby, and images acquired with the confocal microscope. Signal-to-noise 
ratios (SNR) were determined using ‘Plot Profile’ (ImageJ).  
 
The highest SNR in HeLa P4 cells were achieved using the mKO, mKO2 and 
mKOk fluorophores (SNR of 8.37, 4.05 and 7.36, respectively), therefore, further 
analysis of their spectral and fluorescent intensity profiles was conducted to 
establish the fluorophore most suitable for the time course. Maximum emission 
70 
 
was observed at 570 nm for all fluorophores (Fig. 16A). A rapid loss of 
fluorescent intensity (bleaching) was observed, compared to when using arc-
lamp illumination (Table 1), in a semi-quantitative comparison of the intensity 
profiles (Fig. 16B). The fluorescent intensity profiles were indicative of a double 
exponential, as opposed to the single exponential line plot usually observed with 
bleaching kinetics, suggesting that the fluorescent molecule may exist in two 
distinct populations, with one population having a more delayed bleaching profile 
than the other. However, a slight delay in the bleaching kinetics was observed 
with mkO compared to mKO1 and mKOk. As mKO also had the highest SNR in 
our experiments, we used this to label capsid, along with IN-sfGFP in all future 
experiments. 
 
A B 
  
 
Figure 16. Fluorescent spectra and intensity profiles of mKO, mKO2 and mKOk. HeLa P4 
cells were transduced with viruses trans-incorporated with MA-CA-mKO, MA-CA-mKO2 or MA-
CA-mKOk and imaged using confocal microscopy. (A) Graph showing the fluorescent spectra 
obtained for mKO, mKO2 and mKOk. (B) Graph showing the fluorescent intensity profiles of 
mKO, mKO2 and mKOk. The fluorescent spectra and intensity profiles were acquired using the 
HeNe (λ = 543 nm) laser set at 60% and 40% intensity, respectively, with a detection bandwidth of 
550 to 615 nm. 
 
To increase the speed and reduce the bias in image analysis we devised a 
pipeline for the high-throughput deconvolution, segmentation, counting and 
colocalisation of the images. The deconvolution pipeline was designed using 
Python scripting and the DeconvolutionLab open source software package 
(ImageJ), and consisted of a chain of three processing elements – 
deconvolution, segmentation and object counting, and colocalisation (Fig. 17). 
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B         Segmentation 
 
C         Colocalisation 
 
 
 
 
 
 
 
Figure 17. Deconvolution, segmentation, object counting and colocalisation of CA-mKO 
and IN-sfGFP. A pipeline was designed using Python scripting and ImageJ DeconvolutionLab 
open source software. (A) Confocal images were primarily deconvolved using an experimental 
PSF and the Tikhonov-Miller Algorithm. (B) Images were then segmented and the resultant 
objects counted using an empirically derived background threshold and the Image 3D Objects 
counter. (C) Colocalisation was established if two objects (CA-mKO and IN-sfGFP) from the two 
separate channels fell within five pixels’ distance of the central pixel (centroid) of each object. 
 
The images were deconvolved to increase the SNR, as a significant amount of 
noise was still detected in the mKO channel, despite increasing the frame and 
line averages in the image acquisition. It was reasoned that the background 
noise may lead to false spot identification in the semi-automated analysis 
pipeline. Deconvolution was performed using an experimental point spread 
function (PSF) and the Tikhonov-Miller Algorithm with a regularisation factor of 
0.01 and 30 iterations (Fig. 17A). The deconvolved images were then 
segmented using a background threshold derived from the extreme planes of z-
stacks, all pixels with an intensity above this threshold being considered as 
object’s pixels, and the number of spots determined using the 3D Object counter 
plug-in (ImageJ) (Fig. 17B and C). Colocalisation was established if two objects 
(CA-mKO and IN-sfGFP) from the two separate channels fell within five pixels’ 
distance of the central pixel (centroid) of each object. The sensitivity and 
accuracy of the system was verified by comparison with deconvolution through 
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Huygens Remote Manager (Scientific Volume Imaging B.V.) using an 
experimental PSF, and manual object counting and colocalisation using ROI 
Manager (ImageJ). 
 
As there was a slight variation in the SNR between time courses, the optimal 
segmentation thresholds for both mKO and sfGFP needed to be re-evaluated 
within each data set (from 5 to 40 intensity graduations in an 8-bit image). 
Example segmentation threshold boxplots (from data set 7, DMSO control) can 
be seen in Fig. 18. 
 
A 
 
B 
 
 
Figure 18. Segmentation thresholding of CA-mKO and IN-sfGFP. Example graphs (from 
dataset 7, DMSO control) showing the difference in the ratio of colocalisation between CA-mKO 
and IN-sfGFP, after processing with DeconvolutionLab, depending on the segmentation threshold 
employed. Segmentation thresholds for CA-mKO/IN-sfGFP of 10/10 (top) and 40/40 (bottom), led 
to median ratios of colocalisation at the 50 min time point of ~0.58 and ~0.07, respectively, and 
the loss of data points from 110 to 290 min in graph B. 
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A lower segmentation threshold (≤10 in both channels) led to more colocalised 
spots being detected over time (Fig. 18A), but increased the chance of false 
positives being detected. A higher segmentation threshold (≥40) reduced the 
number of false positives being detected due to background noise, but also 
diminished the detection of true signal leading to a loss of genuine positive spots 
recorded. This led to the loss of data points from 170 to 290 min in Fig. 18B. 
This added an element of operator bias to the system, but the optimal thresholds 
were typically ≤10 intensity graduations. 
 
The time course was repeated, as described earlier, with HeLa P4 cells 
transduced with the dual-labelled virus pseudotyped with a HXB2 envelope. 
Nevirapine was used to validate the system because it had been shown to inhibit 
capsid uncoating in a previous study [67], and meant that the same viral 
preparation could be used in both the control and the challenge samples, to 
ensure that any affects observed were due to the action of the compound and 
not through differences in viral preparation. The images were acquired using 
confocal microscopy and then processed, and colocalisation between CA-mKO 
and IN-sfGFP determined using the DeconvolutionLab pipeline. Three readouts 
were produced: the absolute number of CA-mKO and IN-sfGFP colocalised 
spots over time (Fig. 19A), and the number of CA-mKO and IN-sfGFP spots 
colocalising over time divided by the total number of CA-mKO or IN-sfGFP spots, 
i.e. the ratio of colocalisation (Fig. 19B).  
 
For the absolute number of CA-mKO and IN-sfGFP colocalised spots (Fig. 19A) 
a compilation of four datasets showed a significant drop in colocalisation 
(increased uncoating) 170 min post-trypsinisation (P ≤0.01) with both nevirapine 
(blue) and the DMSO control (red). When assessing the ratio of colocalisation 
(number of colocalised spots divided by the total number of CA-mKO spots) (Fig. 
19B), a similar increase in uncoating was observed between 110 and 170 min 
post-trypsinisation. However, a significant delay in uncoating was also 
determined in the presence of nevirapine from 170 to 230 min post-trypsinisation 
compared to the DMSO control. 
 
 
74 
 
A 
 
B 
 
 
Figure 19. Effects of nevirapine on the uncoating kinetics of the dual-labelled virus over 
time. HeLa P4 cells were transduced with the dual-labelled virus ± nevirapine [10 µM] (blue) or 
DMSO control (red), and fixed at regular intervals post-spinoculation. Images were acquired 
using confocal microscopy and the fluorescent puncta counted, and colocalisation determined, 
using the DeconvolutionLab pipeline. (A) Boxplot showing the absolute number of colocalising 
spots over time (min) ± nevirapine as a percentage of the total number of spots, with the IN-
sfGFP (g) segmentation threshold set at 5. SEM of n = 4 datasets (ds). (B) Boxplot of the ratio of 
the CA-mKO spots colocalising with IN-sfGFP spots over time, with the CA-mKO (r) threshold set 
at 5. SEM of n = 5 datasets. 
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3.1.6 Colocalisation of capsid with integrase within the nucleus 
Recent studies have reported the presence of immunostained capsid proteins 
colocalised with integrase-GFP within the nucleus of infected cells using super 
resolution microscopy [55][57]. To ascertain whether we could observe 
colocalised particles within the nucleus using CA-mKO, HeLa P4 cells were 
transduced with the dual-labelled virus pseudotyped with VSV-G and fixed at 4 to 
6 hr post-spinoculation (p.s.) - the period when most PICs complexes are likely to 
be observed within the nucleus [125]. Nuclei were immunostained with anti-
Lamin B polyclonal antibody. Z-stacks of the cells were acquired with a zoom 8 
and a 0.1 µM z-plane, and the images deconvolved using Huygens Remote 
Manager. 
 
Colocalised CA-mKO with IN-sfGFP puncta were observed within the nucleus of 
HeLa P4 cells at 6 h p.s. (Fig. 20), another indicator that the dual-labelled 
fluorescent virus was behaving like WT HIV-1 virus. The plot profile was 
generated along the y axis of the spot in this example, to reduce the offset which 
can be observed between the two channels (Fig. 20B). This offset may have 
been due to under-corrected extra-axial chromatic aberration due to the 
wavelengths converging at different positions along the focal plane. This offset 
could also have influenced the colocalisation analysis in the DeconvolutionLab 
pipeline. To avoid this, individual spots were detected by the local maxima of the 
fluorescence intensity, and colocalisation was determined if the centroid from the 
separate channels fell within 5 pixels distance from each other. 
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Figure 20. Colocalisation of CA-mKO with IN-sfGFP within the nucleus of HeLa P4 cells. 
(A) The dual-labelled virus was pseudotyped with VSV-G and used to transduce HeLa P4 cells 
through spinoculation. Cells were fixed 4-6 hr p.s. and immunostained with anti-Lamin B 
antibody. A Z-stack (0.1 µM) of the nuclei was acquired and images deconvolved using Huygens 
Remote Manager and an experimentally derived PSF. Puncta containing both the CA-mKO and 
IN-sfGFP are marked with white arrows. (B) Plot profiles of the colocalising spot – CA-mKO (top), 
IN-24xST (bottom). 
 
The CA-mKO and IN-sfGFP dual labelled virus behaved similarly to that of WT 
virus in regards to the decrease in colocalisation observed over time, responses 
to the various CA mutations and restriction compounds, and the detection of 
colocalised spots within the nucleus (Fig. 14, 19 and 20). However, even with 
the introduction of DeconvolutionLab analysis, the confocal acquisition of fixed 
cell time points was still a very labour intensive process. There was also a large 
disparity in the number of spots observed per cell, and colocalisation between 
biological repeats, as attested to by the large standard deviations between the 
data sets (Fig. 19). Part of this was likely due to variations inherent to recording 
uncoating events within distinct cell populations at different time points. But there 
were also concerns that fusing a fluorescent molecule on to the CTD of CA may 
affect the assembly of the capsid core [207][212][213]. 
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3.2 SunTag capsid-tag (CA-SunTag) 
Since there were concerns that fusing a 26.9 kDa fluorescent protein on to the 
CTD of capsid might be effecting the maturation and structure of the viral core, 
we tested the SunTag system (SUperNova tagging) as an alternative method for 
labelling capsid proteins [193][70]. This method utilises single-chain variable 
fragment (scFv) antibodies fused to a fluorescent reporter (sfGFP), which can 
bind a short peptide inserted into the target protein (section 1.10.2). Because 
the antibody can be expressed in soluble form within cells, this system can be 
used for live particle tracking.    
 
The cyclophilin-binding loop in the NTD of capsid was selected as a suitable site 
for the insertion of the 19 aa SunTag as it interacts with various host proteins 
during the early phase of infection and therefore would be accessible to the 
scFv-antibody [167]. There were also no reports in the literature of mutations at 
this site affecting capsid uncoating [70][214][215]. Using LOOPP protein folding 
recognition software (http://cbsu.tc.cornell.edu/software/loopp/), it was possible 
to predict the structural effects the insertion of this peptide within the loop would 
have on the capsid protein. 
 
Two sites on the p24CA binding loop were chosen for exchange with the GCN4 
peptide: region 87 to 97 (11 aa) (CA Tag v2.1) (Fig. 21) and region 79 to 94 (16 
aa) (CA Tag v1). The epitopes were cloned into both the pNL4-3 proviral vector 
and the ∆8.91 packaging vector and viruses prepared incorporating increasing 
ratios of the CA-SunTag mutant compared to the original vector, to ascertain the 
effects of these mutants on viral infectivity (Fig. 22A). As the cyclophilin-binding 
loop is known to be important in the interaction with host proteins, we wanted a 
certain proportion of WT capsid monomers to be present within the core to allow 
for this association [154].  
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Figure 21. Schematic of the NTD of p24CA showing the insertion site of the GCN4 peptide 
tag (v2.1) within the cyclophilin A binding loop. Adapted from a figure derived from Schur et 
al., 2015 [42]. 
 
For confocal imaging, viral vectors were produced in both standard 293T cells or 
those stably expressing the scFv-sfGFP fusion antibody, the latter to enable the 
antibody to bind to the capsid tag during viral assembly. Viruses were then 
transduced into HeLa P4 cells ± the scFv-sfGFP fusion antibody and fixed at 
various time points prior to and after viral fusion. Cells were then stained for 
p24CA. 
 
The RTU for viruses prepared with increasing concentrations of ∆8.91-CA-
SunTag were similar to that of viruses containing ∆8.91 alone, but a steady 
decrease in infectivity was observed (Fig. 22A). Initial experiments, transducing 
HeLa P4 cells stably producing the scFv-sfGFP antibody with the ∆8.91-CA-
SunTag v2.1 virus, revealed very few green spots within the cells, and of these 
fewer still colocalised when stained for p24CA. More colocalised spots were 
observed with the transduction of 10 RTU of HXB2 enveloped virus (1/5 ∆8.91-
CA-SunTag v2.1 to 4/5 WT ∆8.91) (Fig. 22B), but the concentration was 
considered too high for use in further experiments. As the infectivity with the 
incorporation of 1/5 ∆8.91-CA-SunTag v2.1 was just under half that of the WT 
virus (Fig. 22A), we reasoned more spots should be visible with this system. We 
therefore tried producing the viruses in 293T cells stably expressing the scFv-
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sfGFP, and also tested the CA-SunTag v1 mutant, inserted into regions 79 to 94 
of the p24CA cyclophilin binding loop. Many more green fluorescent puncta were 
observed in WT HeLa P4 cells transduced with CA-SunTag v1 when produced in 
scFv-sfGFP expressing 293T cells (Fig. 22C). A high proportion of these were 
also observed to colocalise with p24CA stain, suggesting that the two antibody 
sites were not mutually exclusive. No green fluorescent puncta were observed in 
the HeLa P4 cells transduced with wild-type virus produced in scFv-sfGFP 
expressing 293T cells (Fig. 22D), suggesting the incorporation of the intrabody 
was epitope specific. 
 
   A B  
 
 
    C D 
 
 
Figure 22. Infectivity and colocalisation of CA-SunTag v2.1. (A) Infectivity (RLU) of VSV-G 
pseudotyped virus with increasing ratios of the ∆8.91-CA-SunTag v2.1 vs. WT ∆8.91 packaging 
vector. (B) Colocalisation of ∆8.91-CA-SunTag v1 (green) (1/5 ∆8.91-CA-SunTag v2.1 + 4/5 WT 
∆8.91) with p24CA stain (red) in HeLa P4 cells stably expressing scFv-sfGFP [10 RTU]. A 
colocalised spot, along with the respective plot profiles, is shown. (C) Colocalisation of ∆8.91-CA-
SunTag v1 (1/4 ∆8.91-CA-SunTag v1 + 3/4 WT ∆8.91) with p24CA stain in WT HeLa P4 cells, with 
virus produced in 293T cells stably expressing scFv-sfGFP. (D) WT ∆8.91 with p24CA stain (red) 
in WT HeLa P4 cells, with virus produced in 293T cells stably expressing scFv-sfGFP. 
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To test whether the incorporation of the CA-SunTag was influencing the 
maturation of the virus, a western blot was performed on HXB2 pseudotyped 
viral preparations containing decreasing ratios of pNL4-3-CA-SunTag v1 with 
respect to WT pNL4-3 (Fig. 23). Immunostaining for p24CA revealed bands at 
~55 kDa, ~48 kDa, ~41 kDa and ~24 kDa for the control virus (NL4-3 Full) 
representing all the products associated with normal HIV-1 cleavage. Smaller 
bands for MA-CA protein (41 ~kDa) in respect to CA (24 ~kDa) were observed in 
viruses containing ½ and ¼ CA-SunTag compared to the WT virus. For the virus 
containing full CA-SunTag, no bands were observed at 48 kDa or 41 kDa, and 
only a very small band was observed for p24CA. This suggested that normal 
protease cleavage was not occurring in the presence of the CA-SunTag, and that 
the appropriate bands in the viruses prepared with ½ and ¼ CA-SunTag were 
probably derived from WT pNL4-3 that was incorporated with them. 
 
 
 
Figure 23. Western blot of virus containing decreasing ratios of pNL4-3-CA-SunTag v1. 
Viruses were prepared with decreasing ratios of pNL4-3-CA-SunTag v1 with respect to the pNL4-
3 provirus and pseudotyped with HXB2 envelope. Viral supernatant was collected, pelleted and 
analysed using western blot and anti-p24CA antibody. 
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3.3 Studying capsid uncoating with Vpr-IN-24xSunTag 
Because we could not be sure whether the viruses produced when inserting the 
SunTag in the capsid were being correctly cleaved, we decided to try an 
alternative approach that would have less impact on viral maturation. 
Amplification of the signal derived from the scFv-sfGFP antibody could be 
achieved by joining repeat GCN4 peptide epitopes with a short flexible linker 
(GGSGG) [193]. Tests with up to 24 of these epitope arrays have been 
successfully implemented which, when bound by the scFv-sfGFP antibody, have 
produced enough signal amplification to enable live tracking of individual 
particles. We decided to test this system by fusing the repeat GCN4 peptide 
array onto the C-terminus of integrase. Instead of following individually labelled 
capsid particles detaching from a fluorescently labelled PIC, uncoating could be 
measured through the internalisation and binding of the cytoplasmic scFv-sfGFP 
antibodies onto the SunTag array upon disassembly of the capsid core. 
 
The 24x SunTag (24xST) array was cloned onto the C-terminus of Vpr-IN (IN-
24xST) and trans-incorporated IN-24xST viruses produced using the pNL4-3 
transfer vector pseudotyped with VSV-G. The viruses were used to transduce 
HeLa P4 cells stably expressing the scFv-sfGFP fusion antibody, and the cells 
fixed and stained for p24CA at regular intervals p.s. Confocal images of the cells 
revealed very few IN-24xST bound scFv-sfGFP spots at 0 min p.s. with both the 
trans-incorporated vector and the WT control, although the capsid stain revealed 
the presence of the virus on the surface of the cells (Fig. 24A and C). However, 
a high number of IN-24xST (green) spots were observed colocalised with the 
capsid stain (red) at 60 min p.s. with the trans-incorporated vector (Fig. 24D). 
Few green and no colocalised spots were observed with the WT control 60 min 
p.s (Fig. 24B). The green spots observed with the WT control were less localised 
and intense compared to the IN-24xST spots seen with the trans-incorporated 
vector, and were most likely due to aggregations of the scFv-sfGFP and 
autofluorescence. Fewer IN-24xST, capsid and colocalised spots were observed 
at 180 and 240 min p.s. (images not shown). 
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 A                   0 min p.s. B                   60 min p.s. 
Wild type 
 
 
  C                   0 min p.s. D                   60 min p.s. 
Vpr-IN-24xST 
 
 
 
 
Figure 24. Vpr-IN-24xST construct vs. wild type control at 0 and 60 min post-spinoculation. 
HeLa P4 cells stably expressing scFv-sfGFP were transduced with VSV-G pseudotyped viruses 
containing the pNL4-3 proviral vector alone (WT control) or trans-incorporated with Vpr-IN-
24xST, fixed at 0 and 60 min p.s., and immunostained with the anti-p24CA antibody (red). (A and 
B) The capsid stain reveals plenty of viruses on the surface of the cells at 0 min p.s with the WT 
control, but few scFv-sfGFP spots (green) at 0 or 60 min p.s. (C and D) Few green spots at 0 min 
p.s., but many green, red and colocalised (white arrows) spots present 60 min p.s. with the IN-
24xSunTag trans-incorporated virus. 
 
To evaluate whether the appearance of green spots corresponded to capsid 
uncoating events, and whether the IN-24xST containing viruses were functioning 
like WT viruses, time courses were repeated +/- the addition of nevirapine (Fig. 
25). 
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Figure 25. SunTag spots per cell over time. HeLa P4 cells stably expressing scFv-sfGFP were 
transduced with IN-24xST trans-incorporated viruses, fixed at regular intervals p.s., and images 
acquired using confocal microscopy. The number of green spots per time point was calculated 
using 3D Object Counter (ImageJ), threshold 6. (A-E) Graphs showing the number of spots per 
cell over time in individual experiments – SEM of 5 technical repeats. (F) Graph showing the 
number of spots per cell when graphs A-E are assembled (SEM).  
 
In contrast to the dual-labelled system for measuring capsid uncoating (sections 
3.13 and 3.14) which measured the loss of fluorescently labelled CA from 
fluorescently labelled integrase, the SunTag system measures uncoating by 
when the cytoplasmically expressed scFv-sFGFP antibody is able to enter the 
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disassembling capsid core to bind to the epitope peptide array. Thus, analysis 
was performed on the kinetics over time in the fluctuations of scFv-sfGFP bound 
SunTag arrays (green spots). Although CA staining may have provided a useful 
reference/normalisation point for the assay, due the labour intensiveness in the 
acquisition of two-channel images (approximately 18 h per data set for 
acquisition of the dual-labelled viral uncoating in section 3.14), we dispensed 
with the capsid stain and focused on the appearance and loss of SunTag spots 
as indicators of uncoating. As the scFv-sfGFP can be expressed within cells, the 
eventual objective was to use this system in live cell imaging, which precludes 
the immunofluorescent staining of CA. 
 
Few spots were observed in cells fixed directly after spinoculation (Fig. 25A-E), 
consistent with the virus initiating fusion with the target cell, and uncoating having 
not yet taken place. This was followed by a sharp increase in spots, with a peak 
number of spots per cell recorded from 30 to 60 minutes p.s. The addition of 
nevirapine delayed the peak in spots per cell recorded in two of the time courses, 
but a similar kinetic as the DMSO control was observed in two more experiments 
(Fig. 25B-E). When the graphs were compiled, however, a significant delay in 
the peak number of spots per cells was observed with the addition of nevirapine 
(120 min p.s) compared to the DMSO control (45 min p.s) (Fig. 25F). 
 
3.3.1 24xSunTag analysis with Operetta High-Content Imaging 
One of the drawbacks of measuring uncoating using confocal microscopy was 
the requirement to fix the samples, meaning that the images acquired between 
time points were of different cell populations. To track the viral particles within the 
same cells throughout the time course, a series of experiments was performed 
using the Operetta High-Content Imaging System. Viruses were prepared using 
pNL4-3 pseudotyped with VSV-G envelope. HeLa P4 clone cells stably 
expressing scFv-sfGFP were seeded into 96-well cell carrier plates, and 
transduced with IN-24xST trans-incorporated viruses. Viral supernatant was 
replaced with warm fluorobrite media directly after spinoculation and the plate 
was transferred to the Operetta for image acquisition. Images were acquired at 
5-15 minute intervals using the 40x objective, Xenon laser and the standard 
Alexa 488 filter set.  
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~26 min p.s. ~170 min p.s. 
 
Figure 26. Detection of IN-24xST labelled viruses in HeLa P4 cells using the Operetta high-
content imaging system. HeLa P4 cells stably expressing the scFv-sfGFP intrabody were 
transduced with ~0.6 RTU of IN-24xST labelled virus (A and B) or NL4.3 + VSV-G CTRL virus (C 
and D) and imaged at regular intervals p.s. Arrows indicate examples of IN-24xST spots. (A) 
Many spots were observed in cells transduced with the IN-24xST labelled virus at ~26 min p.s., 
far fewer spots were observed ~170 min p.s. (B). Little to no spots observed in the NL4-3 + VSV-
G CTRL (C and D).  
 
Fluorescent puncta were clearly evident within the cytoplasm of infected cells 25 
min p.s. (Fig. 26A), indicating successful fusion and uncoating of the IN-24xST 
trans-incorporated virus. Fewer spots were observed 170 min p.s. suggesting 
most of the viruses had uncoated (Fig. 26B). A 24xST signal profile in relation to 
background levels of scFv-sfGFP over time, indicated that bleaching of the signal 
was not occurring (Fig. S2). 
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Repeat time courses were conducted comparing the original IN-24xST virus 
along with viruses containing CA mutations making the capsid core less stable 
(K203A) and more stable (E45A and E128A/R132A) compared to WT CA, a virus 
containing a mutation in the active site of RT (D110E), and the addition of the 
inhibitory compounds nevirapine, ebselen and PF74. After live acquisition the 
cells and fluorescent puncta were segmented and analysed using the Harmony 
High-Content Imaging and Analysis Software (section 2.9.1). Transduction with 
a VSV-G pseudotyped pNL4-3 virus without IN-24xST provided a negative 
control from which we could optimise the spot segmentation, removing the 
pseudo-spots derived from autofluorescence.  
 
As with confocal imaging, few fluorescent puncta were observed in the initial time 
point, from 4-10 min p.s., however, a consistent peak in the number of spots per 
cell was detected from 20 to 30 min p.s. (Fig. 27A and B). This is in 
concordance with the reports on the 50% capsid uncoating time recorded with 
VSV-G pseudotyped viruses [127][67]. A sharp drop in the number of spots per 
cell was observed thereafter, which levelled off at approximately 60 to 80 min 
p.s. to a population just above that of the WT control.  
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Figure 27. Number of SunTag spots per cell time post-spinoculation. HeLa P4 cells stably 
expressing the scFv-sfGFP intrabody were transduced with ~0.15 RTU IN-24xST labelled virus 
preparations and imaged at 5 min intervals p.s. (A) ± capsid restriction compounds and a RT 
mutant. (B) CA mutations. Error bars indicate the SEM of 6 technical and 2 biological repeats. 
 
Similar kinetics were observed with all the viruses ± the CA mutations or 
restriction compounds, with a sharp peak in the number of spots per cell from 21-
26 min p.s., followed by a sharp decline, levelling off to a point just above that of 
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the WT control at the end of the time course (Fig. 27A and B). The latter, 
suggesting that uncoating was occurring right up until the end of the time course. 
No significant difference was observed for the time point with the peak number of 
spots per cell between the IN-24xST trans-incorporated virus ± nevirapine or the 
RT mutant (Fig. 27A), or with the addition of ebselen and PF74 (Fig. 28A). 
Viruses containing CA mutations also failed to elicit any significant difference in 
peak uncoating (Fig. 27B).  
 
To establish whether the fluorescent puncta observed were fluorescently labelled 
virus particles and not VSV-G enveloped vesicles [124], IN-24xST particles 
pseudotyped with VSV-G were prepared without the pNL4-3 provirus. Trans-
incorporated viruses were also prepared with the HXB2 envelope as earlier 
experiments had shown that these viruses only enter cells expressing the CD4 
receptor (Fig. 12). As expected, background levels of fluorescence similar to that 
of the WT control (minus IN-24xST) were observed with the particles prepared 
with IN-24xST but without the viral genome (Fig. 28A). Fewer puncta were 
detected with viruses prepared with HXB2 envelope compared to VSV-G 
pseudotyped viruses (Fig. 28B), with approximately 1 spot for every 3 cells, but 
this is in accordance with the reports of lower fusion efficiency with the WT 
envelope [216]. However, the peak in the number of SunTag spots per cell 
occurred within the same time frame as that recorded with VSV-G pseudotyped 
particles (22 min p.s.), which is in contrast to that observed by Hulme and co-
workers [67], who reported a delay in fusion of 23 min with WT envelope. Apart 
from the more pronounced peak seen with the VSV-G pseudotyped virus, the 
overall kinetics were similar, with a levelling off after 60 min of around 1 spot for 
every 4 cells with HXB2 enveloped viruses, and 1 spot every 2-3 cells with VSV-
G. Background levels of fluorescence were observed with viruses prepared 
without an envelope (Fig. 28B). 
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Figure 28. Number of SunTag spots per cell time post-spinoculation with addition of HIV-1 
restriction compounds, ± the HXB2 envelope and viruses prepared without the NL4-3 
provirus. HeLa P4 cells stably expressing the scFv-sfGFP intrabody were transduced with ~0.15 
RTU IN-24xST labelled virus preparations. (A) Number of IN-24xST spots per cell over time ± the 
restriction compounds PF74 and ebselen, and a vector prepared without the NL4-3 provirus. (B) 
Number of SunTag spots per cell with vectors prepared ± HXB2 envelope. Error bars indicate the 
SEM of 3 technical repeats. 
 
A number of experiments were conducted to try to generate a change in the time 
when the peak number of spots per cell were observed to verify if we were 
actually tracking uncoating events. Trans-incorporated viruses were produced in 
the presence of saquinavir, a protease inhibitor, to restrict the development of a 
mature capsid core; without a functional capsid core we expected scFv-sfGFP 
SunTag bound spots to be seen immediately upon fusion. A scFv-sfGFP 
expression clone was also developed using the TZM-bl cell line stably 
expressing the TRIM-CypA fusion protein, which is reported to bind to intact 
capsid cores triggering premature uncoating events [209]. Neither of these tests, 
however, significantly altered the time at which the peak number of spots per cell 
was observed (Fig. S3).  
 
3.4 Studying uncoating with APOBEC3-24xSunTag 
As it was difficult to establish whether the spots observed with Vpr-integrase 
trans-incorporation of the SunTag were derived from uncoating events of real 
infective viruses, we decided to test an alternative method for the insertion of the 
repeat peptide epitope array into the viral capsid core. Burdick and co-workers 
managed to track HIV-1 PICs by the fusion of a yellow fluorescent protein on to 
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the C-terminus of the APOBEC human cytidine deaminases APOBEC3F (A3F) 
and APOBEC3G (A3G) (section 1.10.1) [124]. The A3F/G proteins are thought 
to be encapsulated within HIV-1 viral cores through interaction with viral RNA 
and the nucleocapsid domain of the Gag protein [217][195][218]. Although the 
proteins actively restrict Vif-deficient HIV-1 replication [219][220], as uncoating 
occurs in the early phase of infection we reasoned the viral ribonucleoprotein 
targeting properties of A3F/G would provide a suitable alternative method for the 
incorporation the 24xSunTag array into the capsid core.  
 
The 24xSunTag peptide array was fused to the C-terminus of A3F and an A3G 
E259Q mutant (A3G*) reported to reduce the HIV-1 restriction properties of this 
protein [124]. These vectors were used in the production of viruses, along with 
the Vif negative pHR-SIN-Luc molecular clone [221], the ∆8.91 packaging vector 
and VSV-G envelope. The viruses were used to infect HeLa P4 scFv-sfGFP 
stable clone cells in 96-well tissue culture plates and analysed using Operetta 
high-content imaging (Fig. 29). 
 
20 40 60 80 100 120 140 160
0.0
0.5
1.0
1.5
2.0 VIN-24xST + VSV-G
A3F-24xST + VSV-G
A3G* -24xST + VSV-G
NL4.3 + VSV-G
22 min
Time post-spinoculation (min)
S
p
o
ts
 p
e
r 
c
e
ll
 
 
Figure 29. Number of SunTag spots per cell time post-spinoculation with APOBEC3F/G* 
trans-incorporated viruses. HeLa P4 cells stably expressing the scFv-sfGFP intrabody were 
transduced with ~0.15 RTU APOBEC3F/G*-24xST labelled virus preparations and imaged at 5 
min intervals p.s. Error bars indicate the SEM of 3 technical repeats. 
 
As with the Vpr-IN-24xST system, few spots were observed in the initial time 
points p.s., but a sharp increase in spots per cell were seen hereafter, with a 
peak in the number of spots recorded 22 min p.s. This was in the range of the 
peak in spots per cell recorded with Vpr incorporation of the 24xST (20 to 30 
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min), and also other reports on the 50% uncoating time of VSV-G pseudotyped 
viruses [67][127]. In contrast to the Vpr incorporated SunTag, a slower reduction 
in spots per cells was observed with the A3G*-24xST trans-incorporated virus.  
 
3.5 Operetta High-Content Imaging using a 60x objective 
In the above experiments (section 3.3 and 3.4) the images were acquired using 
a 40x objective, and it was suspected that the lower resolution compared to 
confocal acquisition using the 63x objective, meant that some of the subtler 
aspects of uncoating were being lost. This may have contributed to the 
consistent peak of spots per cell observed in the presence of restriction 
compounds and CA mutants. Thus, analysis of the Vpr-IN/A3F-24xST vectors 
was repeated with the Operetta high-content imaging system using a 60x 
objective (Fig. 30). Repeat experiments in the presence of nevirapine or the 
DMSO control showed a significant delay in the reduction of the number of spots 
detected per cell, after the initial peak, in the presence of nevirapine (Fig. 30A, B 
and C). This levelled off to a point just above that of the DMSO control, 
suggesting that in the presence of nevirapine spots were being detected, or 
uncoating was occurring, at a higher rate than with the DMSO control, right up to 
the end of the time course. A less stable CA mutant (K203A) was also analysed 
alongside the non-mutated IN-24xST vector, and a significantly premature peak 
in uncoating (15 min as opposed to 23 min p.s.) was observed with the less 
stable capsid core (Fig. 30D). 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
10 20 30 40 50 60 70 80 90 10
0
11
0
0.0
2.5
5.0
7.5
10.0
12.5
NL4.3 + VSV-G
VIN-24xST
VIN-24xST (K203A)
K203A
VIN-24xST
Time post-spinoculation (min)
S
p
o
ts
 p
e
r 
c
e
ll
10 30 50 70 90 11
0
13
0
15
0
0.0
2.0
4.0
6.0
8.0
A3F-24xST
A3F-24xST + Nevirapine
NL4.3 + VSV-G
Time post-spinoculation (min)
S
p
o
ts
 p
e
r 
c
e
ll
15 25 35 45 55 65 75 85 95 10
5
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
Vpr-IN-24xST
Vpr-IN-24xST + Nevirapine
NL4.3 + VSV-G
Time post-spinoculation (min)
S
p
o
ts
 p
e
r 
c
e
ll
10 20 30 40 50 60 70 80 90 10
0
11
0
0.0
2.5
5.0
7.5
10.0
12.5
VIN-24xST
VIN-24xST + Nevirapine
NL4.3 + VSV-G
Time post-spinoculation (min)
S
p
o
ts
 p
e
r 
c
e
ll
A B 
  
C D 
  
 
Figure 30. Number of SunTag spots per cell time post-spinoculation with Operetta High-
Content Imaging using a 60x objective. HeLa P4 cells stably expressing the scFv-sfGFP 
intrabody were transduced with ~1 RTU Vpr-IN/A3F-24xST labelled virus preparations and 
uncoating analysed using a 60x objective. (A and B) Number of IN-24xST spots per cell over time 
± nevirapine. (C) Number of A3F-24xST spots per cell over time ± nevirapine. (D) Number of Vpr-
IN-24xST compared to a virus prepared with a less stable (K203A) capsid core. SEM of 3 
technical repeats. 
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3.6 NanoBiT luciferase analysis of HIV-1 uncoating 
As there was little significant difference in the timing for the peak number of spots 
per cell observed with the two 24xSunTag array capsid uncoating systems, we 
decided to try an alternative strategy for studying uncoating. One of the 
perceived drawbacks to the 24xST repeat epitope was the size of the non-bound 
~63 kDa SunTag array, and what effect this would have on the assembly of the 
capsid core. NanoLuc Binary Technology (NanoBiT) is a two-subunit system 
used for intracellular detection of protein:protein interactions using an engineered 
luciferase (section 1.10.3) [222][200]. Luminesence is achieved upon binding of 
the 1.3 kDa peptide (HiBiT) with the 18 kDa polypeptide (LgBiT), in the presence 
of substrate. The small size (19 kDa) and stability of the enzyme made it an 
attractive option to use as an alternative to the SunTag.  
 
The 11 aa HiBiT peptide was cloned on to the c-terminus of the A3F/G* proteins, 
and the LgBiT peptide inserted into a pAIB provirus and used in the production of 
HeLa P4 cells stably expressing the LgBiT. Because of the small size of the 
HiBiT we also decided to insert it onto the C-terminus of integrase in the pNL4-3 
proviral vector, as similar sized peptides had previously been inserted here 
without affecting the infectivity of the virus [204]. The fusion of the HiBiT to a 
proviral vector would prevent the formation of labelled VSV-G pseudotyped 
vesicles which may have been present in the previous systems. Viruses were 
prepared using the pHR-SIN-GFP molecular clone and the ∆8.91 packaging 
vector for the A3F/G* trans-incorporated HiBiT or with pNL4-3-HiBiT proviral 
vector alone, and pseudotyped with VSV-G or HXB2 envelope. HeLa P4 cells 
expressing the LgBiT were seeded into 96-well tissue culture plates and 
transduced using spinoculation. Viruses prepared without the HiBiT and 
transfection with the HiBiT containing plasmids were used as negative and 
positive controls, respectively. Nano-Glo Live Cell reagent was added 
immediately after spinoculation and the cells analysed using a TECAN Infinite 
M200 microplate reader for 150 min at 5 min intervals (Fig. 30). 
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Figure 31. Relative luminescent units (RLU) time post-spinoculation for APOBEC3F/G*-
HiBiT trans-incorporated viruses. HeLa P4 cells expressing the Large Bit (LgBiT) enzyme 
fragment were transduced with 1.2 RTU VSV-G pseudotyped A3F/G*-HiBiT labelled virus 
preparations and the plates analysed at 5 min intervals p.s. with the TECAN Infinite M200 
microplate reader. (A) A3F/G*-HiBiT (n = 3 biological repeats). (B) A3F-HiBiT virus ± nevirapine 
[10 µM (n = 3 technical repeats]. (C) A3F-HiBiT alongside a less stable (K203A) or more stable 
(E128A/R132A) capsid mutant (n = 3 technical repeats. (D) A vector prepared without the viral 
genome (2 biological repeats). Error bars show the SEM.  
 
A pronounced peak in RLU was observed with both the A3G* and A3F-HiBiT 
viruses at 35 min and 45 min p.s., respectively, with a slower decline in RLU after 
this point (Fig. 31A). RLU double of that for the A3G*-HiBiT virus were recorded 
with the A3F-HiBiT trans-incorporated virus. The addition of nevirapine to the 
samples failed to change the kinetics of the curve with the A3F-HiBiT (Fig. 31B). 
CA mutations in the ∆8.91 packaging vector which destabilised (K203A) and 
stabilised (E128A/R132A) the viral core, showed an earlier and delayed peak in 
RLU, respectively, compared to the non-mutated virus (Fig. 31C). A 50% 
decrease in RLU was also recorded with the CA mutants. The sharp peak in RLU 
at ~80 min p.s. was a result of an extra orbital shake upon the addition of fresh 
Nano-Glo substrate in one of the wells (Fig. S4). Vectors prepared lacking the 
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viral genome (VLPs) exhibited different RLU kinetics compared to true viruses 
(Fig. 31D), suggesting that the initial increase in RLU observed with normal viral 
vectors (Fig. 31A, B and C) was a result of capsid uncoating rather than VLP 
fusion events.  
 
Preliminary studies using the HiBiT moiety cloned onto the C-terminus of 
integrase in NL4-3 showed a similar peak in RLU to the A3F/G*-HiBiT, at around 
37 min p.s. (Fig. 32). This suggested that the peak in luciferase was a result of 
capsid uncoating, and not through fusion with VSV-G pseudotyped vesicles. A 
shift in the kinetics of the peaks in the presence of capsid restriction compounds 
was also observed. A delay of ~10 min was observed in the presence of PF74 
compared to the DMSO control with both the WT (HXB2) envelope and the VSV-
G pseudotyped viruses (Fig. 32A and B). A premature peak in RLU (~10 min) 
was observed in the presence of ebselen compared to the DMSO control, with 
the VSV-G pseudotyped virus (Fig. 32B). The addition of nevirapine had little 
effect on the peak in the RLU, with only a ~5 min delay compared to the DMSO 
control in viruses prepared with the WT envelope (Fig. 32A).  
 
A B 
  
 
Figure 32. Relative luminescent units (RLU) time post-spinoculation for pNL4-3.Luc.R-
E-HiBiT trans-incorporated viruses. HeLa P4 cells expressing the Large Bit (LgBiT) 
enzyme fragment were transduced with HXB2 (WT) enveloped [8 RTU] or VSV-G 
pseudotyped [3 RTU] NL4-3-HiBiT labelled viruses, in the presence of the restriction 
compounds nevirapine, ebselen, PF74 or the DMSO control. The cells were analysed at 5 
min intervals p.s. with the TECAN Infinite M200 microplate reader. (A) NL4-3-HiBiT + HXB2 
(WT) envelope. (B) NL4-3-HiBiT + VSV-G. SEM of n = 3 technical repeats.  
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DISCUSSION 
The early phase of HIV-1 infection has been intensively studied over the past 35 
years, and it is becoming increasingly clear that the viral capsid (the individual 
proteins and the assembled fullerene core) plays a fundamental role in 
productive infection [44][160][85][94]. Initially, the viral core was thought to be 
solely a vessel for the containment and effective transport of the viral 
ribonucleoprotein into the target cell [15]. However, investigations into HIV-1 
trafficking pathways and integration site preferences using wholescale genomic 
knockdown studies and CA mutations [54][56][58][65][88][89][91][103], 
emphasise the intrinsic role of CA in multiple steps leading up to incorporation 
with the host genome. These insights must have an impact on the historical 
interpretation of uncoating as solely the process by which the capsid core 
dissociates from the RTC [44][223]. Thus, the process of uncoating should be 
understood in the wider context of the large number of host factors with which 
CA interacts during cytoplasmic trafficking and nuclear import of the viral 
genome. 
 
The principal aim of this project was to devise a system with which to study the 
process of uncoating within the spatial and temporal context of the cell, to help 
clarify some of the questions regarding where, when and how the capsid 
disassembles after productive cellular fusion. For this purpose we developed 
three uncoating assays, with each one encompassing different properties which 
in combination would give a more comprehensive picture of in situ CA 
disassembly: 1) a dual-labelled virus, in which uncoating could be measured by 
the separation of fluorescent labels fused to the CTD of both CA and IN; 2) 
capsid incorporation of a repeat peptide array (SunTag),  which facilitates signal 
detection through attachment of cytoplasmically expressed, fluorescently labelled 
antibodies after breaching of the capsid core; and 3) capsid incorporation of a 
small peptide from a split luciferase system, which generates luminescence upon 
fusion with the cytoplasmically expressed polypeptide moiety (in the presence of 
substrate). By approaching capsid uncoating using different techniques it was 
possible to get a more holistic understanding of this process, which can 
otherwise lead to a biased interpretation when using individual systems of 
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analysis. A table summarising the advantages/disadvantages of each system 
can be seen at the end of the discussion (Table 2). 
 
4.1 A dual-fluorescent system for studying uncoating 
The labelling of proteins with fluorescent probes is a well-established method for 
studying intracellular events using high resolution microscopy [187]. This has 
enabled the direct visualisation of interactions between HIV-1 and cellular 
proteins, providing a wealth of information regarding the physical location and 
temporal aspects of these exchanges. Although in vivo analysis of HIV-1 
infection had been performed through the fluorescent labelling of other regions of 
the Gag gene [187], this was the first study whereby a fluorophore was fused 
directly to the CTD of CA. The capsid core is notorious for its sensitivity to CA 
mutations, with even point mutations effecting the stability and consequently the 
infectivity of the virus [65][112]. It has also been reported that the 
peptides/proteins, and the correct cleavage events of the Gag polyprotein, 
downstream from CA can have a direct effect on the proper assembly and 
functioning of the capsid core [207][212][213]. The production of viable capsid 
cores containing CA monomers with fluorophores fused to the CTD of the protein 
was made possible by the ability of the Gag protein to multimerise (primarily 
through interactions with the CTD of CA) at the cellular membrane before viral 
assembly and budding [36][224]. Thus, through the co-transfection of a vector 
containing the gene for a full Gag polyprotein (pNL4-3) and the vector containing 
a fluorophore fused to the CTD of CA, it was possible to produce infectious 
virions with correctly assembled, fluorescently labelled, capsid core. A system for 
tracking the RTC/PIC up to and including nuclear entry had already been 
developed by Albanese and co-workers, through the fusion of a fluorophore on to 
the CTD of IN [125]. This, in turn, was fused to HIV-1 Vpr, with the inclusion of a 
proteolytic cleavage site, which enabled the efficient trans-incorporation of the 
fluorescently labelled IN into the assembling capsid core through protease 
activation during viral maturation. A titration assay was performed to determine 
the optimal concentration of vectors to use in the production of CA and IN 
fluorescently labelled (dual-labelled) viruses (Fig. 10). A plasmid transfection 
concentration was selected which limited the loss of infectivity to 18% of that 
compared to WT virus. Although this was significantly lower than the WT virus, 
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subsequent confocal analysis ensured that enough fluorescently labelled virus 
was present for visualisation of colocalisation (Fig. 12).  
 
Western blot analysis of viral supernatant produced when transfecting with 
increasing concentrations of MA-CA-GFP vector, revealed bands corresponding 
to the expected cleavage products (Fig. 11), including CA-GFP (~52 kDa).  A 
large proportion of the matrix, however, remained attached to CA-GFP. This may 
have been due to the presence of immature viruses within the viral supernatant. 
Alternatively, the MA-CA-GFP protein may have been overly expressed in the 
producer cells and was in excess to that which could be processed by the NL4-3 
protease. The absence of the proteins downstream from the MA-CA-GFP vector 
may also have had an effect on the upstream protease cleavage [206][207].  
 
When the dual-labelled virus was pseudotyped with an HXB2 (WT) envelope and 
used to infect cell lines stably expressing the CD4 receptor (HeLa P4) or WT 
HeLa cells, CA-GFP and IN-mCherry colocalised particles were observed only in 
the CD4 expressing cell line (Fig. 12). The lack of fluorescent spots within WT 
HeLa cells indicated that the spots observed within the HeLa P4 cells entered 
productively through fusion with the CD4 receptor, rather than through 
endocytosis. A high percentage of colocalisation could also be observed 
between the CA-GFP and IN-mCherry signals, and the subsequent loss of 
colocalisation when imaging the dual-labelled virus at later time points post-
infection lent further evidence for its potential use for the tracking of uncoating 
events (Fig. 13). 
 
4.1.1 Validation of dual-labelled virus 
A series of time courses were performed with the dual-labelled virus in the 
presence of CA-targeting restrictive compounds, and with the addition of 
mutations in the CA known to affect the stability of the capsid (Fig. 14). These 
were performed to verify whether the loss of colocalisation between the CA-GFP 
and IN-mCherry was a marker of real uncoating events, and from this to 
ascertain whether the dual-labelled virus was functioning like WT HIV-1 virus. 
Analysis in conjunction with a Vpr-IN-mCherry only trans-incorporated virus, 
stained with an anti-p24CA antibody, showed a similar trend in loss of 
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colocalisation over time (Fig. 14A), with both viruses containing a residual 
proportion of the population that retained CA up until the end of the time course. 
This could also be observed directly under the confocal microscope (Fig. 13D). 
Visibly larger fluorescent puncta were obtained with the p24CA stain compared to 
the fluorescently labelled CA, probably due to stoichiometric effects i.e. only a 
portion of the CA monomers present within the capsid core would be directly 
labelled by the fluorophore (trans-incorporation along with WT CA), whereas a 
higher percentage would be available for staining. This would account for the 
constantly higher percentage of colocalisation observed over time for the CA 
stained particles.  
 
The addition of restriction compounds had a similar effect on the uncoating of the 
dual-labelled virus as has been reported in other uncoating assays 
[67][111][127]. The addition of the RT inhibitor, nevirapine, significantly delayed 
uncoating (Fig. 14B), in accordance with reports of a functional link between 
reverse transcription and CA disassembly [67][127][129]. The addition of PF74 
[10 µM] promoted a moderate but significant increase in uncoating at 60 min 
prior to that of the DMSO control (Fig. 14C), consistent with reports that the 
capsid core destabilises in the presence of high concentrations [≥5µM] of PF74 
[47][115][130][225]. A 50% half-time of uncoating was observed for both viruses 
at the 180 min time point post-trypsinisation. PF74 has also been reported to 
inhibit the binding of CA with the phenylalanine-glycine (FG) repeats of Nup358 
and Nup153, impeding the interaction of these Nups with capsid at the nuclear 
envelope [46][91][105][130][131][176]. This may account for the levelling-off of 
colocalisation observed from 180 to 240 min post-trypsinisation in the presence 
of PF74 compared to the DMSO control. 
 
The infection of TZM-bl cells stably expressing the TRIM-CypA restriction factor 
and a dual-labelled virus containing a less stable capsid core (K203A), both 
showed premature uncoating compared to the control viruses, in agreement with 
other reports (Fig. 14D and E) [67][127]. TRIM-CypA has been reported to target 
intact capsid cores soon after viral cellular entry, leading to premature capsid 
uncoating [122][123]. Both conditions exhibited increased uncoating at the ‘0 min 
plus trypsin’ compared to the ‘0 min minus trypsin’ time point. In our assay, we 
allowed a 50 min incubation period post-spinoculation before trypsinisation, for 
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the optimal fusion of the HXB2 (WT) envelope with the cellular membrane. This 
is in line with previous experiments and a report on the half-time for HXB2 fusion 
[67]. However, a large amount of virus was still entering the cells before the ‘0 
min’ time point, and these studies suggest that uncoating was occurring almost 
immediately after viral entry (before the 30 min post-trypsinisation time point). 
Compared to the directly fixed non-trypsinised cells (0 min minus trypsin), which 
would contain a large proportion of colocalised virions outside of the cell, a 
significant increase in uncoating could be observed within the trypsinised cells. 
Although spinoculation at 16°C increased the synchronisation of viral fusion 
events, these experiments highlight the dynamic kinetics of HIV-1 fusion, and the 
complications entailed in studying the uncoating events of bulk populations of 
viruses.  
 
Finally, a double mutation (E128A/R132A) was introduced into the CA of the 
dual-labelled virus which has been reported to increase the stability of the capsid 
core, leading to delayed uncoating kinetics [65][67][124]. When assayed 
alongside a non-mutated dual-labelled virus, a similar trend in uncoating kinetics 
could be observed with both viruses (Fig. 14F). However, when the threshold for 
CA colocalisation with IN was raised (i.e. a higher intensity of CA within the 
segmented IN region was required to establish colocalisation) an almost 3-fold 
lower colocalisation (represented by the area under the curve – AUC) was 
observed with WT compared to the CA mutant virus (Fig. 14G). This means that 
a significantly larger proportion of capsid was remaining with the viral genome 
with the CA mutant compared to with the WT capsid, suggesting that the 
mutation was also affecting the stability of the remaining core after the initial 
uncoating event. This is similar to what was observed by Xu and co-workers 
[111]. 
 
A relative increase in colocalisation was occasionally observed at the end of the 
time course with this assay (Fig. 14 A, F/G), and visual inspection of the images 
revealed a number of colocalised particles. Some authors have reported a 
delayed uncoating at the periphery of the nucleus [15][86][142]. As the 
percentage of colocalisation using the 3D manager plugin was determined by the 
number of colocalised particles divided by the total number of IN-labelled 
particles, what we may be observing here is a loss of IN-labelled particles from 
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previously uncoated PICs (through diffusion or proteasome degradation) in 
comparison to the colocalised ‘intact’ capsid particles, which are remaining 
relatively stable in numbers. Thus, we are not actually observing an increase in 
total colocalisation, but an increase compared to the number of IN-labelled 
particles. 
 
Taken together, these results show a decrease in colocalisation (capsid 
uncoating) over time, with a proportion of the CA remaining colocalised with IN 
up until the end of the time course - up to 6 hr post-spinoculation in some of the 
time courses (Fig. 14A, B, D and F/G). This is the period when most of the PICs 
were observed associated within the nucleus in a study performed by Albanese 
and co-workers [125]. There is the possibility that the colocalised particles 
observed at the end of the time course were aberrant viruses, and one of the 
current drawbacks in using imaging methods for tracking HIV-1 uncoating is the 
inability to distinguish between these and the particles which will eventually lead 
to productive infection [44][226]. However, it is tempting to speculate that the 
PICs containing a residual amount of CA may be the ones that lead to nuclear 
translocation, and subsequent integration into the host genome.  
 
4.1.2 High-throughput analysis of uncoating 
The tracking of the dual-labelled viruses using confocal microscopy was a very 
labour intensive process, taking up to 18 h just to acquire the images for a data 
set. To speed up the process a pipeline was devised using DeconvolutionLab 
open source software (ImageJ), which performed the automatic deconvolution, 
segmentation, counting and colocalisation of the images (Fig. 17). The IN-
mCherry fluorophore was replaced with sfGFP, and the CA-GFP fluorophore 
subsequently swapped for mKO. In combination, these fluorophores provided a 
brighter fluorescence, enabling the reduction of the pinhole from 1.5 to 1.0 AU 
(Table 1; Fig. 15). This, in turn, reduced the background signal in the images, 
and resulted in smaller and more defined puncta. Time courses were repeated 
with the dual-fluorescent virus in the presence of nevirapine or the DMSO 
control. This enabled the use of the same virus stock between conditions, 
reducing the confounding effects associated with using two different viruses (i.e. 
those prepared with CA mutations). Again, the optimal segmentation 
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thresholding had to be adjusted manually, due to slight differences in the SNR 
between data sets (Fig. 18). This system drastically reduced the time it took to 
analyse the images (from a few days to a few hours). The accuracy of the 
DeconvolutionLab analysis was assessed by manual counting. Uncoating was 
determined by both the loss of the absolute number of CA-mKO and IN-sfGFP 
colocalised spots over time (Fig. 19A), and the number of colocalised spots 
divided by either the total number of CA-mKO (Fig. 19B) or IN-sfGFP spots. A 
clear drop in colocalisation, similar to that seen in Fig. 14, was observed over 
time using DeconvolutionLab analysis (Fig. 19). When assessing the absolute 
number of colocalised spots, a 50% half-time of uncoating was observed 
between the 110 and 170 min time points post-trypsinisation for both the 
nevirapine and the DMSO control samples (Fig. 19A). An additional sampling 
between these two time points may have enabled the elucidation of the capsid 
stabilising effects of nevirapine. However, when assessing the ratio of 
colocalised spots a significant delay in uncoating was recorded in the presence 
of nevirapine compared to the DMSO control at the 170 to 230 min time points 
(Fig. 19B). The disparity in results derived from these different systems for 
calculating uncoating can be explained by the fact that the first system considers 
solely the total number of colocalised spots, without addressing the uncoated 
particles. As the spot counts were derived from separate cell populations at 
different time points, it is highly likely that there were fluctuations in the number 
of viral particles per cell between disparate time points i.e. it is unlikely that each 
cell will be infected with exactly the same number of viral particles. When 
calculating the ratio of colocalisation, however, the method considers the number 
of CA-mKO or IN-sfGFP puncta in relation to the total number of colocalised 
particles, which should not be effected by disparities in cellular infection.  
 
Although high-throughput analysis drastically reduced the time it took to analyse 
samples, and a clear difference in uncoating kinetics could be observed for the 
dual-labelled virus plus/minus the addition of nevirapine (Fig. 19B), a large 
deviation in the percentage/ratio of colocalisation was detected between 
separate time courses (Fig. 19A and B). There are many factors involved in an 
experiment of this sort – differences between viral productions, quality of the 
cells, even disparities through confocal acquisition on separate days. The 
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analysis of different cell populations within separate time points presented an 
additional factor that could lead to fluctuations within biological repeats. 
 
4.1.3 Colocalisation within the nucleus 
Contrary to some of the early studies, suggesting a model of complete capsid 
uncoating from the VNC directly after cellular entry of the virus [16][50], two 
groups have recently published the first images of CA particles colocalised with 
IN within the nucleus [55][57]. Both groups used the Vpr-IN-GFP system for 
labelling the PIC, and capsid colocalisation was detected using p24CA antibody 
staining. Super-resolution microscopy was required in both cases because of the 
low levels of CA associated with the PICs in the nuclear compartment, with Peng 
and co-workers using photoactivated localisation microscopy (PALM) alongside 
direct stochastical optical reconstruction microscopy (dSTORM), whilst the 
Hulme group employed high resolution structured illumination microscopy (SIM). 
Using CA-mKO in conjunction with IN-sfGFP, we were also able to detect capsid 
particles colocalised with IN within the nucleus using conventional confocal 
microscopy and Huygens Remote Manager deconvolution software (Fig. 20). 
However, with the dual-fluorescently labelled virus it should be possible to track 
the translocation of the PIC through the nuclear membrane in real time, enabling 
live visualisation of the interaction of CA with the proteins involved in the nuclear 
import pathway (Nup358, Nup153, TNPO2, CPSF6). This presents many exciting 
possibilities for the further elucidation of viral interactions at the nuclear pore, and 
may confirm the growing literature reports suggesting a link with HIV-1 CA and 
PIC nuclear translocation and integration [85][86][87][91]. 
 
4.2 SUperNova tagging (SunTag) system – CA-SunTag 
Reports that interfering with the protease cleavage sites and proteins 
downstream of the CA protein of Gag [207][212][213] might affect the maturation 
and assembly of a correctly functioning capsid core, led us to try an alternative 
method for labelling the capsid core. The SunTag provided an attractive 
alternative system for labelling of the capsid core because of its relatively small 
size 19 aa (2.3 kDa) compared to a fluorophore (27 kDa) [193]. The fluorescently 
labelled reporter antibody (scFv-sfGFP) was ideally suited for targeting the 
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SunTag, because the fused light and heavy chains of its epitope-binding regions 
enabled its productive expression within cells – facilitating its use in live 
microscopy. The CypA-binding loop was selected as the site for the incorporation 
of the SunTag peptide because of its prominent location on the surface of the 
capsid core, and literature reviews and protein folding algorithms suggested 
minimum impact for peptide insertion within this domain [65][112][215][214]. A 
mature capsid core is composed of approximately 1500 CA monomers [39][43]. 
Thus, it was reasoned that trans-incorporation of a viral vector containing the CA 
SunTag in conjunction with a standard viral vector, would provide enough sites 
for the binding of the fluorescently labelled antibody (scFv-sfGFP) for confocal 
visualisation, and the binding of cellular factors (e.g. CypA) necessary for 
productive infection.  
 
Viral infectivity was significantly reduced for the CA-SunTag incorporated virus, 
but this could be rescued to almost half of the WT infectivity levels through co-
transfection with greater ratios of a non-tagged packaging vector (Fig. 22A). 
When infecting HeLa P4 cells stably expressing scFv-sfGFP, very few spots 
were observed at various time points post-spinoculation (Fig. 22B). However, 
many spots could be observed in target cells when the CA-SunTag virus was 
produced in 293T cells stably expressing the scFv-sfGFP antibody (Fig. 22C). 
This may have been due to increased accessibility of the CA-SunTag epitope to 
the scFv-sfGFP antibodies during viral production. These spots were also shown 
to colocalise with a p24CA antibody stain, which meant that the CA-SunTag 
system did not interfere with AG3.0 antibody binding. Finally, no CA-SunTag 
spots were observed when WT virus was produced in 293T cells expressing the 
scFv-sfGFP, and used to infect HeLa P4 cells (Fig. 22D); confirming that 
antibody incorporation was epitope specific. 
 
Western blot analysis, however, revealed that proper protease cleavage was not 
occurring in viruses produced solely using the viral vector containing the CA-
SunTag (Fig. 23). Bands of the correct size were observed when the CA-SunTag 
was co-transfected together with a non-mutated packaging vector, but these may 
just represent the cleavage products derived from the non-mutated vector. If the 
polyproteins derived from the CA-SunTag vector were not being correctly 
cleaved, then properly assembled capsid cores would not be formed, and the 
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CA-SunTag spots observed colocalised with the p24CA antibody stain likely 
contained amalgamations of cleaved and non-cleaved Gag products. Many 
studies report the sensitivity of CA to mutations [65][112][227][129], and so it was 
decided to try an alternative strategy for studying capsid uncoating which did not 
involve manipulation of the CA protein.  
 
4.3 Non-capsid based reporter assays 
An alternative strategy for determining initial capsid uncoating events, is to label 
a component of the VNC within the capsid core that can produce a signal upon 
binding with an externalised capsid component. The SunTag system was ideally 
suited for this as the small epitopes could be linked together to form an array 
containing up to 24 repeats of this peptide [193]. Studies showed that the peptide 
epitopes within the array could be fully occupied by the fluorescently labelled 
antibody without steric hindrance, enabling massive signal amplification. The use 
of the scFv antibody fused to sfGFP also enabled successful expression in 
soluble form within the cell, with limited aggregation, facilitating its use in live cell 
microscopy. The 24x repeat peptide array was fused to both the CTD of Vpr-IN 
(IN-24xST) and the APOBEC 3F/3G* proteins (A3F/G*-24xST), for incorporation 
into the capsid core via interactions with the Gag p6 domain [183][184] and viral 
RNA [195][228], respectively. The principle behind this system was that when the 
capsid core started to disassemble, the fluorescently labelled antibodies present 
within the cytoplasm of the cell would be able to enter the capsid and bind to the 
SunTag peptide array, creating a signal.  
 
Preliminary studies showed this to be a creditable candidate for studying 
uncoating, with many more spots observed in HeLa P4 cells at 60 min compared 
to 0 min post-infection with the 24xST virus, suggestive of uncoating events (Fig. 
24). Staining with a p24CA antibody revealed colocalised and CA only stained 
puncta, indicative of newly uncoated and intact cores, respectively. The IN-
24xST system was initially tested in fixed cells using confocal microscopy, with 
viruses prepared in the presence of DMSO or nevirapine (Fig. 25). Five 
biological replicates showed an initial peak of uncoating in the DMSO control 
from 30 to 60 min post-spinoculation (Fig. 25A-C). The addition of nevirapine 
delayed the uncoating kinetics in two of the replicates (Fig. 25C and E), but no 
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significant difference compared to the DMSO control was observed in two more 
experiments (Fig. 25B and D). When the data sets were combined, however, a 
significant delay in peak uncoating from 45 to 120 mins p.s. (75 min) could be 
observed in the presence of nevirapine compared to the DMSO control (Fig. 
25F). This was almost exactly the same delay recorded by Hulme and co-
workers in the presence of nevirapine (73 min) when using the CsA washout 
assay for studying uncoating [67]. This also correlates with the delay in uncoating 
recorded with the dual-labelled virus in the presence of nevirapine, with a delay 
of 85 min and 60 min observed when using 3D manager (Fig. 14B), or 
DeconvolutionLab (Fig. 19B) for establishing colocalisation, respectively. 
Interestingly, uncoating events were still observed with the 24xST system right 
up to the end of the time course, 240 min post-spinoculation. 
 
4.4 High-throughput analysis of uncoating 
4.4.1 Analysis of the 24xSunTag with High-content imaging 
The considerable signal amplification provided by the 24x repeat array opened 
up new options for image acquisition, including Operetta High-Content Imaging. 
Although Operetta has a lower resolution capacity compared to confocal 
microscopy, a wide field of view enables the imaging of many cells within the 
specimen area. Also, an inbuilt temperature and CO2 regulator allows the 
tracking of viruses within the same cells over time, thus dispensing with the issue 
of different infection levels within different sampling populations associated with 
fixed cell analysis. Many well-defined spots could be observed at the initial time 
points, with a loss of spots per cell clearly seen over time (Fig. 26). Repeat time 
courses showed a significant peak in the number of spots per cell from 
approximately 20 to 30 minutes p.s., followed by a sharp decline to a level just 
above the negative control (Fig. 27). This peak is consistent with the 50% half-
time recorded when using the CsA washout method for studying uncoating [67], 
suggesting that with this system the peak in spots per cell determines the half-
time of uncoating. However, in contrast to the CsA washout study, no significant 
difference in the peak number of spots per cell was observed with the 
introduction of various CA mutants known to effect capsid stability, or the 
introduction of restriction compounds reported to alter the kinetics of capsid 
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uncoating (Fig. 27, and 28A). In fact, a slightly premature peak was observed 
with the more stable CA mutants (E45A and E128A/R132A) compared to the 
non-mutated virus (Fig. 27B). This lack of kinetic change raised concerns that 
we were observing viral fusion, rather than actual uncoating events. However, 
repeating the assay with vectors prepared without a viral genome, which 
produces VSV-G enveloped vesicles without a capsid core, elicited a response 
equal to that of the negative control (Fig. 28A). 
 
Viruses were produced in the presence of saquinavir, a protease inhibitor which 
obstructs the cleavage of the Gag and Pol polyproteins by HIV-1 protease, 
preventing the formation of capsid cores. The rationale behind this being that 
prevention of capsid core formation would lead to the production of SunTag 
spots directly after viral fusion with the cellular membrane. Unfortunately, no shift 
in peak spot formation kinetics was observed in this experiment (Fig. S3A). This 
may in part be due, however, to issues with viral quantification, as protease 
inhibition also prevented the production of the RT used in PERT analysis. As 
such, equivalent volumes of viral preparation were used in both the control 
viruses, and those produced in the presence of saquinavir. As a result, a 6-fold 
increase in the number of SunTag spots was observed with the latter, which may 
have influenced the kinetics of spot formation. To properly analyse the effects of 
saquinavir, the experiment needs to be repeated with viral stocks adjusted to 
allow for the equivalent numbers of SunTag spots. 
 
Hope and co-workers also reported a delay in uncoating kinetics when using a 
HIV-1 WT envelope as opposed to VSV-G pseudotyped viruses [67], which they 
attributed to the slower viral fusion with the cellular membrane. However, viruses 
prepared with an HXB2 envelope showed a similar, albeit less pronounced, peak 
with Operetta analysis (Fig. 28B). Interestingly, unlike VSV-G pseudotyped 
viruses, no sharp decline in spots per cell was observed with the HXB2 
enveloped viruses, with more of a low, residual count over time; but this may be 
due to the low efficiency in infectivity recorded with WT as opposed to VSV-G 
pseudotyped particles [216]. 
 
In an alternative strategy to confirm whether the spots observed in this assay 
were depicting real uncoating events, we made use of the viral RNA binding 
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priorities of the APOBEC proteins for the incorporation of the SunTag into the 
capsid core [124]. Fascinatingly, a peak in the number of spots per cell was 
recorded within the same time frame for the APOBEC3 incorporation of the 24x 
repeat array, as with Vpr-IN incorporation (Fig. 29). The only difference in the 
kinetics between these two systems being a slower decline after the peak with 
APOBEC3G* incorporation of the SunTag. 
 
The use of the Operetta high-content imaging system with a 60x objective 
increased the resolution of the images, enabling the discernment of a small but 
significant change in the kinetics of SunTag spot formation in the presence of 
nevirapine, after the initial peak (Fig. 30A-C). A premature peak in the number of 
SunTag spots per cell was also observed with a less stable CA mutant (K203A), 
indicative of earlier capsid uncoating (Fig. 30D). It is possible that the 40x 
objective was only able to detect the larger, bulk events of capsid uncoating, and 
the more intricate events detected using confocal acquisition (Fig. 25) were 
missed. Unfortunately, further analysis with the 60x objective was curtailed as 
the objective was available on a short-term lease. 
 
Taken together, the 24x SunTag system seems to suggest a prominent initial 
uncoating event occurring soon after (20-60 min) viral fusion (Fig. 25, 27-30), 
with further uncoating events occurring towards the end of the time course, as 
ascertained by confocal microscopy (Fig. 25); the resolution of the Operetta 
being too low to capture these later events. Further validation of the 24x SunTag 
needs to be carried out, but this system would be ideally suited for live 
microscopy performed with higher resolution. 
 
4.4.2 Luciferase analysis of capsid uncoating using the NanoBiT  
Capsid uncoating was also analysed using the NanoBiT split luciferase system, 
with the small bit (HiBiT) of the split enzyme fused to both the ABOPEC3F/G* 
proteins, and to the CTD of IN in a viral vector. A HeLa P4 cell line was prepared 
stably expressing the large polypeptide (LgBiT). Similar to the SunTag peptide 
array system, uncoating was measured upon capsid disassembly, in this case 
allowing the entry and binding of the cytoplasmic LgBiT with the capsid 
internalised HiBiT, eliciting luminesce in the presence of the NanoLuc substrate.  
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Initial tests showed very repeatable peaks of luciferase (representing uncoating) 
at approximately 35 min and 45 min p.s. with the HiBiT fused to A3G* and A3F, 
respectively (Fig. 31A). An explanation for the difference could be the action of 
the A3F cytidine deaminase inhibiting minus strand DNA transcription, thus 
impeding uncoating. Cytidine deaminase activity was restricted with the A3G* 
mutant [124], therefore reverse transcription and uncoating could proceed as 
normal [67]. Further analysis of the A3F incorporated HiBiT revealed no 
difference in the RLU in the presence of nevirapine compared to a DMSO control 
(Fig. 31B). As reverse transcription may already be affected with this cytidine 
deaminase, further studies using the NNRTI might be more appropriate with 
A3G* HiBiT incorporation. The introduction of the destabilising (K203A) and 
stabilising (E128A/R132A) CA mutations caused slightly premature and delayed 
peaks in RLU, respectively, compared to the non-mutated CA (Fig. 31C). 
 
Replications of the assay using vectors lacking the viral genome generated 
different RLU kinetics compared to true viruses (Fig. 31D), indicating the 
observation of uncoating events rather than the fusion of VLPs. This was also 
substantiated by transfection with the A3F/G* plasmid alone, which showed 
similar RLU kinetics as the VLPs (Fig. S4).  
 
The HiBiT moiety fused directly to the integrase domain of the molecular clone 
resulted in similar peaks in RLU as those derived from the A3F/G* incorporated 
HiBiT (~37 min p.s.) (Fig. 32), indicating that the luminescence kinetics were 
derived from the disassembly of the capsid core, rather than from non-specific 
events consequent of VSV-G pseudotyped vesicles. A change in the luminescent 
kinetics in the presence of restriction compounds known to affect the timing of 
uncoating, lent further support to the validity of this assay in tracking capsid 
uncoating events. Although some studies suggest that PF74 has a destabilising 
effect on the capsid core at high concentrations (≥ 5 µM) [111][115][130] (Fig. 
14C), and we observed a delay in uncoating indicative of capsid stabilisation with 
this assay, recent work by Saito and co-workers have suggested a multi-modal 
action of PF74 on capsid uncoating, depending on the concentrations used [131]. 
This highlights the complexity surrounding this process, which is likely to be cell 
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line dependent, and the requirement for further validation of this assay, also 
within distinct cell lines.  
 
The table below (Table 2) highlights some of the strengths and weaknesses of 
the three capsid uncoating systems developed in this project. 
 
Method Criteria Score Comments 
CA-
GFP/mKO +  
Vpr-Integrase 
(Confocal) 
Sensitivity/ 
Specificity 
 
Very sensitive (x,y resolution <300 nm), detects 
restriction compound/CA mutant specific changes 
in uncoating kinetics 
Robustness  
Imaging different cell sets over time, large 
difference in kinetics between biological replicates 
High-
throughput 
 
Preparation of samples on separate coverslips and 
confocal acquisition of individual time points very 
labour intensive; two conditions per assay 
Cost-
effectiveness 
 
Standard reagents used (with the exception of 
microscope slides and VECTASHIELD mounting 
medium) 
24xSunTag 
(Operetta) 
Sensitivity/ 
Specificity 
 
Limited kinetic changes upon addition of restriction 
compounds or capsid mutations 
Robustness  Similar fluorescence kinetics between assays 
High-
throughput 
 
96-well plate, many conditions per assay 
Cost-
effectiveness 
 
Requires use of CellCarrier-96-well, tissue culture-
treated plates with optically clear base 
HiBiT 
(Tecan) 
Sensitivity/ 
Specificity 
 
Small kinetic changes upon addition of restriction 
compounds or capsid mutations 
Robustness  Similar luminescence kinetics between assays 
High-
throughput 
 
96-well plate, many conditions per assay 
Cost-
effectiveness 
 
Requires use of 96 well plates, white flat bottom 
tissue culture plates and Nano-Glo® Live Cell 
Reagent 
 
Table 2. Summary of the three systems developed for studying capsid uncoating. The table 
shows a qualitative summary of the strengths and weaknesses of the three assays developed in 
this project, using the criteria – sensitivity and specificity, robustness, high-throughput capability 
and cost-effectiveness. Sensitivity and specificity was judged on the response of the capsid 
uncoating assay to CA mutations and restriction compounds and, in the case of the dual-labelled 
assay, comparison with manual counting of spots for false positives/negatives. 
 
 
 
 
 
 
 
110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
CONCLUSION 
Much is yet unknown about the process of capsid uncoating. The fragility of the 
capsid core and its sensitivity to structural and chemical manipulation make it 
very difficult to study in vivo, which can be attested to by the diverse techniques 
that have been employed to investigate capsid uncoating (section 1.7). Different 
results can be obtained depending upon the system employed to study it, which 
is why three models of uncoating have been proposed (section 1.5). Capsid 
disassembly can also vary depending on the cell type infected, and is affected by 
the envelope used for pseudotyping (Fig. 28) [67][150][229]. This is likely to be 
due to the large number of cellular host factors that CA has been reported to bind 
and interact with (section 1.8.3) [58][54][56], which would be expressed in 
variable amounts depending on the cell line used. Using three distinct systems 
for studying uncoating: 1) dual-fluorescent labelling, 2) incorporation of a SunTag 
peptide array, and 3) a split luciferase reporter, we have shown that capsid 
uncoating is likely to be a biphasic process, with an initial peak of uncoating 
shortly after cellular entry (Fig. 25, 27-32) followed by a more gradual 
disassembly as the PIC traffics towards the nucleus (Fig. 14 and 19). A portion 
of the capsid is likely to remain with the PIC to facilitate docking with nuclear 
proteins at the NPC (section 1.4.5). This may explain the observation of CA 
colocalisation with IN at the end of the time courses, when studying uncoating 
with the dual-fluorescently labelled virus using confocal microscopy (Fig. 14). 
That a portion of the capsid remains with the PIC until nuclear translocation, fits 
well with the view that the capsid core may act as a shield to protect the viral 
genome from detection by cellular innate immune sensors (section 1.4.2). The 
visualisation of CA colocalised with IN in the nucleus of infected cells (Fig. 20), 
also lends further evidence to the notion of a potential role for CA in the nuclear 
import and integration of the PIC (section 1.4.5/6). 
Finally, preliminary studies using the split-luciferase system for measuring capsid 
uncoating, show great potential for the development of a high-throughput assay 
for screening candidate compounds that restrict HIV-1 infection by targeting the 
stability of the capsid core. The conservative nature of the viral core and the 
large number of cellular factors it has been shown to associate with, suggests 
that it is very unlikely to be able to evolve resistance to restriction factors, making 
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it an ideal target for therapeutic intervention. Restriction compounds that speed 
up uncoating would be particularly effective, as this would have the twofold 
action of impairing infection due to the close interconnectedness between timely 
uncoating and optimal integration; and the activation of an innate cellular antiviral 
response through the exposure of the viral genome. 
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FUTURE PERSPECTIVES 
All three systems developed for analysing uncoating need further validation to 
determine the sensitivity and specificity of these assays. Analysis of these 
assays within separate cells lines will also determine the robustness of these 
systems, and provide essential new understanding on the host-specific effects on 
uncoating.  
 
The dual-labelled virus and the 24xSunTag assays will be further optimised for 
use with high-resolution live microscopy, such as the TILL Photonics iMic2 total 
internal reflection (TIRF) system. This will enable more sensitive live analysis of 
the uncoating events occurring towards the end of the time courses, at the point 
at which the PIC attaches to the NPC. 
 
Further investigation of the dual-labelled virus in conjunction with protein 
knockdowns or the fluorescent labelling of cellular proteins (e.g. CypA, Nup358, 
Nup153, TNPO3 and CPSF6) would be useful for analysis of the interaction of 
CA with these proteins during nuclear import and viral integration.  
  
High-resolution live microscopy of the repeat peptide SunTag system with 
viruses prepared with the S15-mCherry membrane marker (a fluorescently 
labelled fusion protein containing the 15 N-terminal amino acid membrane 
targeting domain of the Src tyrosine kinase p60c-Src [192]), would allow better 
elucidation of the uncoating events occurring directly after membrane fusion.  
 
Finally, further analysis needs to be done on the split-luciferase system of 
analysing uncoating, including additional tests with the HiBiT peptide fused 
directly to the CTD of IN in the NL4.3 molecular clone. The advantage of the 
latter being that VLPs are less likely to be produced when using full length viral 
vectors in the production of viruses. The speed, sensitivity and reproducibility of 
the split-luciferase capsid uncoating assay, makes this an ideal system for the 
screening of candidate compounds restricting one of the more conserved events 
of the HIV-1 lifecycle. 
 
 
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
REFERENCES 
[1] Centers for Disease Control (CDC), “Kaposi’s sarcoma and Pneumocystis 
pneumonia among homosexual men - New York and California,” Morb. 
Mortal. Wkly. Rep., vol. 30, no. 25, pp. 305–308, 1981. 
[2] D. T. Durack, “Opportunistic infections and Kaposi’s sarcoma in 
homosexual men,” N Engl J Med, vol. 305, no. 24, pp. 1465–1467, 1981. 
[3] K. Hymes, J. Greene, A. Marcus, D. William, T. Cheung, N. Prose, H. 
Ballard, and L. Laubenstein, “Kaposi’S Sarcoma in Homosexual Men—a 
Report of Eight Cases,” Lancet, vol. 318, no. 8247, pp. 598–600, 1981. 
[4] F. Barre-Sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamarat, J. 
Gruest, C. Dauget, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. 
Rozenbaum, and L. Montagnier, “Isolation of a T-lymphotropic retrovirus 
from a patient at risk for acquired immune deficiency syndrome (AIDS).,” 
Science (80-. )., vol. 220(4599), pp. 868–71, 1983. 
[5] R. C. Gallo, S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. 
Haynes, T. J. Palker, R. Redfield, J. Oleske, B. Safai, and  al. et, “Frequent 
detection and isolation of cytopathic retroviruses (HTLV-III) from patients 
with AIDS and at risk for AIDS.,” Science, vol. 224, no. 4648, pp. 500–3, 
1984. 
[6] M. Popovic, M. G. Sarngadharan, E. Read, and R. C. Gallo, “Detection, 
isolation, and continuous production of cytopathic retroviruses (HTLV-III) 
from patients with AIDS and pre-AIDS.,” Science, vol. 224, no. 4648, pp. 
497–500, 1984. 
[7] K. Case, “Nomenclature: Human Immunodeficiency Virus,” Ann. Intern. 
Med., vol. 105, no. 1, pp. 133–133, 1986. 
[8] M. H. Merson, J. O’Malley, D. Serwadda, and C. Apisuk, “The history and 
challenge of HIV prevention,” The Lancet, vol. 372, no. 9637. pp. 475–488, 
2008. 
[9] B. N. Fields, P. M, D. E, G. Editor, R. A, L. Editor, M. A, M. Editor, R. 
Editor, S. E, S. Editor, D. M, Knipe, E. By, L. Williams, A. J. Levine, R. C. 
Condit, S. C. Harrison, L. A. Ball, N. Fields, B. N. Fields, D. M. Knipe, and 
P. M. Howley, Field Virology, 4th ed. Lippincott Williams & Wilkins, 2001. 
 
 
116 
 
[10] J. M. Watts, K. K. Dang, R. J. Gorelick, C. W. Leonard, J. W. Bess, R. 
Swanstrom, C. L. Burch, and K. M. Weeks, “Architecture and secondary 
structure of an entire HIV-1 RNA genome.,” Nature, vol. 460, no. 7256, pp. 
711–6, 2009. 
[11] B. M. Peterlin and D. Trono, “Hide, shield and strike back: how HIV-
infected cells avoid immune eradication,” Nat. Rev. Immunol., vol. 3, no. 2, 
pp. 97–107, 2003. 
[12] Y. Kobayashi, J. Zhuang, S. Peltz, and J. Dougherty, “Identification of a 
cellular factor that modulates HIV-1 programmed ribosomal frameshifting,” 
J. Biol. Chem., vol. 285, no. 26, pp. 19776–19784, 2010. 
[13] P. Biswas, X. Jiang, A. L. Pacchia, J. P. Dougherty, and S. W. Peltz, “The 
human immunodeficiency virus type 1 ribosomal frameshifting site is an 
invariant sequence determinant and an important target for antiviral 
therapy.,” J. Virol., vol. 78, no. 4, pp. 2082–7, 2004. 
[14] R. W. Doms and D. Trono, “The plasma membrane as a combat zone in 
the HIV battlefield,” Genes and Development, vol. 14, no. 21. pp. 2677–
2688, 2000. 
[15] N. Arhel, “Revisiting HIV-1 uncoating.,” Retrovirology, vol. 7, no. 1, p. 96, 
Jan. 2010. 
[16] M. D. Miller, C. M. Farnet, and F. D. Bushman, “Human immunodeficiency 
virus type 1 preintegration complexes: studies of organization and 
composition.,” J. Virol., vol. 71, no. 7, pp. 5382–5390, 1997. 
[17] Y. Suzuki and R. Craigie, “The road to chromatin - nuclear entry of 
retroviruses.,” Nat. Rev. Microbiol., vol. 5, no. 3, pp. 187–96, 2007. 
[18] A. Trkola, “HIV-host interactions: Vital to the virus and key to its inhibition,” 
Current Opinion in Microbiology, vol. 7, no. 4. pp. 407–411, 2004. 
[19] D. F. Purcell and M. A. Martin, “Alternative splicing of human 
immunodeficiency virus type 1 mRNA modulates viral protein expression, 
replication, and infectivity.,” J. Virol., vol. 67, no. 11, pp. 6365–6378, 1993. 
[20] C. Hellmund and A. M. L. Lever, “Coordination of genomic RNA packaging 
with viral assembly in HIV-1,” Viruses, vol. 8, no. 7. 2016. 
[21] D. Muriaux, J. Mirro, D. Harvin, and A. Rein, “RNA is a structural element 
in retrovirus particles.,” Proc. Natl. Acad. Sci. U. S. A., vol. 98, no. 9, pp. 
5246–51, 2001. 
 
117 
 
[22] S. Campbell and A. Rein, “In Vitro Assembly Properties of Human 
Immunodeficiency Virus Type 1 Gag Protein Lacking the p6 Domain,” J. 
Virol., vol. 73, no. 3, pp. 2270–2279, 1999. 
[23] A. Cimarelli, S. Sandin, S. Höglund, and J. Luban, “Basic Residues in 
Human Immunodeficiency Virus Type 1 Nucleocapsid Promote Virion 
Assembly via  Interaction with RNA,” J. Virol., vol. 74, no. 7, pp. 3046–
3057, 2000. 
[24] E. Mailler, S. Bernacchi, R. Marquet, J.-C. Paillart, V. Vivet-Boudou, and R. 
P. Smyth, “The Life-Cycle of the HIV-1 Gag-RNA Complex.,” Viruses, vol. 
8, no. 9, Sep. 2016. 
[25] J. S. Saad, J. Miller, J. Tai, A. Kim, R. H. Ghanam, and M. F. Summers, 
“Structural basis for targeting HIV-1 Gag proteins to the plasma membrane 
for virus assembly.,” Proc. Natl. Acad. Sci. U. S. A., vol. 103, no. 30, pp. 
11364–9, 2006. 
[26] V. Chukkapalli and A. Ono, “Molecular determinants that regulate plasma 
membrane association of HIV-1 Gag,” Journal of Molecular Biology, vol. 
410, no. 4. pp. 512–524, 2011. 
[27] S. E. El Meshri, D. Dujardin, J. Godet, L. Richert, C. Boudier, J. L. Darlix, 
P. Didier, Y. Mély, and H. De Rocquigny, “Role of the nucleocapsid domain 
in HIV-1 gag oligomerization and trafficking to the plasma membrane: A 
fluorescence lifetime imaging microscopy investigation,” J. Mol. Biol., vol. 
427, no. 6, pp. 1480–1494, 2015. 
[28] J. Chen, S. A. Rahman, O. A. Nikolaitchik, D. Grunwald, L. Sardo, R. C. 
Burdick, S. Plisov, E. Liang, S. Tai, V. K. Pathak, and W.-S. Hu, “HIV-1 
RNA genome dimerizes on the plasma membrane in the presence of Gag 
protein.,” Proc. Natl. Acad. Sci. U. S. A., vol. 113, no. 2, pp. E201-8, 2016. 
[29] L. VerPlank, F. Bouamr, T. J. LaGrassa, B. Agresta, A. Kikonyogo, J. Leis, 
and C. A. Carter, “Tsg101, a homologue of ubiquitin-conjugating (E2) 
enzymes, binds the L domain in HIV type 1 Pr55(Gag).,” Proc. Natl. Acad. 
Sci. U. S. A., vol. 98, no. 14, pp. 7724–9, 2001. 
[30] B. Strack, A. Calistri, S. Craig, E. Popova, and H. G. Göttlinger, “AIP1/ALIX 
is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding,” 
Cell, vol. 114, no. 6, pp. 689–699, 2003. 
[31] W. I. Sundquist and H. G. Krausslich, “HIV-1 assembly, budding, and 
maturation,” Cold Spring Harb. Perspect. Med., vol. 2, pp. 1–24, 2012. 
118 
 
[32] Y. Suzuki and Y. Suzuki, “Gene Regulatable Lentiviral Vector System,” in 
Viral Gene Therapy, InTech, 2011. 
[33] A. H. Kaplan, M. Manchester, and R. Swanstrom, “The activity of the 
protease of human immunodeficiency virus type 1 is initiated at the 
membrane of infected cells before the release of viral proteins and is 
required for release to occur with maximum efficiency.,” J. Virol., vol. 68, 
no. 10, pp. 6782–6, Oct. 1994. 
[34] S. K. Lee, M. Potempa, and R. Swanstrom, “The choreography of HIV-1 
proteolytic processing and virion assembly,” Journal of Biological 
Chemistry, vol. 287, no. 49. pp. 40867–40874, 2012. 
[35] S. Mattei, F. K. Schur, and J. A. Briggs, “Retrovirus maturation - An 
extraordinary structural transformation,” Curr. Opin. Virol., vol. 18, pp. 27–
35, 2016. 
[36] W. I. Sundquist and H.-G. Kräusslich, “HIV-1 assembly, budding, and 
maturation.,” Cold Spring Harb. Perspect. Med., vol. 2, no. 7, p. a006924, 
Jul. 2012. 
[37] S. Mattei, M. Anders, J. Konvalinka, H.-G. Kräusslich, J. A. G. Briggs, and 
B. Müller, “Induced maturation of human immunodeficiency virus.,” J. 
Virol., vol. 88, no. 23, pp. 13722–31, 2014. 
[38] K. Wiegers, G. Rutter, H. Kottler, U. Tessmer, H. Hohenberg, and H. G. 
Kräusslich, “Sequential steps in human immunodeficiency virus particle 
maturation revealed by alterations of individual Gag polyprotein cleavage 
sites.,” J. Virol., vol. 72, no. 4, pp. 2846–2854, 1998. 
[39] B. K. Ganser-Pornillos, A. Cheng, and M. Yeager, “Structure of Full-Length 
HIV-1 CA: A Model for the Mature Capsid Lattice,” Cell, vol. 131, no. 1, pp. 
70–79, 2007. 
[40] S. Thenin-Houssier, I. M. S. De Vera, L. Pedro-Rosa, A. Brady, A. Richard, 
B. Konnick, S. Opp, C. Buffone, J. Fuhrmann, S. Kota, B. Billack, M. 
Pietka-Ottlik, T. Tellinghuisen, H. Choe, T. Spicer, L. Scampavia, F. Diaz-
Griffero, D. J. Kojetin, and S. T. Valentea, “Ebselen, a small-molecule 
capsid inhibitor of HIV-1 replication,” Antimicrob. Agents Chemother., vol. 
60, no. January, pp. 2195–2208, 2016. 
[41] T. Galal, P. Nardin, and J. Mignot, An analysis for solar central receiver 
systems with terminal concentrators or variable apertures, vol. 41, no. 2. 
1988. 
119 
 
[42] F. K. M. Schur, W. J. H. Hagen, M. Rumlová, T. Ruml, B. Müller, H.-G. 
Kräusslich, and J. a G. Briggs, “Structure of the immature HIV-1 capsid in 
intact virus particles at 8.8 Å resolution.,” Nature, vol. 517, pp. 505–508, 
2015. 
[43] J. a G. Briggs, M. N. Simon, I. Gross, H.-G. Kräusslich, S. D. Fuller, V. M. 
Vogt, and M. C. Johnson, “The stoichiometry of Gag protein in HIV-1.,” 
Nat. Struct. Mol. Biol., vol. 11, no. 7, pp. 672–675, 2004. 
[44] E. M. Campbell and T. J. Hope, “HIV-1 capsid: the multifaceted key player 
in HIV-1 infection,” Nat. Rev. Microbiol., vol. 13, no. 8, pp. 471–483, 2015. 
[45] L. Lamorte, S. Titolo, C. T. Lemke, N. Goudreau, J. F. Mercier, E. 
Wardrop, V. B. Shah, U. K. Von Schwedler, C. Langelier, S. S. R. Banik, C. 
Aiken, W. I. Sundquist, and S. W. Mason, “Discovery of novel small-
molecule HIV-1 replication inhibitors that stabilize capsid complexes,” 
Antimicrob. Agents Chemother., vol. 57, no. 10, pp. 4622–4631, 2013. 
[46] A. J. Price, D. A. Jacques, W. A. McEwan, A. J. Fletcher, S. Essig, J. W. 
Chin, U. D. Halambage, C. Aiken, and L. C. James, “Host Cofactors and 
Pharmacologic Ligands Share an Essential Interface in HIV-1 Capsid That 
Is Lost upon Disassembly,” PLoS Pathog., vol. 10, no. 10, 2014. 
[47] W. S. Blair, C. Pickford, S. L. Irving, D. G. Brown, M. Anderson, R. Bazin, 
J. Cao, G. Ciaramella, J. Isaacson, L. Jackson, R. Hunt, A. Kjerrstrom, J. 
A. Nieman, A. K. Patick, M. Perros, A. D. Scott, K. Whitby, H. Wu, and S. 
L. Butler, “HIV capsid is a tractable target for small molecule therapeutic 
intervention,” PLoS Pathog., vol. 6, no. 12, 2010. 
[48] Z. Zhang, 1, F. Zhang, 1, C. Yang, 1, J. Qi, 1, S. Gao, 1, S. Li, 2 1, Y. Gu, 
2 1, and * and Ningshao Xia, “HIV-1 Capsid as a Target for Antiviral 
Therapy,” J. AIDS Clin. Res., vol. 7, no. 1, pp. 1–6, 2011. 
[49] O. Pornillos, B. K. Ganser-Pornillos, and M. Yeager, “Atomic-level 
modelling of the HIV capsid.,” Nature, vol. 469, no. 7330, pp. 424–7, 2011. 
[50] A. Fassati and S. P. Goff, “Characterization of intracellular reverse 
transcription complexes of human immunodeficiency virus type 1,” J Virol, 
vol. 75, no. 8, pp. 3626–3635, 2001. 
 
 
 
 
120 
 
[51] N. K. Heinzinger, M. I. Bukrinsky, S. A. Haggerty, A. M. Ragland, V. 
Kewalramani, M. A. Lee, H. E. Gendelman, L. Ratner, M. Stevenson, and 
M. Emerman, “The Vpr protein of human immunodeficiency virus type 1 
influences nuclear localization of viral nucleic acids in nondividing host 
cells.,” Proc. Natl. Acad. Sci. U. S. A., vol. 91, no. 15, pp. 7311–5, Jul. 
1994. 
[52] M. I. Bukrinsky, N. Sharova, T. L. McDonald, T. Pushkarskaya, W. G. 
Tarpley, and M. Stevenson, “Association of integrase, matrix, and reverse 
transcriptase antigens of human immunodeficiency virus type 1 with viral 
nucleic acids following acute infection.,” Proc. Natl. Acad. Sci. U. S. A., vol. 
90, no. July, pp. 6125–6129, 1993. 
[53] D. McDonald, M. A. Vodicka, G. Lucero, T. M. Svitkina, G. G. Borisy, M. 
Emerman, and T. J. Hope, “Visualization of the intracellular behavior of 
HIV in living cells.,” J. Cell Biol., vol. 159, no. 3, pp. 441–52, Nov. 2002. 
[54] R. König, Y. Zhou, D. Elleder, T. L. Diamond, G. M. C. Bonamy, J. T. 
Irelan, C.-Y. Chiang, B. P. Tu, P. D. De Jesus, C. E. Lilley, S. Seidel, A. M. 
Opaluch, J. S. Caldwell, M. D. Weitzman, K. L. Kuhen, S. Bandyopadhyay, 
T. Ideker, A. P. Orth, L. J. Miraglia, F. D. Bushman, J. a Young, and S. K. 
Chanda, “Global analysis of host-pathogen interactions that regulate early-
stage HIV-1 replication.,” Cell, vol. 135, no. 1, pp. 49–60, Oct. 2008. 
[55] A. E. Hulme, Z. Kelley, D. Foley, and T. J. Hope, “Complementary Assays 
Reveal a Low Level of CA Associated with Viral Complexes in the Nuclei of 
HIV-1-Infected Cells.,” J. Virol., vol. 89, no. March, pp. 5350–61, 2015. 
[56] A. L. Brass, D. M. Dykxhoorn, Y. Benita, N. Yan, A. Engelman, R. J. 
Xavier, J. Lieberman, and S. J. Elledge, “Identification of host proteins 
required for HIV infection through a functional genomic screen,” Science 
(80-. )., vol. 319, no. 5865, pp. 921–926, 2008. 
[57] K. Peng, W. Muranyi, B. Glass, V. Laketa, S. R. Yant, L. Tsai, T. Cihlar, B. 
Müller, and H.-G. Kräusslich, “Quantitative microscopy of functional HIV 
post-entry complexes reveals association of replication with the viral 
capsid.,” Elife, vol. 3, no. 2013, p. e04114, 2014. 
[58] H. Zhou, M. Xu, Q. Huang, A. T. Gates, X. D. Zhang, J. C. Castle, E. Stec, 
M. Ferrer, B. Strulovici, D. J. Hazuda, and A. S. Espeseth, “Genome-Scale 
RNAi Screen for Host Factors Required for HIV Replication,” Cell Host 
Microbe, vol. 4, no. 5, pp. 495–504, 2008. 
121 
 
[59] R. Welker, H. Hohenberg, U. Tessmer, C. Huckhagel, and H. G. 
Kräusslich, “Biochemical and structural analysis of isolated mature cores of 
human immunodeficiency virus type 1.,” J. Virol., vol. 74, no. 3, pp. 1168–
77, 2000. 
[60] J. Rasaiyaah, C. P. Tan, A. J. Fletcher, A. J. Price, C. Blondeau, L. 
Hilditch, D. A. Jacques, D. L. Selwood, L. C. James, M. Noursadeghi, and 
G. J. Towers, “HIV-1 evades innate immune recognition through specific 
cofactor recruitment.,” Nature, vol. 503, no. 7476, pp. 402–5, Nov. 2013. 
[61] D. Gao, J. Wu, Y.-T. Wu, F. Du, C. Aroh, N. Yan, L. Sun, and Z. J. Chen, 
“Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other 
retroviruses.,” Science, vol. 341, no. 6148, pp. 903–906, 2013. 
[62] N. Yan, A. D. Regalado-Magdos, B. Stiggelbout, M. A. Lee-Kirsch, and J. 
Lieberman, “The cytosolic exonuclease TREX1 inhibits the innate immune 
response to human immunodeficiency virus type 1.,” Nat. Immunol., vol. 
11, no. 11, pp. 1005–13, 2010. 
[63] X. Lahaye, T. Satoh, M. Gentili, S. Cerboni, C. Conrad, I. Hurbain, A. El 
Marjou, C. Lacabaratz, J.-D. Lelièvre, and N. Manel, “The capsids of HIV-1 
and HIV-2 determine immune detection of the viral cDNA by the innate 
sensor cGAS in dendritic cells.,” Immunity, vol. 39, no. 6, pp. 1132–42, 
Dec. 2013. 
[64] J. Melchjorsen, “Learning from the messengers: Innate sensing of viruses 
and cytokine regulation of immunity-clues for treatments and vaccines,” 
Viruses, vol. 5, no. 2. pp. 470–527, 2013. 
[65] B. M. Forshey, U. von Schwedler, W. I. Sundquist, and C. Aiken, 
“Formation of a human immunodeficiency virus type 1 core of optimal 
stability is crucial for viral replication.,” J. Virol., vol. 76, no. 11, pp. 5667–
77, 2002. 
[66] G. J. Klarmann, C. A. Schauber, and B. D. Preston, “Template-directed 
pausing of DNA synthesis by HIV-1 reverse transcriptase during 
polymerization of HIV-1 sequences in vitro,” J. Biol. Chem., vol. 268, no. 
13, pp. 9793–9802, 1993. 
[67] A. E. Hulme, O. Perez, and T. J. Hope, “Complementary assays reveal a 
relationship between HIV-1 uncoating and reverse transcription.,” Proc. 
Natl. Acad. Sci. U. S. A., vol. 108, no. 24, pp. 9975–80, 2011. 
 
122 
 
[68] Y. Yang, T. Fricke, and F. Diaz-Griffero, “Inhibition of reverse transcriptase 
activity increases stability of the HIV-1 core.,” J. Virol., vol. 87, no. 1, pp. 
683–7, 2013. 
[69] S. J. Rihn, S. J. Wilson, N. J. Loman, M. Alim, S. E. Bakker, D. Bhella, R. 
J. Gifford, F. J. Rixon, and P. D. Bieniasz, “Extreme Genetic Fragility of the 
HIV-1 Capsid,” PLoS Pathog., vol. 9, no. 6, 2013. 
[70] U. K. von Schwedler, K. M. Stray, J. E. Garrus, and W. I. Sundquist, 
“Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid 
Protein,” J. Virol., vol. 77, no. 9, pp. 5439–5450, 2003. 
[71] K. Warren, T. Wei, D. Li, F. Qin, D. Warrilow, M.-H. Lin, H. Sivakumaran, 
A. Apolloni, C. M. Abbott, A. Jones, J. L. Anderson, and D. Harrich, 
“Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse 
transcription cofactors.,” Proc. Natl. Acad. Sci. U. S. A., vol. 109, no. 24, 
pp. 9587–92, 2012. 
[72] D. Warrilow, G. Tachedjian, and D. Harrich, “Maturation of the HIV reverse 
transcription complex: Putting the jigsaw together,” Reviews in Medical 
Virology, vol. 19, no. 6. pp. 324–337, 2009. 
[73] S. Li, C. P. Hill, W. I. Sundquist, and J. T. Finch, “Image reconstructions of 
helical assemblies of the HIV-1 CA protein.,” Nature, vol. 407, no. 6802, 
pp. 409–413, 2000. 
[74] M. P. Dodding and M. Way, “Coupling viruses to dynein and kinesin-1,” 
EMBO J., vol. 30, no. 17, pp. 3527–3539, 2011. 
[75] Z. Lukic, A. Dharan, T. Fricke, F. Diaz-Griffero, and E. M. Campbell, “HIV-1 
uncoating is facilitated by dynein and kinesin 1.,” J. Virol., vol. 88, no. 23, 
pp. 13613–25, 2014. 
[76] V. Malikov, E. S. da Silva, V. Jovasevic, G. Bennett, D. a. de Souza 
Aranha Vieira, B. Schulte, F. Diaz-Griffero, D. Walsh, and M. H. Naghavi, 
“HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward 
movement to the nucleus,” Nat. Commun., vol. 6, p. 6660, 2015. 
[77] Y. Sabo, D. Walsh, D. S. Barry, S. Tinaztepe, K. D. L. Santos, S. P. Goff, 
G. G. Gundersen, and M. H. Naghavi, “NIH Public Access,” vol. 14, no. 5, 
2014. 
 
 
 
123 
 
[78] N. Arhel, A. Genovesio, K.-A. Kim, S. Miko, E. Perret, J.-C. Olivo-Marin, S. 
Shorte, and P. Charneau, “Quantitative four-dimensional tracking of 
cytoplasmic and nuclear HIV-1 complexes.,” Nat. Methods, vol. 3, no. 10, 
pp. 817–824, 2006. 
[79] M. Yamashita and M. Emerman, “Capsid Is a Dominant Determinant of 
Retrovirus Infectivity in Nondividing Cells,” J. Virol., vol. 78, no. 11, pp. 
5670–5678, 2004. 
[80] P. F. Lewis1 ’ and M. Emerman2, “Passage through Mitosis Is Required for 
Oncoretroviruses but Not for the Human Immunodeficiency Virus,” J. Virol., 
vol. 68, no. 1, pp. 510–516, 1994. 
[81] T. Roe, T. C. Reynolds, G. Yu, and P. O. Brown, “Integration of murine 
leukemia virus DNA depends on mitosis.,” EMBO J., vol. 12, no. 5, pp. 
2099–2108, 1993. 
[82] A. Fassati, “HIV infection of non-dividing cells: a divisive problem.,” 
Retrovirology, vol. 3, p. 74, 2006. 
[83] R. A. Katz, J. G. Greger, and A. M. Skalka, “Effects of cell cycle status on 
early events in retroviral replication,” Journal of Cellular Biochemistry, vol. 
94, no. 5. pp. 880–889, 2005. 
[84] M. Yamashita and M. Emerman, “Retroviral infection of non-dividing cells: 
Old and new perspectives,” Virology, vol. 344, no. 1. pp. 88–93, 2006. 
[85] K. a. Matreyek and A. Engelman, “Viral and cellular requirements for the 
nuclear entry of retroviral preintegration nucleoprotein complexes,” 
Viruses, vol. 5, pp. 2483–2511, 2013. 
[86] L. Hilditch and G. J. Towers, “A model for cofactor use during HIV-1 
reverse transcription and nuclear entry,” Curr. Opin. Virol., vol. 4, pp. 32–
36, 2014. 
[87] Z. Ambrose and C. Aiken, “HIV-1 uncoating: Connection to nuclear entry 
and regulation by host proteins,” Virology, vol. 454–455, no. 1. pp. 371–
379, 2014. 
[88] M. Yamashita, O. Perez, T. J. Hope, and M. Emerman, “Evidence for direct 
involvement of the capsid protein in HIV infection of nondividing cells,” 
PLoS Pathog., vol. 3, no. 10, pp. 1502–1510, 2007. 
 
 
 
124 
 
[89] D. J. Dismuke and C. Aiken, “Evidence for a Functional Link between 
Uncoating of the Human Immunodeficiency Virus Type 1 Core and Nuclear 
Import of the Viral Preintegration Complex,” J. Virol., vol. 80, no. 8, pp. 
3712–3720, 2006. 
[90] K. E. Lee, Z. Ambrose, T. D. Martin, I. Oztop, A. Mulky, J. G. Julias, N. 
Vandegraaff, J. G. Baumann, R. Wang, W. Yuen, T. Takemura, K. Shelton, 
I. Taniuchi, Y. Li, J. Sodroski, D. R. Littman, J. M. Coffin, S. H. Hughes, D. 
Unutmaz, A. Engelman, and V. N. KewalRamani, “Flexible Use of Nuclear 
Import Pathways by HIV-1,” Cell Host Microbe, vol. 7, no. 3, pp. 221–233, 
2010. 
[91] T. Schaller, K. E. Ocwieja, J. Rasaiyaah, A. J. Price, T. L. Brady, S. L. 
Roth, S. Hué, A. J. Fletcher, K. Lee, V. N. KewalRamani, M. Noursadeghi, 
R. G. Jenner, L. C. James, F. D. Bushman, and G. J. Towers, “HIV-1 
capsid-cyclophilin interactions determine nuclear import pathway, 
integration targeting and replication efficiency,” PLoS Pathog., vol. 7, no. 
12, 2011. 
[92] K. a Matreyek and A. Engelman, “The requirement for nucleoporin 
NUP153 during human immunodeficiency virus type 1 infection is 
determined by the viral capsid.,” J. Virol., vol. 85, no. 15, pp. 7818–7827, 
2011. 
[93] A. De Iaco, F. Santoni, A. Vannier, M. Guipponi, S. Antonarakis, and J. 
Luban, “TNPO3 protects HIV-1 replication from CPSF6-mediated capsid 
stabilization in the host cell cytoplasm.,” Retrovirology, vol. 10, no. 1, p. 20, 
2013. 
[94] A. Fassati, “Multiple roles of the capsid protein in the early steps of HIV-1 
infection,” Virus Research, vol. 170, no. 1–2. pp. 15–24, 2012. 
[95] A. R. W. Schröder, P. Shinn, H. Chen, C. Berry, J. R. Ecker, and F. 
Bushman, “HIV-1 integration in the human genome favors active genes 
and local hotspots,” Cell, vol. 110, no. 4, pp. 521–529, 2002. 
[96] A. Ciuffi, M. Llano, E. Poeschla, C. Hoffmann, J. Leipzig, P. Shinn, J. R. 
Ecker, and F. Bushman, “A role for LEDGF/p75 in targeting HIV DNA 
integration.,” Nat. Med., vol. 11, no. 12, pp. 1287–1289, 2005. 
 
 
 
125 
 
[97] M. C. Shun, N. K. Raghavendra, N. Vandegraaff, J. E. Daigle, S. Hughes, 
P. Kellam, P. Cherepanov, and A. Engelman, “LEDGF/p75 functions 
downstream from preintegration complex formation to effect gene-specific 
HIV-1 integration,” Genes Dev., vol. 21, no. 14, pp. 1767–1778, 2007. 
[98] G. A. Sowd, E. Serrao, H. Wang, W. Wang, H. J. Fadel, E. M. Poeschla, 
and A. N. Engelman, “A critical role for alternative polyadenylation factor 
CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin.,” 
Proc. Natl. Acad. Sci. U. S. A., vol. 113, no. 8, pp. E1054-63, 2016. 
[99] C. R. Chin, J. M. Perreira, G. Savidis, J. M. Portmann, A. M. Aker, E. M. 
Feeley, M. C. Smith, and A. L. Brass, “Direct Visualization of HIV-1 
Replication Intermediates Shows that Capsid and CPSF6 Modulate HIV-1 
Intra-nuclear Invasion and Integration,” Cell Rep., vol. 13, no. 8, pp. 1717–
1731, 2015. 
[100] F. Di Nunzio, T. Fricke, A. Miccio, J. C. Valle-Casuso, P. Perez, P. 
Souque, E. Rizzi, M. Severgnini, F. Mavilio, P. Charneau, and F. Diaz-
Griffero, “Nup153 and Nup98 bind the HIV-1 core and contribute to the 
early steps of HIV-1 replication,” Virology, vol. 440, no. 1, pp. 8–18, 2013. 
[101] K. E. Ocwieja, T. L. Brady, K. Ronen, A. Huegel, S. L. Roth, T. Schaller, L. 
C. James, G. J. Towers, J. A. T. Young, S. K. Chanda, R. König, N. 
Malani, C. C. Berry, and F. D. Bushman, “HIV integration targeting: A 
pathway involving transportin-3 and the nuclear pore protein RanBP2,” 
PLoS Pathog., vol. 7, no. 3, 2011. 
[102] Y. Koh, X. Wu, A. L. Ferris, K. a. Matreyek, S. J. Smith, K. Lee, V. N. 
KewalRamani, S. H. Hughes, and A. Engelman, “Differential Effects of 
Human Immunodeficiency Virus Type 1 Capsid and Cellular Factors 
Nucleoporin 153 and LEDGF/p75 on the Efficiency and Specificity of Viral 
DNA Integration,” Journal of Virology, vol. 87, no. 1. pp. 648–658, 2012. 
[103] N.-Y. Chen, L. Zhou, P. J. Gane, S. Opp, N. J. Ball, G. Nicastro, M. 
Zufferey, C. Buffone, J. Luban, D. Selwood, F. Diaz-Griffero, I. Taylor, and 
A. Fassati, “HIV-1 capsid is involved in post-nuclear entry steps.,” 
Retrovirology, vol. 13, p. 28, 2016. 
[104] C. Aiken, “Cell-free assays for HIV-1 uncoating,” Methods Mol. Biol., vol. 
485, pp. 41–53, 2009. 
 
 
126 
 
[105] K. A. Matreyek, S. S. Yücel, X. Li, and A. Engelman, “Nucleoporin NUP153 
Phenylalanine-Glycine Motifs Engage a Common Binding Pocket within the 
HIV-1 Capsid Protein to Mediate Lentiviral Infectivity,” PLoS Pathog., vol. 
9, no. 10, 2013. 
[106] A. R. Lowe, J. J. Siegel, P. Kalab, M. Siu, K. Weis, and J. T. Liphardt, 
“Selectivity mechanism of the nuclear pore complex characterized by 
single cargo tracking.,” Nature, vol. 467, no. 7315, pp. 600–3, 2010. 
[107] N. Pante and M. Kann, “Nuclear Pore Complex Is Able to Transport 
Macromolecules with Diameters of 39 nm,” Mol. Biol. Cell, vol. 13, no. 2, 
pp. 425–434, 2002. 
[108] M. Bukrinsky, “A hard way to the nucleus,” Mol. Med., vol. 10, no. 1–6, pp. 
1–5, 2004. 
[109] J. Lehmann-Che and A. Saïb, “Early stages of HIV replication: How to 
hijack cellular functions for a successful infection,” AIDS Reviews, vol. 6, 
no. 4. pp. 199–207, 2004. 
[110] J. D. Dvorin and M. H. Malim, “Intracellular trafficking of HIV-1 cores: 
journey to the center of the cell,” Curr Top Microbiol Immunol, vol. 281, pp. 
179–208, 2003. 
[111] H. Xu, T. Franks, G. Gibson, K. Huber, N. Rahm, C. Strambio De Castillia, 
J. Luban, C. Aiken, S. Watkins, N. Sluis-Cremer, and Z. Ambrose, 
“Evidence for biphasic uncoating during HIV-1 infection from a novel 
imaging assay.,” Retrovirology, vol. 10, no. 1, p. 70, 2013. 
[112] U. K. von Schwedler, K. M. Stray, J. E. Garrus, and W. I. Sundquist, 
“Functional surfaces of the human immunodeficiency virus type 1 capsid 
protein.,” J. Virol., vol. 77, no. 9, pp. 5439–50, 2003. 
[113] G. B. Mortuza, L. F. Haire, A. Stevens, S. J. Smerdon, J. P. Stoye, and I. a 
Taylor, “High-resolution structure of a retroviral capsid hexameric amino-
terminal domain.,” Nature, vol. 431, no. 2000, pp. 481–485, 2004. 
[114] O. Pornillos, B. K. Ganser-Pornillos, B. N. Kelly, Y. Hua, F. G. Whitby, C. 
D. Stout, W. I. Sundquist, C. P. Hill, and M. Yeager, “X-Ray Structures of 
the Hexameric Building Block of the HIV Capsid,” Cell, vol. 137, no. 7, pp. 
1282–1292, 2009. 
[115] J. Shi, J. Zhou, V. B. Shah, C. Aiken, and K. Whitby, “Small-molecule 
inhibition of human immunodeficiency virus type 1 infection by virus capsid 
destabilization,” J. Virol., vol. 85, no. 1, pp. 542–549, 2011. 
127 
 
[116] V. B. Shah and C. Aiken, “<em>In vitro</em> Uncoating of HIV-1 Cores,” 
J. Vis. Exp., no. November, pp. 2–5, 2011. 
[117] M. Stremlau, M. Perron, M. Lee, Y. Li, B. Song, H. Javanbakht, F. Diaz-
Griffero, D. J. Anderson, W. I. Sundquist, and J. Sodroski, “Specific 
recognition and accelerated uncoating of retroviral capsids by the 
TRIM5alpha restriction factor.,” Proc. Natl. Acad. Sci. U. S. A., vol. 103, no. 
14, pp. 5514–9, 2006. 
[118] T. Fricke, T. E. White, B. Schulte, D. a de Souza Aranha Vieira, A. Dharan, 
E. M. Campbell, A. Brandariz-Nuñez, and F. Diaz-Griffero, “MxB binds to 
the HIV-1 core and prevents the uncoating process of HIV-1.,” 
Retrovirology, vol. 11, p. 68, 2014. 
[119] S. B. Kutluay, D. Perez-Caballero, and P. D. Bieniasz, “Fates of Retroviral 
Core Components during Unrestricted and TRIM5-Restricted Infection,” 
PLoS Pathog., vol. 9, no. 3, 2013. 
[120] P. Pawlica and L. Berthoux, “Cytoplasmic dynein promotes HIV-1 
uncoating,” Viruses, vol. 6, no. 11, pp. 4195–4211, 2014. 
[121] D. M. Sayah, E. Sokolskaja, L. Berthoux, and J. Luban, “Cyclophilin A 
retrotransposition into TRIM5 explains owl monkey resistance to HIV-1.,” 
Nature, vol. 430, no. 6999, pp. 569–573, 2004. 
[122] B. M. Forshey, J. Shi, and C. Aiken, “Structural requirements for 
recognition of the human immunodeficiency virus type 1 core during host 
restriction in owl monkey cells.,” J. Virol., vol. 79, no. 2, pp. 869–75, 2005. 
[123] J. Sastri and E. M. Campbell, “Recent insights into the mechanism and 
consequences of TRIM5α retroviral restriction.,” AIDS Res. Hum. 
Retroviruses, vol. 27, no. 3, pp. 231–238, 2011. 
[124] R. C. Burdick, W.-S. Hu, and V. K. Pathak, “Nuclear import of APOBEC3F-
labeled HIV-1 preintegration complexes.,” Proc. Natl. Acad. Sci. U. S. A., 
vol. 110, pp. E4780-9, 2013. 
[125] A. Albanese, D. Arosio, M. Terreni, and A. Cereseto, “HIV-1 pre-integration 
complexes selectively target decondensed chromatin in the nuclear 
periphery,” PLoS One, vol. 3, no. 6, 2008. 
[126] E. M. Campbell, O. Perez, J. L. Anderson, and T. J. Hope, “Visualization of 
a proteasome-independent intermediate during restriction of HIV-1 by 
rhesus TRIM5alpha.,” J. Cell Biol., vol. 180, no. 3, pp. 549–61, Feb. 2008. 
 
128 
 
[127] A. C. Francis, M. Marin, J. Shi, C. Aiken, and G. B. Melikyan, “Time-
Resolved Imaging of Single HIV-1 Uncoating In Vitro and in Living Cells,” 
PLoS Pathog., vol. 12, no. 6, 2016. 
[128] A. S. Reicin, A. Ohagen, L. Yin, S. Hoglund, and S. P. Goff, “The role of 
Gag in human immunodeficiency virus type 1 virion morphogenesis and 
early steps of the viral life cycle.,” J. Virol., vol. 70, no. 12, pp. 8645–52, 
Dec. 1996. 
[129] A. E. Hulme, Z. Kelley, E. a Okocha, and T. J. Hope, “Identification of 
capsid mutations that alter the rate of HIV-1 uncoating in infected cells.,” J. 
Virol., vol. 89, no. 1, pp. 643–51, 2015. 
[130] A. Bhattacharya, S. L. Alam, T. Fricke, K. Zadrozny, J. Sedzicki, A. B. 
Taylor, B. Demeler, O. Pornillos, B. K. Ganser-Pornillos, F. Diaz-Griffero, 
D. N. Ivanov, and M. Yeager, “Structural basis of HIV-1 capsid recognition 
by PF74 and CPSF6.,” Proc. Natl. Acad. Sci. U. S. A., vol. 111, no. 52, pp. 
18625–30, 2014. 
[131] A. Saito, D. Ferhadian, G. A. Sowd, E. Serrao, J. Shi, U. D. Halambage, S. 
Teng, J. Soto, M. A. Siddiqui, A. N. Engelman, C. Aiken, and M. 
Yamashita, “Roles of capsid-interacting host factors in multimodal inhibition 
of HIV-1 by PF74.,” J. Virol., vol. 90, no. 12, pp. 5808–5823, 2016. 
[132] S. Thenin-Houssier, I. M. S. de Vera, L. Pedro-Rosa, A. Brady, A. Richard, 
B. Konnick, S. Opp, C. Buffone, J. Fuhrmann, S. Kota, B. Billack, M. 
Pietka-Ottlik, T. Tellinghuisen, H. Choe, T. Spicer, L. Scampavia, F. Diaz-
Griffero, D. J. Kojetin, and S. T. Valente, “Ebselen, a small molecule 
capsid-inhibitor of HIV-1 replication,” Antimicrob. Agents Chemother., no. 
JANUARY, p. AAC.02574-15, 2016. 
[133] K. Das, S. E. Martinez, J. D. Bauman, and E. Arnold, “HIV-1 reverse 
transcriptase complex with DNA and nevirapine reveals non-nucleoside 
inhibition mechanism,” Nat. Struct. Mol. Biol., vol. 19, no. 2, pp. 253–259, 
2012. 
[134] V. J. Merluzzi, K. D. Hargrave, M. Labadia, K. Grozinger, M. Skoog, J. C. 
Wu, C. K. Shih, K. Eckner, S. Hattox, and J. Adams, “Inhibition of HIV-1 
replication by a nonnucleoside reverse transcriptase inhibitor.,” Science, 
vol. 250, no. 4986, pp. 1411–1413, 1990. 
 
 
129 
 
[135] O. Cosnefroy, P. J. Murray, and K. N. Bishop, “HIV-1 capsid uncoating 
initiates after the first strand transfer of reverse transcription.,” 
Retrovirology, vol. 13, no. 1, p. 58, 2016. 
[136] R. Li and G. G. Gundersen, “Beyond polymer polarity: how the 
cytoskeleton builds a polarized cell.,” Nat. Rev. Mol. Cell Biol., vol. 9, no. 
11, pp. 860–73, 2008. 
[137] M. A. Welte, “Bidirectional transport along microtubules,” Current Biology, 
vol. 14, no. 13. 2004. 
[138] E. M. Campbell and T. J. Hope, “Gene therapy progress and prospects: 
viral trafficking during infection.,” Gene Ther., vol. 12, no. 18, pp. 1353–
1359, 2005. 
[139] M. H. Naghavi and S. P. Goff, “Retroviral proteins that interact with the 
host cell cytoskeleton,” Current Opinion in Immunology, vol. 19, no. 4. pp. 
402–407, 2007. 
[140]  a Bukrinskaya, B. Brichacek,  a Mann, and M. Stevenson, “Establishment 
of a functional human immunodeficiency virus type 1 (HIV-1) reverse 
transcription complex involves the cytoskeleton.,” J. Exp. Med., vol. 188, 
no. 11, pp. 2113–2125, 1998. 
[141] X. Contreras, O. Mzoughi, F. Gaston, M. B. Peterlin, and E. Bahraoui, 
“Protein kinase C-delta regulates HIV-1 replication at an early post-entry 
step in macrophages.,” Retrovirology, vol. 9, p. 37, 2012. 
[142] N. J. Arhel, S. Souquere-Besse, S. Munier, P. Souque, S. Guadagnini, S. 
Rutherford, M.-C. Prévost, T. D. Allen, and P. Charneau, “HIV-1 DNA Flap 
formation promotes uncoating of the pre-integration complex at the nuclear 
pore.,” EMBO J., vol. 26, no. 12, pp. 3025–37, 2007. 
[143] G. Fischer, B. Wittmann-Liebold, K. Lang, T. Kiefhaber, and F. X. Schmid, 
“Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical 
proteins.,” Nature, vol. 337, no. 6206. pp. 476–478, 1989. 
[144] T. R. Gamble, F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. 
I. Sundquist, and C. P. Hill, “Crystal structure of human cyclophilin A bound 
to the amino-terminal domain of HIV-1 capsid,” Cell, vol. 87, no. 7, pp. 
1285–1294, 1996. 
[145] J. Luban, K. L. Bossolt, E. K. Franke, G. V Kalpana, and S. P. Goff, 
“Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A 
and B.,” Cell, vol. 73, no. 6, pp. 1067–1078, 1993. 
130 
 
[146] E. Sokolskaja, D. M. Sayah, and J. Luban, “Target cell cyclophilin A 
modulates human immunodeficiency virus type 1 infectivity.,” J. Virol., vol. 
78, no. 23, pp. 12800–8, 2004. 
[147] T. Hatziioannou, D. Perez-Caballero, S. Cowan, and P. D. Bieniasz, 
“Cyclophilin interactions with incoming human immunodeficiency virus type 
1 capsids with opposing effects on infectivity in human cells.,” J. Virol., vol. 
79, no. 1, pp. 176–83, 2005. 
[148] D. a Bosco, E. Z. Eisenmesser, S. Pochapsky, W. I. Sundquist, and D. 
Kern, “Catalysis of cis/trans isomerization in native HIV-1 capsid by human 
cyclophilin A.,” Proc. Natl. Acad. Sci. U. S. A., vol. 99, no. 8, pp. 5247–52, 
2002. 
[149] T. Fricke, A. Brandariz-Nuñez, X. Wang, A. B. Smith, and F. Diaz-Griffero, 
“Human cytosolic extracts stabilize the HIV-1 core.,” J. Virol., vol. 87, no. 
19, pp. 10587–97, 2013. 
[150] V. B. Shah, J. Shi, D. R. Hout, I. Oztop, L. Krishnan, J. Ahn, M. S. 
Shotwell,  a. Engelman, and C. Aiken, “The Host Proteins Transportin 
SR2/TNPO3 and Cyclophilin A Exert Opposing Effects on HIV-1 
Uncoating,” J. Virol., vol. 87, no. 1, pp. 422–432, 2012. 
[151] C. Liu, J. R. Perilla, J. Ning, M. Lu, G. Hou, R. Ramalho, B. A. Himes, G. 
Zhao, G. J. Bedwell, I.-J. Byeon, J. Ahn, A. M. Gronenborn, P. E. 
Prevelige, I. Rousso, C. Aiken, T. Polenova, K. Schulten, and P. Zhang, 
“Cyclophilin A stabilizes the HIV-1 capsid through a novel non-canonical 
binding site.,” Nat. Commun., vol. 7, p. 10714, 2016. 
[152] Y. Li, A. K. Kar, and J. Sodroski, “Target cell type-dependent modulation of 
human immunodeficiency virus type 1 capsid disassembly by cyclophilin 
A.,” J. Virol., vol. 83, no. 21, pp. 10951–62, 2009. 
[153] S. Matsuoka, E. Dam, D. Lecossier, F. Clavel, and A. J. Hance, 
“Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag 
sequence and target cell type.,” Retrovirology, vol. 6, p. 21, 2009. 
[154] D. Braaten, E. K. Franke, and J. Luban, “Cyclophilin A is required for an 
early step in the life cycle of human immunodeficiency virus type 1 before 
the initiation of reverse transcription.,” J. Virol., vol. 70, no. 6, pp. 3551–60, 
1996. 
 
 
131 
 
[155] E. K. Franke and J. Luban, “Inhibition of HIV-1 replication by cyclosporine 
A or related compounds correlates with the ability to disrupt the Gag-
cyclophilin A interaction.,” Virology, vol. 222, no. 1, pp. 279–282, 1996. 
[156] O. Haller and G. Kochs, “Human MxA Protein: An Interferon-Induced 
Dynamin-Like GTPase with Broad Antiviral Activity,” J. Interf. Cytokine 
Res., vol. 31, no. 1, pp. 79–87, 2011. 
[157] C. Goujon, O. Moncorgé, H. Bauby, T. Doyle, C. C. Ward, T. Schaller, S. 
Hué, W. S. Barclay, R. Schulz, and M. H. Malim, “Human MX2 is an 
interferon-induced post-entry inhibitor of HIV-1 infection,” Nature, vol. 502, 
no. 7472, pp. 559–62, 2013. 
[158] M. Kane, S. S. Yadav, J. Bitzegeio, S. B. Kutluay, T. Zang, S. J. Wilson, J. 
W. Schoggins, C. M. Rice, M. Yamashita, T. Hatziioannou, and P. D. 
Bieniasz, “MX2 is an interferon-induced inhibitor of HIV-1 infection.,” 
Nature, vol. 502, no. 7472, pp. 563–6, 2013. 
[159] Z. Liu, Q. Pan, S. Ding, J. Qian, F. Xu, J. Zhou, S. Cen, F. Guo, and C. 
Liang, “The interferon-inducible MxB protein inhibits HIV-1 infection,” Cell 
Host Microbe, vol. 14, no. 4, pp. 398–410, 2013. 
[160] V. Le Sage, A. J. Mouland, and F. Valiente-Echeverría, “Roles of HIV-1 
capsid in viral replication and immune evasion,” Virus Res., vol. 193, pp. 
116–129, 2014. 
[161] F. Diaz-Griffero, “The Role of TNPO3 in HIV-1 Replication.,” Mol Biol Int, 
vol. 2012, p. 868597, 2012. 
[162] N. Kataoka, J. L. Bachorik, and G. Dreyfuss, “Transportin-SR, a nuclear 
import receptor for SR proteins,” J. Cell Biol., vol. 145, no. 6, pp. 1145–
1152, 1999. 
[163] L. Zhou, E. Sokolskaja, C. Jolly, W. James, S. A. Cowley, and A. Fassati, 
“Transportin 3 promotes a nuclear maturation step required for efficient 
HIV-1 integration,” PLoS Pathog., vol. 7, no. 8, 2011. 
[164] A. De Iaco and J. Luban, “Inhibition of HIV-1 infection by TNPO3 depletion 
is determined by capsid and detectable after viral cDNA enters the 
nucleus,” Retrovirology, vol. 8, no. 1, p. 98, 2011. 
[165] J. C. Valle-Casuso, F. Di Nunzio, Y. Yang, N. Reszka, M. Lienlaf, N. Arhel, 
P. Perez, A. L. Brass, and F. Diaz-Griffero, “TNPO3 is required for HIV-1 
replication after nuclear import but prior to integration and binds the HIV-1 
core.,” J. Virol., vol. 86, no. 10, pp. 5931–6, 2012. 
132 
 
[166] U. Rüegsegger, D. Blank, and W. Keller, “Human Pre-mRNA Cleavage 
Factor I m Is Related to Spliceosomal SR Proteins and Can Be 
Reconstituted In Vitro from Recombinant Subunits,” Mol. Cell, vol. 1, no. 2, 
pp. 243–253, 1998. 
[167] A. J. Price, A. J. Fletcher, T. Schaller, T. Elliott, K. E. Lee, V. N. 
KewalRamani, J. W. Chin, G. J. Towers, and L. C. James, “CPSF6 Defines 
a Conserved Capsid Interface that Modulates HIV-1 Replication,” PLoS 
Pathog., vol. 8, no. 8, 2012. 
[168] K. Lee, A. Mulky, W. Yuen, T. D. Martin, N. R. Meyerson, L. Choi, H. Yu, S. 
L. Sawyer, and V. N. Kewalramani, “HIV-1 capsid-targeting domain of 
cleavage and polyadenylation specificity factor 6.,” J. Virol., vol. 86, no. 7, 
pp. 3851–60, 2012. 
[169] T. Hori, H. Takeuchi, H. Saito, R. Sakuma, Y. Inagaki, and S. Yamaoka, “A 
carboxy-terminally truncated human CPSF6 lacking residues encoded by 
exon 6 inhibits HIV-1 cDNA synthesis and promotes capsid disassembly.,” 
J. Virol., vol. 87, no. 13, pp. 7726–36, 2013. 
[170] T. Fricke, J. C. Valle-Casuso, T. E. White, A. Brandariz-Nuñez, W. J. 
Bosche, N. Reszka, R. Gorelick, and F. Diaz-Griffero, “The ability of 
TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.,” 
Retrovirology, vol. 10, p. 46, 2013. 
[171] A. A. Labokha and A. F. Fassati, “Viruses challenge selectivity barrier of 
nuclear pores,” Viruses, vol. 5, no. 10, pp. 2410–2423, 2013. 
[172] C. Strambio-De-Castillia, M. Niepel, and M. P. Rout, “The nuclear pore 
complex: bridging nuclear transport and gene regulation,” Nat Rev Mol Cell 
Biol, vol. 11, no. 7, pp. 490–501, 2010. 
[173] J. Wu, M. J. Matunis, D. Kraemer, G. Blobel, and E. Coutavas, “Nup358, a 
cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP 
binding sites, zinc fingers, a cyclophilin A homologous domain, and a 
leucine-rich region,” J. Biol. Chem., vol. 270, no. 23, pp. 14209–14213, 
1995. 
[174] D. H. Lin, S. Zimmermann, T. Stuwe, E. Stuwe, and A. Hoelz, “Structural 
and functional analysis of the C-terminal domain of Nup358/RanBP2,” J. 
Mol. Biol., vol. 425, no. 8, pp. 1318–1329, 2013. 
 
 
133 
 
[175] K. Bichel, A. J. Price, T. Schaller, G. J. Towers, S. M. V Freund, and L. C. 
James, “HIV-1 capsid undergoes coupled binding and isomerization by the 
nuclear pore protein NUP358.,” Retrovirology, vol. 10, no. 1, p. 81, 2013. 
[176] F. Di Nunzio, A. Danckaert, T. Fricke, P. Perez, J. Fernandez, E. Perret, P. 
Roux, S. Shorte, P. Charneau, F. Diaz-Griffero, and N. J. Arhel, “Human 
Nucleoporins Promote HIV-1 Docking at the Nuclear Pore, Nuclear Import 
and Integration,” PLoS One, vol. 7, no. 9, 2012. 
[177] A. M. Meehan, D. T. Saenz, R. Guevera, J. H. Morrison, M. Peretz, H. J. 
Fadel, M. Hamada, J. van Deursen, and E. M. Poeschla, “A Cyclophilin 
Homology Domain-Independent Role for Nup358 in HIV-1 Infection,” PLoS 
Pathog., vol. 10, no. 2, 2014. 
[178] F. Bin Hamid, J. Kim, and C.-G. Shin, “Cellular and viral determinants of 
retroviral nuclear entry.,” Can. J. Microbiol., vol. 62, no. 1, pp. 1–15, 2015. 
[179] P. Enarson, M. Enarson, R. Bastos, and B. Burke, “Amino-terminal 
sequences that direct nucleoporin Nup153 to the inner surface of the 
nuclear envelope,” Chromosoma, vol. 107, no. 4, pp. 228–236, 1998. 
[180] B. Fahrenkrog, B. Maco, A. M. Fager, J. Köser, U. Sauder, K. S. Ullman, 
and U. Aebi, “Domain-specific antibodies reveal multiple-site topology of 
Nup153 within the nuclear pore complex,” in Journal of Structural Biology, 
2002, vol. 140, no. 1–3, pp. 254–267. 
[181] R. Y. H. Lim, N.-P. P. Huang, J. Köser, J. Deng, K. H. A. Lau, K. Schwarz-
Herion, B. Fahrenkrog, and U. Aebi, “Flexible phenylalanine-glycine 
nucleoporins as entropic barriers to nucleocytoplasmic transport,” Proc. 
Natl. Acad. Sci., vol. 103, no. 25, pp. 9512–9517, 2006. 
[182] S. M. Paulillo, E. M. Phillips, J. Köser, U. Sauder, K. S. Ullman, M. A. 
Powers, and B. Fahrenkrog, “Nucleoporin domain topology is linked to the 
transport status of the nuclear pore complex,” J. Mol. Biol., vol. 351, no. 4, 
pp. 784–798, 2005. 
[183] W. Paxton, R. I. Connor, and N. R. Landau, “Incorporation of Vpr into 
human immunodeficiency virus type 1 virions: requirement for the p6 
region of gag and mutational analysis.,” J. Virol., vol. 67, no. 12, pp. 7229–
37, 1993. 
 
 
 
134 
 
[184] H. Wu, H. Liu, H. Xiao, J. Kim, P. Seshaiah, G. Natsoulis, J. D. Boeke, B. 
H. Hahn, and J. C. Kappes, “Targeting foreign proteins to human 
immunodeficiency virus particles via fusion with Vpr and Vpx.,” J. Virol., 
vol. 69, no. 6, pp. 3389–3398, 1995. 
[185] B. Müller, U. Tessmer, U. Schubert, and H. G. Kräusslich, “Human 
immunodeficiency virus type 1 Vpr protein is incorporated into the virion in 
significantly smaller amounts than gag and is phosphorylated in infected 
cells.,” J. Virol., vol. 74, no. 20, pp. 9727–31, 2000. 
[186] S. P. Singh, P. Tungaturthi, M. Cartas, B. Tomkowicz, T. A. Rizvi, S. A. 
Khan, V. S. Kalyanaraman, and A. Srinivasan, “Virion-associated HIV-1 
Vpr: variable amount in virus particles derived from cells upon virus 
infection or proviral DNA transfection.,” Virology, vol. 283, no. 1, pp. 78–83, 
2001. 
[187] C. M. Danielson and T. J. Hope, “Imaging of HIV/host protein interactions,” 
Current Topics in Microbiology and Immunology, vol. 339, no. 1. pp. 103–
123, 2009. 
[188] C. Hoffmann, G. Gaietta, A. Zürn, S. R. Adams, S. Terrillon, M. H. 
Ellisman, R. Y. Tsien, and M. J. Lohse, “Fluorescent labeling of 
tetracysteine-tagged proteins in intact cells.,” Nat. Protoc., vol. 5, no. 10, 
pp. 1666–77, 2010. 
[189] B. A. Griffin, S. R. Adams, R. Y. Tsien, R. Y. Tsien, E. Kalef, C. Gitler, V. 
P. Whittaker, G. Merutka, W. Shalongo, E. Stellwagen, W. G. Lowe, C. S. 
Hamilton, C. Spang, F. T. Edelmann, M. Noltemeyer, H. W. Roesky, R. 
Heim, R. Y. Tsien, A. Miyawaki, M. Ormö, F. Denizot, R. Lang, G. 
Zlokarnik, C. F. Ford, I. Suominen, C. E. Glatz, G. R. Crabtree, and S. L. 
Schreiber, “Specific covalent labeling of recombinant protein molecules 
inside live cells.,” Science, vol. 281, no. 5374, pp. 269–72, 1998. 
[190] G. Gaietta, T. J. Deerinck, S. R. Adams, J. Bouwer, O. Tour, D. W. Laird, 
G. E. Sosinsky, R. Y. Tsien, and M. H. Ellisman, “Multicolor and electron 
microscopic imaging of connexin trafficking,” Science (80-. )., vol. 296, no. 
5567, pp. 503–507, 2002. 
[191] K. a Page, T. Liegler, and M. B. Feinberg, “Use of a green fluorescent 
protein as a marker for human immunodeficiency virus type 1 infection.,” 
AIDS Res. Hum. Retroviruses, vol. 13, no. 13, pp. 1077–81, 1997. 
 
135 
 
[192] E. M. Campbell, O. Perez, M. Melar, and T. J. Hope, “Labeling HIV-1 
virions with two fluorescent proteins allows identification of virions that 
have productively entered the target cell,” Virology, vol. 360, no. 2, pp. 
286–293, 2007. 
[193] M. E. Tanenbaum, L. a. Gilbert, L. S. Qi, J. S. Weissman, and R. D. Vale, 
“A protein-tagging system for signal amplification in gene expression and 
fluorescence imaging,” Cell, vol. 159, no. 3, pp. 635–646, 2014. 
[194] J. L. Smith, W. Bu, R. C. Burdick, and V. K. Pathak, “Multiple ways of 
targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug 
development,” Trends in Pharmacological Sciences, vol. 30, no. 12. pp. 
638–646, 2009. 
[195] L. Apolonia, R. Schulz, T. Curk, P. Rocha, C. M. Swanson, T. Schaller, J. 
Ule, and M. H. Malim, “Promiscuous RNA Binding Ensures Effective 
Encapsidation of APOBEC3 Proteins by HIV-1,” PLoS Pathog., vol. 11, no. 
1, pp. 1–22, 2015. 
[196] J. L. Mbisa, W. Bu, and V. K. Pathak, “APOBEC3F and APOBEC3G inhibit 
HIV-1 DNA integration by different mechanisms.,” J. Virol., vol. 84, no. 10, 
pp. 5250–5259, 2010. 
[197] A. Wörn, A. A. Der Maur, D. Escher, A. Honegger, A. Barberis, and A. 
Plückthun, “Correlation between in vitro stability and in vivo performance of 
anti- GCN4 intrabodies as cytoplasmic inhibitors,” J. Biol. Chem., vol. 275, 
no. 4, pp. 2795–2803, 2000. 
[198] J.-D. Pédelacq, S. Cabantous, T. Tran, T. C. Terwilliger, and G. S. Waldo, 
“Engineering and characterization of a superfolder green fluorescent 
protein.,” Nat. Biotechnol., vol. 24, no. 1, pp. 79–88, 2006. 
[199] A. M. Gronenborn, D. R. Filpula, N. Z. Essig, A. Achari, M. Whitlow, P. T. 
Wingfield, and G. M. Clore, “A novel, highly stable fold of the 
immunoglobulin binding domain of streptococcal protein G.,” Science, vol. 
253, no. 5020, pp. 657–61, 1991. 
[200] M. P. Hall, J. Unch, B. F. Binkowski, M. P. Valley, B. L. Butler, M. G. Wood, 
P. Otto, K. Zimmerman, G. Vidugiris, T. MacHleidt, M. B. Robers, H. A. 
Benink, C. T. Eggers, M. R. Slater, P. L. Meisenheimer, D. H. Klaubert, F. 
Fan, L. P. Encell, and K. V. Wood, “Engineered luciferase reporter from a 
deep sea shrimp utilizing a novel imidazopyrazinone substrate,” ACS 
Chem. Biol., vol. 7, no. 11, pp. 1848–1857, 2012. 
136 
 
[201] A. S. Dixon, M. K. Schwinn, M. P. Hall, K. Zimmerman, P. Otto, T. H. 
Lubben, B. L. Butler, B. F. Binkowski, T. MacHleidt, T. a. Kirkland, M. G. 
Wood, C. T. Eggers, L. P. Encell, and K. V. Wood, “NanoLuc 
Complementation Reporter Optimized for Accurate Measurement of 
Protein Interactions in Cells,” ACS Chem. Biol., vol. 11, pp. 400–408, 2016. 
[202] J. Vermeire, E. Naessens, H. Vanderstraeten, A. Landi, V. Iannucci, A. 
Van Nuffel, T. Taghon, M. Pizzato, and B. Verhasselt, “Quantification of 
reverse transcriptase activity by real-time PCR as a fast and accurate 
method for titration of HIV, lenti- and retroviral vectors.,” PLoS One, vol. 7, 
no. 12, p. e50859, 2012. 
[203] M. Pizzato, O. Erlwein, D. Bonsall, S. Kaye, D. Muir, and M. O. McClure, 
“A one-step SYBR Green I-based product-enhanced reverse transcriptase 
assay for the quantitation of retroviruses in cell culture supernatants.,” J. 
Virol. Methods, vol. 156, no. 1–2, pp. 1–7, Mar. 2009. 
[204] C. Petit, O. Schwartz, and F. Mammano, “Oligomerization within virions 
and subcellular localization of human immunodeficiency virus type 1 
integrase.,” J. Virol., vol. 73, no. 6, pp. 5079–88, 1999. 
[205] C. F. Pereira, P. C. Ellenberg, K. L. Jones, T. L. Fernandez, R. P. Smyth, 
D. J. Hawkes, M. Hijnen, V. Vivet-Boudou, R. Marquet, I. Johnson, and J. 
Mak, “Labeling of multiple HIV-1 proteins with the biarsenical-tetracysteine 
system,” PLoS One, vol. 6, no. 2, 2011. 
[206] S. K. Lee, M. Potempa, M. Kolli, A. ??zen, C. A. Schiffer, and R. 
Swanstrom, “Context surrounding processing sites is crucial in determining 
cleavage rate of a subset of processing sites in HIV-1 gag and gag-pro-pol 
polyprotein precursors by viral protease,” J. Biol. Chem., vol. 287, no. 16, 
pp. 13279–13290, 2012. 
[207] S. C. Pettit, M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V Nantermet, C. 
A. Klein, and R. Swanstrom, “The p2 domain of human immunodeficiency 
virus type 1 Gag regulates sequential proteolytic processing and is 
required to produce fully infectious virions.,” J. Virol., vol. 68, no. 12, pp. 
8017–27, 1994. 
[208] U. O’Doherty, W. J. Swiggard, and M. H. Malim, “Human 
immunodeficiency virus type 1 spinoculation enhances infection through 
virus binding.,” J. Virol., vol. 74, no. 21, pp. 10074–80, 2000. 
 
137 
 
[209] M. R. Neagu, P. Ziegler, T. Pertel, C. Strambio-De-Castillia, C. Grütter, G. 
Martinetti, L. Mazzucchelli, M. Grütter, M. G. Manz, and J. Luban, “Potent 
inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from 
human components,” J. Clin. Invest., vol. 119, no. 10, pp. 3035–3047, 
2009. 
[210] N. C. Shaner, P. a Steinbach, and R. Y. Tsien, “A guide to choosing 
fluorescent proteins.,” Nat. Methods, vol. 2, no. 12, pp. 905–909, 2005. 
[211] S. Karasawa, T. Araki, T. Nagai, H. Mizuno, and A. Miyawaki, “Cyan-
emitting and orange-emitting fluorescent proteins as a donor/acceptor pair 
for fluorescence resonance energy transfer.,” Biochem. J., vol. 381, no. Pt 
1, pp. 307–12, 2004. 
[212] H. G. Kräusslich, M. Fäcke, A. M. Heuser, J. Konvalinka, and H. Zentgraf, 
“The spacer peptide between human immunodeficiency virus capsid and 
nucleocapsid proteins is essential for ordered assembly and viral 
infectivity.,” J. Virol., vol. 69, no. 6, pp. 3407–19, 1995. 
[213] L. V Coren, J. A. Thomas, E. Chertova, R. C. Sowder, T. D. Gagliardi, R. J. 
Gorelick, and D. E. Ott, “Mutational analysis of the C-terminal gag 
cleavage sites in human immunodeficiency virus type 1,” J. Virol., vol. 81, 
no. 18, pp. 10047–10054, 2007. 
[214] G. Zhao, J. R. Perilla, E. L. Yufenyuy, X. Meng, B. Chen, J. Ning, J. Ahn, 
A. M. Gronenborn, K. Schulten, C. Aiken, and P. Zhang, “Mature HIV-1 
capsid structure by cryo-electron microscopy and all-atom molecular 
dynamics.,” Nature, vol. 497, no. 7451, pp. 643–646, 2013. 
[215] S. Abdurahman, S. Höglund, A. Höglund, and A. Vahlne, “Mutation in the 
loop C-terminal to the cyclophilin A binding site of HIV-1 capsid protein 
disrupts proper virus assembly and infectivity.,” Retrovirology, vol. 4, p. 19, 
2007. 
[216] C. Aiken, “Pseudotyping Human Immunodeficiency Virus Type 1 (HIV-1) 
by the Glycoprotein of Vesicular Stomatitis Virus Targets HIV-1 Entry to an 
Endocytic Pathway and Suppresses both the Requirement for Nef and the 
Sensitivity to Cyclosporin A,” J. Virol., vol. 71, no. 8, pp. 5871–5877, 1997. 
[217] K. Strebel and M. a Khan, “APOBEC3G encapsidation into HIV-1 virions: 
which RNA is it?,” Retrovirology, vol. 5, p. 55, 2008. 
 
 
138 
 
[218] X. Wang, X. Li, J. Ma, L. Zhang, L. Ma, Z. Mi, J. Zhou, F. Guo, L. Kleiman, 
and S. Cen, “Human APOBEC3F incorporation into human 
immunodeficiency virus type 1 particles,” Virus Res., vol. 191, no. 1, pp. 
30–38, 2014. 
[219] Y.-L. Chiu and W. C. Greene, “APOBEC3G: an intracellular centurion.,” 
Philos. Trans. R. Soc. Lond. B. Biol. Sci., vol. 364, no. 1517, pp. 689–703, 
2009. 
[220] Y.-H. Zheng, D. Irwin, T. Kurosu, K. Tokunaga, T. Sata, and B. M. Peterlin, 
“Human APOBEC3F is another host factor that blocks human 
immunodeficiency virus type 1 replication.,” J. Virol., vol. 78, no. 11, pp. 
6073–6, 2004. 
[221] C. Demaison, K. Parsley, G. Brouns, M. Scherr, K. Battmer, C. Kinnon, M. 
Grez, and A. J. Thrasher, “High-level transduction and gene expression in 
hematopoietic repopulating cells using a human immunodeficiency 
[correction of imunodeficiency] virus type 1-based lentiviral vector 
containing an internal spleen focus forming virus promoter.,” Hum. Gene 
Ther., vol. 13, no. 7, pp. 803–13, May 2002. 
[222] A. S. Dixon, M. K. Schwinn, M. P. Hall, K. Zimmerman, P. Otto, T. H. 
Lubben, B. L. Butler, B. F. Binkowski, T. MacHleidt, T. A. Kirkland, M. G. 
Wood, C. T. Eggers, L. P. Encell, and K. V. Wood, “NanoLuc 
Complementation Reporter Optimized for Accurate Measurement of 
Protein Interactions in Cells,” ACS Chem. Biol., vol. 11, no. 2, pp. 400–408, 
2016. 
[223] C. Aiken, “Viral and cellular factors that regulate HIV-1 uncoating.,” Curr. 
Opin. HIV AIDS, vol. 1, pp. 194–199, 2006. 
[224] J. O. Maldonado, J. L. Martin, J. D. Mueller, W. Zhang, and L. M. Mansky, 
“New insights into retroviral Gag-Gag and Gag-membrane interactions,” 
Frontiers in Microbiology, vol. 5, no. JUN. 2014. 
[225] T. Fricke, C. Buffone, S. Opp, J. Valle-Casuso, and F. Diaz-Griffero, “BI-2 
destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 
to the HIV-1 Capsid.,” Retrovirology, vol. 11, p. 120, 2014. 
[226] J. a Thomas, D. E. Ott, and R. J. Gorelick, “Efficiency of human 
immunodeficiency virus type 1 postentry infection processes: evidence 
against disproportionate numbers of defective virions.,” J. Virol., vol. 81, 
no. 8, pp. 4367–70, 2007. 
139 
 
[227] S. Manocheewa, J. E. Mittler, R. Samudrala, and J. I. Mullins, “Composite 
sequence-structure stability models as screening tools for identifying 
vulnerable targets for HIV drug and vaccine development,” Viruses, vol. 7, 
pp. 5718–5735, 2015. 
[228] A. York, S. B. Kutluay, M. Errando, and P. D. Bieniasz, “The RNA Binding 
Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 
Nucleocapsid.,” PLoS Pathog., vol. 12, no. 8, p. e1005833, Aug. 2016. 
[229] S. Brun, M. Solignat, B. Gay, E. Bernard, L. Chaloin, D. Fenard, C. 
Devaux, N. Chazal, and L. Briant, “VSV-G pseudotyping rescues HIV-1 CA 
mutations that impair core assembly or stability.,” Retrovirology, vol. 5, p. 
57, Jul. 2008. 
http://www.who.int/mediacentre/factsheets/fs360/en/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
140 
 
 
 
 
  
141 
 
6 26 46 66 86 106 126 146 166
1.05
1.10
1.15
1.20
1.25
1.30
Spot to region intensity
Time post-spinoculation (min)
S
p
o
t 
to
 R
e
g
io
n
 I
n
te
n
s
it
y
0 40 80 12
0
16
0
20
0
24
0
0
200
400
600
800
1000
GFP spots (mCherry channel)
Bin Centre
N
o
. 
o
f 
s
p
o
ts
SUPPORTING INFORMATION 
 
 
 
Figure S1. Graph showing the bleed-through from the GFP into the mCherry channel. HeLa 
P4 cells were transduced with 1 RTU of a HXB2 enveloped NL4-3 virus trans-incorporated with 
MA-CA-GFP only, and confocal images acquired using the standard settings for mCherry 
fluorophore acquisition (ex. at 543 nm, emission capture from 560 to 800 nm). 
 
 
 
Figure S2. Bleaching profile of SunTag spots over time. HeLa P4 cells stably producing scFv-
sfGFP were transduced with SunTag incorporated viruses and the spot intensity in relation to the 
background scFv-sfGFP in the cellular cytoplasm measured over time. SEM n = 4 technical 
repeats. 
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Figure S3. Number of SunTag spots per cell time post-spinoculation with viruses 
produced in the presence of saquinavir and in virus restricting TRIM-CypA producing cell 
lines. (A) IN-24xST viruses were produced in the presence of the protease inhibitor saquinavir 
and used to infect HeLa P4 cells stably producing the scFv-sfGFP antibody. (B) Transduction of 
scFv-sfGFP TZM-bl clone cells stably producing TRIMCypA or the TRIMCypA mutant. SEM n = 3 
technical repeats. 
 
 
 
Figure S4. Depletion of Nano-Glo substrate. To ascertain whether we were observing the 
kinetics of capsid uncoating, and not the depletion of the Nano-Glo substrate, the experiment was 
repeated using the A3F-HiBiT virus with the addition of extra substrate at 75 min p.s. (when a 
reduction in signal in previous tests was detected). An immediate increase in signal was 
observed, with an instantaneous depletion in RLU after this time point, suggesting the addition of 
substrate fuelled the enzyme already present. Also shown is the pBTe2-A3F plasmid only 
positive control, which displays completely different RLU kinetics to the HiBiT incorporated 
viruses. SEM n = 3 technical repeats.  
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